<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Hypofractionation for clinically localized prostate cancer - Hickey, BE - 2019 | Cochrane Library</title> <meta content="Hypofractionation for clinically localized prostate cancer - Hickey, BE - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011462.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Hypofractionation for clinically localized prostate cancer - Hickey, BE - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011462.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011462.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Hypofractionation for clinically localized prostate cancer" name="citation_title"/> <meta content="Brigid E Hickey" name="citation_author"/> <meta content="Melissa L James" name="citation_author"/> <meta content="Christchurch Hospital" name="citation_author_institution"/> <meta content="melissacollier@xtra.co.nz" name="citation_author_email"/> <meta content="Tiffany Daly" name="citation_author"/> <meta content="Princess Alexandra Hospital" name="citation_author_institution"/> <meta content="Feng‐Yi Soh" name="citation_author"/> <meta content="NHS Highland" name="citation_author_institution"/> <meta content="Mark Jeffery" name="citation_author"/> <meta content="Christchurch Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD011462.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/09/02" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011462.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011462.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011462.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Prostatic Neoplasms [*radiotherapy]; Quality of Life; *Radiation Dose Hypofractionation; Randomized Controlled Trials as Topic; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011462.pub2&amp;doi=10.1002/14651858.CD011462.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="f00EizoA";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011462\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011462\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011462\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011462\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","de","zh_HANS","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011462.pub2",title:"Hypofractionation for clinically localized prostate cancer",firstPublishedDate:"Sep 2, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=f00EizoA&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011462.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011462.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011462.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011462.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011462.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011462.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011462.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011462.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011462.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011462.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5309 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011462.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-sec-0148"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-sec-0032"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-sec-0033"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-sec-0075"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-sec-0142"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/appendices#CD011462-sec-0153"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/table_n/CD011462StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/table_n/CD011462StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Hypofractionation for clinically localized prostate cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/information#CD011462-cr-0002">Brigid E Hickey</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/information#CD011462-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Melissa L James</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/information#CD011462-cr-0004">Tiffany Daly</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/information#CD011462-cr-0005">Feng‐Yi Soh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011462.pub2/information#CD011462-cr-0006">Mark Jeffery</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/information/en#CD011462-sec-0167">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 02 September 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011462.pub2">https://doi.org/10.1002/14651858.CD011462.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011462-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011462-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011462-abs-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011462-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011462-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011462-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011462-abs-0001" lang="en"> <section id="CD011462-sec-0001"> <h3 class="title" id="CD011462-sec-0001">Background</h3> <p>Using hypofractionation (fewer, larger doses of daily radiation) to treat localized prostate cancer may improve convenience and resource use. For hypofractionation to be feasible, it must be at least as effective for cancer‐related outcomes and have comparable toxicity and quality of life outcomes as conventionally fractionated radiation therapy. </p> </section> <section id="CD011462-sec-0002"> <h3 class="title" id="CD011462-sec-0002">Objectives</h3> <p>To assess the effects of hypofractionated external beam radiation therapy compared to conventionally fractionated external beam radiation therapy for men with clinically localized prostate cancer. </p> </section> <section id="CD011462-sec-0003"> <h3 class="title" id="CD011462-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE (Ovid), Embase (Ovid) and trials registries from 1946 to 15 March 2019 with reference checking, citation searching and contact with study authors. Searches were not limited by language or publication status. We reran all searches within three months (15th March 2019) prior to publication. </p> </section> <section id="CD011462-sec-0004"> <h3 class="title" id="CD011462-sec-0004">Selection criteria</h3> <p>Randomized controlled comparisons which included men with clinically localized prostate adenocarcinoma where hypofractionated radiation therapy (external beam radiation therapy) to the prostate using hypofractionation (greater than 2 Gy per fraction) compared with conventionally fractionated radiation therapy to the prostate delivered using standard fractionation (1.8 Gy to 2 Gy per fraction). </p> </section> <section id="CD011462-sec-0005"> <h3 class="title" id="CD011462-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methodology. Two authors independently assessed trial quality and extracted data. We used Review Manager 5 for data analysis and meta‐analysis. We used the inverse variance method and random‐effects model for data synthesis of time‐to‐event data with hazard ratios (HR) and 95% confidence intervals (CI) reported. For dichotomous data, we used the Mantel‐Haenzel method and random‐effects model to present risk ratios (RR) and 95% CI. We used GRADE to assess evidence quality for each outcome. </p> </section> <section id="CD011462-sec-0006"> <h3 class="title" id="CD011462-sec-0006">Main results</h3> <p>We included 10 studies with 8278 men in our analysis comparing hypofractionation with conventional fractionation to treat prostate cancer. </p> <p><b>Primary outcomes</b> </p> <p>Hypofractionation may result in little or no difference in prostate cancer‐specific survival [PC‐SS] (HR 1.00, 95% CI 0.72 to 1.39; studies = 8, participants = 7946; median follow‐up 72 months; low‐certainty evidence). For men in the intermediate‐risk group undergoing conventional fractionation this corresponds to 976 per 1000 men alive after 6 years and 0 more (44 fewer to 18 more) alive per 1000 men undergoing hypofractionation. </p> <p>We are uncertain about the effect of hypofractionation on late radiation therapy gastrointestinal (GI) toxicity (RR 1.10, 95% CI 0.68 to 1.78; studies = 4, participants = 3843; very low‐certainty evidence). </p> <p>Hypofractionation probably results in little or no difference to late radiation therapy genitourinary (GU) toxicity (RR 1.05, 95% CI 0.93 to 1.18; studies = 4, participants = 3843; moderate‐certainty evidence). This corresponds to 262 per 1000 late GU radiation therapy toxicity events with conventional fractionation and 13 more (18 fewer to 47 more) per 1000 men when undergoing hypofractionation. </p> <p><b>Secondary outcomes</b> </p> <p>Hypofractionation results in little or no difference in overall survival (HR 0.94, 95% CI 0.83 to 1.07; 10 studies, 8243 participants; high‐certainty evidence). For men in the intermediate‐risk group undergoing conventional fractionation this corresponds to 869 per 1000 men alive after 6 years and 17 fewer (54 fewer to 17 more) participants alive per 1000 men when undergoing hypofractionation. </p> <p>Hypofractionation may result in little to no difference in metastasis‐free survival (HR 1.07, 95% CI 0.65 to 1.76; 5 studies, 4985 participants; low‐certainty evidence). This corresponds to 981 men per 1000 men metastasis‐free at 6 years when undergoing conventional fractionation and 5 more (58 fewer to 19 more) metastasis‐free per 1000 when undergoing hypofractionation. </p> <p>Hypofractionation likely results in a small, possibly unimportant reduction in biochemical recurrence‐free survival based on Phoenix criteria (HR 0.88, 95% CI 0.68 to 1.13; studies = 5, participants = 2889; median follow‐up 90 months to 108 months; moderate‐certainty evidence). In men of the intermediate‐risk group, this corresponds to 804 biochemical‐recurrence free men per 1000 participants at six years with conventional fractionation and 42 fewer (134 fewer to 37 more) recurrence‐free men per 1000 participants with hypofractionation </p> <p>Hypofractionation likely results in little to no difference to acute GU radiation therapy toxicity (RR 1.03, 95% CI 0.95 to 1.11; 4 studies, 4174 participants at 12 to 18 weeks' follow‐up; moderate‐certainty evidence). This corresponds to 360 episodes of toxicity per 1000 participants with conventional fractionation and 11 more (18 fewer to 40 more) per 1000 when undergoing hypofractionation. </p> </section> <section id="CD011462-sec-0007"> <h3 class="title" id="CD011462-sec-0007">Authors' conclusions</h3> <p>These findings suggest that moderate hypofractionation (up to a fraction size of 3.4 Gy) results in similar oncologic outcomes in terms of disease‐specific, metastasis‐free and overall survival. There appears to be little to no increase in both acute and late toxicity. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011462-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011462-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011462-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011462-abs-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011462-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011462-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011462-abs-0004" lang="en"> <h3>Use of shorter radiation treatments for prostate cancer</h3> <p><b>Review question</b> </p> <p>We asked if giving radiation therapy (cancer treatment with high energy x‐rays) for localized prostate cancer in fewer fractions (treatment visits for radiation) and shorter overall treatment time with a larger dose (more than 2 Gray) given each day, works as well as the usual (conventional) number of fractions (1.8 Gray per day to 2 Gray per day) for cancer control and had similar side effects. </p> <p><b>Background</b> </p> <p>Using fewer fractions, with a larger dose given at each visit is possibly better for treating prostate cancer with radiation. Radiation therapy for prostate cancer can cause bladder and bowel side effects, and affect sexual function. If using larger doses for each treatment, with fewer treatments overall (called hypofractionation), works as well for cancer control, and the side effects and effects on certainty of life are about the same, then hypofractionation may benefit men with prostate cancer contained within the prostate (localized) who are treated with radiation therapy. If cancer control is as good, and the side effects about the same, then using fewer (but larger dose) radiation treatments may be more convenient for men with prostate cancer, use fewer resources and save money. </p> <p><b>Study characteristics</b> </p> <p>This evidence is current to 15 March 2019. The men studied were ages 64 years and over and had prostate cancer limited to the pelvis. </p> <p><b>Key results</b> </p> <p>We studied the use of fewer, but larger doses of radiation to treat 8278 men with prostate cancer. We found 10 studies. </p> <p>We found that using hypofractionation may result in similar risk of dying from prostate cancer (low‐certainty evidence) but are uncertain how it affects late bowel side effects (very low‐certainty evidence). It probably results in similar rates of late bladder side effects (moderate‐certainty evidence). </p> <p>Using hypofractionation results in similar overall survival (high‐certainty evidence) and may be similar for metastasis‐free survival (low‐certainty evidence). Acute bladder side effects may be similar (moderate‐certainty evidence). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011462-sec-0148" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011462-sec-0148"></div> <h3 class="title" id="CD011462-sec-0149">Implications for practice</h3> <section id="CD011462-sec-0149"> <p>Moderate hypofractionation (up to a fraction size of 3.4 Gy) when compared to standard fractionation for prostate cancer appears to have minimal effect on cancer‐related outcomes, can be delivered with similar late gastrointestinal and genitourinary toxicity but comes at the cost of a likely slight increase in acute gastrointestinal toxicity and without detriment to quality of life. </p> </section> <h3 class="title" id="CD011462-sec-0150">Implications for research</h3> <section id="CD011462-sec-0150"> <p>Updating data in published randomized controlled trials with longer follow‐up will likely add precision to these findings. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011462-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011462-sec-0022"></div> <div class="table" id="CD011462-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Altered fraction schedules compared to conventional fractionation for clinically localized prostate cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Altered fraction schedules compared to conventional fractionation for clinically localized prostate cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : clinically localized prostate cancer<br/> <b>Setting</b> :<b>h</b> ospitals and cancer centers<br/> <b>Intervention</b> : altered fraction schedules<br/> <b>Comparison</b>: conventional fractionation </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with conventional fractionation</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with altered fraction schedules</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Prostate cancer‐specific survival</b> </p> <p>Follow‐up: median 60–108 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="6" valign="top"> <p>7946<br/> (8 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 1.00</b><br/> (0.72 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>996 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 more per 1000<br/> (15 fewer to 4 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Intermediate<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>976 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 more per 1000<br/> (44 fewer to 18 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>962 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 more per 1000<br/> (57 fewer to 27 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Late gastrointestinal RT toxicity</b><br/> ≥ Grade II RTOG/EORTC </p> <p>Follow‐up: median 60 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3843<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1a,f,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.10</b><br/> (0.68 to 1.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109 per 1000<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 more per 1000<br/> (35 fewer to 85 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Late genitourinary RT toxicity</b><br/> ≥ Grade II RTOG/EORTC </p> <p>Follow‐up: median 60 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3843<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.05</b><br/> (0.93 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 per 1000<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 more per 1000<br/> (13 fewer to 47 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Overall survival</b> </p> <p>Follow‐up: median 12–108 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="6" valign="top"> <p>8243<br/> (10 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 0.94</b><br/> (0.83 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>905 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 fewer per 1000<br/> (47 fewer to 14 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Intermediate<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>869 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 fewer per 1000<br/> (54 fewer to 17 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>851 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 fewer per 1000<br/> (57 fewer to 19 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Metastasis‐free survival</b> </p> <p>Follow‐up: median 68.4–100.5 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4985<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 1.07</b><br/> (0.65 to 1.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>j</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>981 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 more per 1000<br/> (58 fewer to 19 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Biochemical relapse‐free survival</b> </p> <p>Follow‐up: median 90–108 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>2889<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,k,l</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>HR 0.88</b><br/> (0.68 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>907 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 fewer per 1000<br/> (106 fewer to 25 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Intermediate<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>804 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 fewer per 1000<br/> (134 fewer to 37 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute GU RT toxicity</b><br/> assessed with: ≥ Grade II RTOG/EORTC </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4174<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.03</b><br/> (0.95 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>h</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 more per 1000<br/> (15 fewer to 34 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>EORTIC:</b> European Organisation for Research and Treatment of Cancer; <b>HR:</b> hazard ratio; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>RT:</b> radiation therapy; <b>RTOG:</b> Radiation Therapy Oncology Group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for study limitations (lack of blinding with risk of performance of detection bias).<br/> <sup>b</sup>Downgraded one level for imprecision because there were fewer than 300 events.<br/> <sup>c</sup><a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a> was used for control event rate: a contemporary study that used highly conformal radiation therapy with image guidance in a low‐risk population.<br/> <sup>d</sup><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a> was used for control event rate: a contemporary study that used highly conformal radiation therapy with image guidance in an intermediate‐risk population.<br/> <sup>e</sup><a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a> was used for control event rate: a contemporary study that used highly conformal radiation therapy with image guidance in a population that had 74% of participants with high‐risk prostate cancer.<br/> <sup>f</sup>Downgraded one level because there may have been moderate heterogeneity (I<sup>2</sup> = 76%).<br/> <sup>g</sup>Downgraded one level for imprecision; although it met optimum information size, the 95% confidence interval included both clinically meaningful and clinically insignificant harms.<br/> <sup>h</sup><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a> was used for control event rate: a contemporary source of prospectively collected toxicity data that used highly conformal radiation therapy with image guidance in an intermediate‐risk population.<br/> <sup>i</sup>Downgraded one level for study limitations (lack of blinding with risk of performance of detection bias) and attrition bias.<br/> <sup>j</sup>Control event rate was derived from the included studies for this outcome.<br/> <sup>k</sup>Although there may have been meaningful heterogeneity (P = 0.09, I<sup>2</sup> = 55%), this could be explained by excluding the two studies for which biochemical relapse‐free survival was not a compound endpoint (P = 0.36, I<sup>2</sup> = 0%). For the other studies, biochemical relapse‐free survival was a compound endpoint, incorporating prostate‐specific antigen failure, deaths and salvage therapy.<br/> <sup>l</sup>Downgraded for study limitations (attrition bias). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011462-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011462-sec-0023"></div> <p>The use of hypofractionated external beam radiation therapy (EBRT) regimens for prostate cancer has become an area of interest, due to better understanding of the radiobiology of prostate cancer. Hypofractionated EBRT could potentially improve therapeutic outcome through the use of large‐sized daily fractions (<a href="./references#CD011462-bbs2-0052" title="FowlerJ , ChappellR , RitterM . Is α/β for prostate tumors really low?. International Journal of Radiation Oncology, Biology, Physics2001;50(4):1021‐31. ">Fowler 2001</a>; <a href="./references#CD011462-bbs2-0053" title="FowlerJF . The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncologica (Stockholm, Sweden)2005;44(3):265‐76. ">Fowler 2005</a>). Hypofractionation also offers a reduction in the number of fractions and thus the total treatment duration. This results in a reduction in treatment cost and increased convenience for patients. While conventional fractionation radiation regimens usually employ fractions of 1.8 Gy to 2.0 Gy daily, hypofractionation refers to the delivery of the radiation therapy (RT) dose in a smaller number of treatments than would be used in a traditional dosing scheme. Therefore, the daily fraction size is larger than that given in standard fractionation. Hypofractionated EBRT for prostate cancer has been used clinically for a number of years, particularly in the UK (<a href="./references#CD011462-bbs2-0036" title="CollinsCD ,  Lloyd‐DaviesRW ,  SwanAV . Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique. Clinical Oncology (Royal College of Radiologists (Great Britain))1991;3(3):127‐32. ">Collins 1991</a>). </p> <p>Toxicity to normal tissues is an important consideration in prostate EBRT as the prostate gland lies in close proximity to the rectum, bladder and neurovascular bundles. In radiobiology, the α/β ratio (defined as the dose at which killing of a cell by linear (α) and quadratic (β) components are equal) is used to quantify the fractionation sensitivity of both normal tissues and tumors. It is a theoretical measure of a tissue's predicted response to a dose of radiation, relative to the size of the dose delivered per fraction. The α/β ratio of prostate cancer may be as low as 1.2 Gy, in contrast with higher values of about 10 Gy for many other tumor types (<a href="./references#CD011462-bbs2-0031" title="BentzenSM , RitterMA . The α/β ratio for prostate cancer: what is it, really?. Radiotherapy and Oncology2005;76(1):1‐3. ">Bentzen 2005</a>; <a href="./references#CD011462-bbs2-0034" title="Brenner DJ ,  Hall EJ . Fractionation and protraction for radiotherapy of prostate carcinoma. International Journal of Radiation Oncology, Biology, Physics1999;43(5):1095‐101. ">Brenner 1999</a>; <a href="./references#CD011462-bbs2-0035" title="BrennerDJ , MartinezAA , EdmundsonGK , MitchellC , ThamesHD , ArmourEP . Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late‐responding normal tissue. International Journal of Radiation Oncology, Biology, Physics2002;52(1):6‐13. ">Brenner 2002</a>; <a href="./references#CD011462-bbs2-0045" title="DaşuA , Toma‐DaşuI . Prostate alpha/beta revisited – an analysis of clinical results from 14168 patients. Acta Oncologica (Stockholm, Sweden)2012;51(8):963‐74. ">Daşu 2012</a>; <a href="./references#CD011462-bbs2-0049" title="Duchesne GM ,  Peters LJ . What is the α/β ratio for prostate cancer? Rationale for hypofractionated high‐dose‐rate brachytherapy. International Journal of Radiation Oncology, Biology, Physics1999;44(4):747‐8. ">Duchesne 1999</a>; <a href="./references#CD011462-bbs2-0052" title="FowlerJ , ChappellR , RitterM . Is α/β for prostate tumors really low?. International Journal of Radiation Oncology, Biology, Physics2001;50(4):1021‐31. ">Fowler 2001</a>; <a href="./references#CD011462-bbs2-0071" title="LeborgneF , FowlerJ , LeborgneJH , MezzeraJ . Later outcomes and alpha/beta estimate from hypofractionated conformal three‐dimensional radiotherapy versus standard fractionation for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;82(3):1200‐7. ">Leborgne 2012</a>; <a href="./references#CD011462-bbs2-0111" title="VogeliusIR , BentzenSM . Meta‐analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?. International Journal of Radiation Oncology, Biology, Physics2013;85(1):89‐94. ">Vogelius 2013</a>). Higher α/β ratios mean that tumor response is less dependent on the amount of radiation administered with each fraction, and therefore that a lower radiation dose per treatment can typically be used, in order to limit toxicity to normal tissues. Conversely, if the α/β ratio for prostate cancer is lower than that of the nearby normal tissues, then a therapeutic advantage can be gained by using fewer and larger fractions to improve efficacy in terms of tumor control (<a href="./references#CD011462-bbs2-0053" title="FowlerJF . The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncologica (Stockholm, Sweden)2005;44(3):265‐76. ">Fowler 2005</a>). </p> <p>Quality of life is an important issue when making treatment decisions for men with prostate cancer (<a href="./references#CD011462-bbs2-0092" title="PensonDF , LitwinMS . Quality of life after treatment for prostate cancer. Current Urology Reports2003;4(3):185‐95. [PUBMED: 12756081] ">Penson 2003</a>; <a href="./references#CD011462-bbs2-0094" title="PotoskyAL , DavisWW , HoffmanRM , StanfordJL , StephensonRA , PensonDF , et al. Five‐year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. Journal of the National Cancer Institute2004;96(18):1358‐67. [PUBMED: 15367568] ">Potosky 2004</a>). Concerns have been raised as to the possibility of an increase in acute and late toxicities with these hypofractionated schedules, which may adversely affect quality of life after RT (<a href="./references#CD011462-bbs2-0070" title="KupelianPA , ReddyCA , KleinEA , WilloughbyTR . Short‐course intensity‐modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. International Journal of Radiation Oncology, Biology, Physics2001;51(4):988‐93. ">Kupelian 2001</a>). However, a limited but growing number of hypofractionation trials in prostate cancer have reported acceptable short‐term toxicities and biochemical control, although most have insufficient follow‐up to be sure of the long‐term safety and efficacy of this approach. This review will critically appraise the entire body of evidence to include the most recent trials. If current and future data affirm the efficacy and safety of hypofractionated prostate EBRT, the adoption of such regimens as a standard of care could profoundly influence the future management of clinically localized prostate cancer. </p> <section id="CD011462-sec-0024"> <h3 class="title" id="CD011462-sec-0024">Description of the condition</h3> <p>Prostate cancer is the second most common cause of cancer in men worldwide. In 2018, an estimated 1.6 million new cases of prostate cancer will be diagnosed (19% of all new cancer diagnoses in men) (<a href="./references#CD011462-bbs2-0103" title="SiegelRL , MillerKD , JemalA . Cancer statistics 2018. CA Cancer Clinical Journal2018;768:7‐30. ">Siegel 2018</a>), and there are predictions that by 2030 the number of new cases will almost have doubled (<a href="./references#CD011462-bbs2-0033" title="BrayF , JemalA , GreyN , FerlayJ , FormanD . Global cancer transitions according to the Human Development Index (2008‐2030): a population‐based study. Lancet Oncology2012;13(8):790‐801. ">Bray 2012</a>). Prostate cancer incidence rates are highest in Australia and New Zealand, followed by Northern Europe (<a href="./references#CD011462-bbs2-0054" title="International Agency for Research on Cancer. 27 – Prostate cancer fact sheet. gco.iarc.fr/today/data/factsheets/cancers/27‐Prostate‐fact‐sheet.pdf (accessed 23 February 2010). ">GLOBOCAN 2018</a>). It is estimated that the lifetime risk of being diagnosed with prostate cancer for men living in the US is 11%, with the risk of dying from prostate cancer at 2.5% (<a href="./references#CD011462-bbs2-0084" title="National Cancer Institute. Cancer statistical facts: prostate cancer. seer.cancer.gov/statfacts/html/prost.html (accessed 4 February 2019). ">NCI</a>). </p> <p>EBRT is considered a standard treatment for clinically localized prostate cancer, with cure rates similar to those achieved with surgery (radical prostatectomy) (<a href="./references#CD011462-bbs2-0116" title="WolffRF , RyderS , BossiA , BrigantiA , CrookJ , HenryA , et al. A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. European Journal of Cancer2015;51(16):2345‐67. ">Wolff 2015</a>). Clinically localized prostate cancer is defined as cancer confined to the prostate gland. Using the American Joint Committee on Cancer (AJCC) nomenclature, these tumors are clinical stage T1c (normal digital rectal exam [DRE]), T2 (abnormal DRE but no evidence of disease beyond the prostate gland), T3 (disease extending through the prostate capsule or with seminal vesicle invasion, or both), N0 to Nx (no evidence of spread to regional lymph nodes or regional lymph nodes were not assessed) and M0 (no evidence of metastatic spread) (<a href="./references#CD011462-bbs2-0026" title="American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th Edition. New York (NY): Springer, 2010. ">AJCC 2010</a>). EBRT may be chosen as a treatment option due to patient preference, medical comorbidities precluding surgical management or adverse effect profile. </p> </section> <section id="CD011462-sec-0025"> <h3 class="title" id="CD011462-sec-0025">Description of the intervention</h3> <section id="CD011462-sec-0026"> <h4 class="title">Standard intervention</h4> <p>EBRT is a non‐surgical curative treatment modality for clinically localized prostate cancer, using megavoltage (high‐energy) x‐rays. Typically, EBRT is delivered to a total dose of 70 Gy to 78 Gy in daily fractions (episodes of treatment requiring attendance at a radiation oncology department). The conventional fraction size is 1.8 Gy to 2 Gy, given five days per week, requiring a total of 35 to 39 fractions. This is called conventional fractionation. Curative EBRT for prostate cancer can require daily attendance for close to eight weeks. This can be onerous for the patient, requiring significant time spent on commuting to the treatment facility, and interruption to work and family life. Curative treatments using conventional fractionation are time‐consuming and resource‐intensive which may lengthen delays for other patients. </p> <p>The quality of the RT delivered is important (and confirmed by compliance with rigorous quality assurance [QA]). Delivery of high‐quality RT is associated with improvements in both local control and survival. In head and neck cancer, delivery of poor‐quality RT (plan not compliant with QA requirements) is associated with a 20% decrease in survival and a 29% decrease in locoregional control (<a href="./references#CD011462-bbs2-0093" title="PetersLJ , O'SullivanB , GiraltJ , FitzgeraldTJ , TrottiA , BernierJ , et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. Journal of Clinical Oncology2010;28(18):2996‐3001. ">Peters 2010</a>). </p> </section> <section id="CD011462-sec-0027"> <h4 class="title">Experimental intervention</h4> <p>If EBRT is delivered in larger fraction sizes (greater than 2 Gy per fraction), this is called hypofractionation. When hypofractionation is used, courses of EBRT are shorter, with fewer fractions and participant attendances required. This approach has been validated in the treatment of early breast cancer (<a href="./references#CD011462-bbs2-0104" title="The START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology2008;9(4):331‐41. ">START A 2008</a>; <a href="./references#CD011462-bbs2-0105" title="The START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet2008;371(9618):1098‐107. ">START B 2008</a>; <a href="./references#CD011462-bbs2-0113" title="WhelanT , MacKenzieR , JulianJ , LevineM , ShelleyW , GrimardL , et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node‐negative breast cancer. Journal of the National Cancer Institute2002;94(15):1143‐50. ">Whelan 2002</a>), and in the palliative treatment of lung cancer (<a href="./references#CD011462-bbs2-0072" title="LesterJF , MacbethF , ToyE , ColesB . Palliative radiotherapy regimens for non‐small cell lung cancer. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD002143.pub2] ">Lester 2006</a>), and bone metastases (<a href="./references#CD011462-bbs2-0078" title="McQuayHJ , CollinsS , CarrollD , MooreRA . Radiotherapy for the palliation of painful bone metastases. Cochrane Database of Systematic Reviews1999, Issue 3. [DOI: 10.1002/14651858.CD001793] ">McQuay 1999</a>; <a href="./references#CD011462-bbs2-0086" title="NielsenOS , BentzenSM , SandbergE , GadebergCC , TimothyAR . Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiotherapy and Oncology1998;47(3):233‐40. ">Nielsen 1998</a>; <a href="./references#CD011462-bbs2-0095" title="PriceP , HoskinPJ , EastonD , AustinD , PalmerSG , YarnoldJR . Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiotherapy and Oncology1986;6(4):247‐55. ">Price 1986</a>). Hypofractionated EBRT must be shown to achieve similar tumor control to conventional EBRT without increased toxicity before it can become an acceptable approach for men with clinically localized prostate cancer. </p> <p>The aim of hypofractionated EBRT for men with prostate cancer is to deliver a tumoricidal dose in fewer fractions, without increasing toxicity (especially rectal, urethral and bladder toxicity). </p> <section id="CD011462-sec-0028"> <h5 class="title">Acute effects of radiation therapy</h5> <p>Acute effects (early adverse effects of RT) are complications or side effects that occur within three months after completing treatment. The cells of early responding tissues (with short cell cycle times measured in days, e.g. the intestinal mucosa) express toxicity quickly. Tissues that are particularly susceptible to early effects, which influence treatment tolerability for men with prostate cancer, include the rectum (expressed as rectal urgency and frequency) and bladder (expressed as frequency and urgency). Cells with short cell cycle times have a significant linear component to their cell survival curves, and total dose rather than fraction size determines the severity of early effects. Acute effects are less dependent on fraction size than late effects. Thus, for these cells, we expect similar rates or severity of acute toxicity when comparing hypofractionation to conventional fractionation regimens, provided both deliver the same total dose over the same treatment duration. However, the severity of early toxicity can also be dependent on the dose density of RT. This means that a similar total dose delivered over a much shorter treatment duration can result in more severe toxicities to the early reacting tissues surrounding the prostate. This severe early toxicity may predispose to the development of subsequent late toxicity, called 'consequential' late toxicity (<a href="./references#CD011462-bbs2-0050" title="DörrW , HendryJH . Consequential late effects in normal tissues. Radiotherapy and Oncology2001;61(3):223‐31. [PUBMED: 11730991] ">Dörr 2001</a>). </p> </section> <section id="CD011462-sec-0029"> <h5 class="title">Late effects of radiation therapy</h5> <p>Late effects of RT are complications present or persisting three months (90 days) or more after the end of treatment. Late effects (side effects seen in tissues with long cell cycle times) are more sensitive to the increase in fraction size. When prostate cancer is treated with EBRT, the tissues particularly susceptible to late effects include the rectum, bladder and urethra. Unwanted late effects in these tissues can include rectal ulceration, urethral stricture or bladder contracture. Hypofractionation may result in increased late and long‐term effects of radiation on these tissues, thus lowering the therapeutic ratio (<a href="./references#CD011462-bbs2-0034" title="Brenner DJ ,  Hall EJ . Fractionation and protraction for radiotherapy of prostate carcinoma. International Journal of Radiation Oncology, Biology, Physics1999;43(5):1095‐101. ">Brenner 1999</a>). </p> </section> </section> </section> <section id="CD011462-sec-0030"> <h3 class="title" id="CD011462-sec-0030">How the intervention might work</h3> <p>Normal tissues usually have low α/β ratios, which is consistent with a greater capacity for repair between fractions. This results in greater relative sparing with small fraction sizes than for tumors, with their typically higher α/β ratios. However, tumors with low α/β ratios are also more sensitive to fraction size, so fraction sizes more than 2.0 Gy may offer a therapeutic advantage in terms of increased tumor control. Thus, the potential radiobiologic advantage for hypofractionated prostate EBRT is related to the estimated range of the α/β ratio of prostate cancer. </p> <p>The α/β ratio of prostate cancer is estimated to be between 1.4 Gy and 1.86 Gy (<a href="./references#CD011462-bbs2-0031" title="BentzenSM , RitterMA . The α/β ratio for prostate cancer: what is it, really?. Radiotherapy and Oncology2005;76(1):1‐3. ">Bentzen 2005</a>; <a href="./references#CD011462-bbs2-0034" title="Brenner DJ ,  Hall EJ . Fractionation and protraction for radiotherapy of prostate carcinoma. International Journal of Radiation Oncology, Biology, Physics1999;43(5):1095‐101. ">Brenner 1999</a>; <a href="./references#CD011462-bbs2-0035" title="BrennerDJ , MartinezAA , EdmundsonGK , MitchellC , ThamesHD , ArmourEP . Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late‐responding normal tissue. International Journal of Radiation Oncology, Biology, Physics2002;52(1):6‐13. ">Brenner 2002</a>; <a href="./references#CD011462-bbs2-0045" title="DaşuA , Toma‐DaşuI . Prostate alpha/beta revisited – an analysis of clinical results from 14168 patients. Acta Oncologica (Stockholm, Sweden)2012;51(8):963‐74. ">Daşu 2012</a>; <a href="./references#CD011462-bbs2-0049" title="Duchesne GM ,  Peters LJ . What is the α/β ratio for prostate cancer? Rationale for hypofractionated high‐dose‐rate brachytherapy. International Journal of Radiation Oncology, Biology, Physics1999;44(4):747‐8. ">Duchesne 1999</a>; <a href="./references#CD011462-bbs2-0052" title="FowlerJ , ChappellR , RitterM . Is α/β for prostate tumors really low?. International Journal of Radiation Oncology, Biology, Physics2001;50(4):1021‐31. ">Fowler 2001</a>; <a href="./references#CD011462-bbs2-0071" title="LeborgneF , FowlerJ , LeborgneJH , MezzeraJ . Later outcomes and alpha/beta estimate from hypofractionated conformal three‐dimensional radiotherapy versus standard fractionation for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;82(3):1200‐7. ">Leborgne 2012</a>; <a href="./references#CD011462-bbs2-0080" title="MiralbellR , RobertsSA , ZubizarretaE , HendryJH . Dose‐fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional data‐sets: α/β = 1.4 (0.9–2.2) Gy. International Journal of Radiation Oncology, Biology, Physics2012;82(1):e17‐24. [PUBMED: 21324610] ">Miralbell 2012</a>; <a href="./references#CD011462-bbs2-0096" title="Proust‐LimaC , TaylorJM , SécherS , SandlerH , KestinL , PicklesT , et al. Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation therapy alone using a post‐treatment repeated‐measures model for PSA dynamics. International Journal of Radiation Oncology, Biology, Physics2011;79(1):195‐201. [PUBMED: 20381268] ">Proust‐Lima 2011</a>; <a href="./references#CD011462-bbs2-0111" title="VogeliusIR , BentzenSM . Meta‐analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?. International Journal of Radiation Oncology, Biology, Physics2013;85(1):89‐94. ">Vogelius 2013</a>). This suggests that prostate cancer may be more sensitive to fraction size than the late‐responding organs at risk (OAR), as the α/β ratio for late complications in the rectum or bladder is estimated to be about 3 Gy (<a href="./references#CD011462-bbs2-0058" title="HeemsbergenWD , PeetersST , KoperPC , HoogemanMS , LebesqueJV . Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage. International Journal of Radiation Oncology, Biology, Physics2006;66(1):3‐10. ">Heemsbergen 2006</a>; <a href="./references#CD011462-bbs2-0109" title="TuckerSL , ThamesHD , MichalskiJM , BoschWR , MohanR , WinterK , et al. Estimation of α/β for late rectal toxicity based on RTOG 94‐06. International Journal of Radiation Oncology, Biology, Physics2011;81(2):600‐5. ">Tucker 2011</a>). As such, hypofractionated prostate EBRT is of increasing interest due to this potential improvement in the therapeutic ratio. </p> <p>There are other potential advantages to hypofractionation. These include the participant‐related benefits of decreased overall treatment time, increased convenience and the treatment facility benefits of increased participant capacity because less machine time is used treating prostate cancer patients. </p> <p>However, concerns have been raised as to the efficacy (tumor control) and the safety (acute and late toxicity) of these hypofractionated schedules. </p> </section> <section id="CD011462-sec-0031"> <h3 class="title" id="CD011462-sec-0031">Why it is important to do this review</h3> <p>The optimum fraction size for the treatment of clinically localized prostate cancer with EBRT is unknown; a systematic review and meta‐analysis may answer this question. One systematic review with a search date of 2012 identified 16 randomized controlled trials (RCTs), which included hypofractionated prostate EBRT (<a href="./references#CD011462-bbs2-0118" title="ZaorskyNG , OhriN , ShowalterTN , DickerAP , DenRB . Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treatment Reviews2013;39(7):728‐36. ">Zaorsky 2013</a>). Their meta‐analysis used surrogate outcomes as primary endpoints, but these outcomes have little relevance for consumers and clinicians. Another systematic review of prostate EBRT with a search date of 2011 found four RCTs examining fraction size in prostate cancer, but analyzed cohort studies and RCTs together (<a href="./references#CD011462-bbs2-0029" title="BannuruRR , DvorakT , ObadanN , YuWW , PatelK , ChungM , et al. Comparative evaluation of radiation treatments for clinically localized prostate cancer: an updated systematic review. Annals of Internal Medicine2011;155(3):171‐8. ">Bannuru 2011</a>). </p> <p>Our systematic review and meta‐analysis used a comprehensive search strategy, rigorous systematic review methodology, focused on RCTs, patient‐important outcomes and used GRADE to rate the evidence certainty. This review includes both disease and self‐reported outcomes of hypofractionation, and assessed the quality of RT delivered. If shorter EBRT courses can provide equivalent outcomes in men, this approach may reduce healthcare costs and medical personnel workload through the more efficient use of radiation services, and may improve participant experience and convenience with a more expedient treatment. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011462-sec-0032" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011462-sec-0032"></div> <p>To assess the effects of hypofractionated external beam radiation therapy compared to conventionally fractionated external beam radiation therapy for men with clinically localized prostate cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011462-sec-0033" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011462-sec-0033"></div> <section id="CD011462-sec-0034"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011462-sec-0035"> <h4 class="title">Types of studies</h4> <p>We only considered randomized controlled comparisons for inclusion. We excluded cluster‐randomized trials and cross‐over trials. Studies were included regardless of publication language or publication status. </p> </section> <section id="CD011462-sec-0036"> <h4 class="title">Types of participants</h4> <p>Men with histologically confirmed, clinically localized prostate adenocarcinoma (AJCC T1 to T3N0M0) (<a href="./references#CD011462-bbs2-0026" title="American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th Edition. New York (NY): Springer, 2010. ">AJCC 2010</a>). Biopsies and transurethral resection of the prostate (TURP) were permitted, but we excluded men who had a radical prostatectomy. We included studies that included subsets of relevant participants if the data for the relevant subsets were reported separately, but we only included the data for the relevant subsets. </p> </section> <section id="CD011462-sec-0037"> <h4 class="title">Types of interventions</h4> <p>We investigated the comparison of hypofractionated versus conventionally fractionated RT. </p> <p><b>Intervention:</b> hypofractionated EBRT to the prostate plus or minus the seminal vesicles using hypofractionation (greater than 2 Gy per fraction) </p> <p><b>Comparator:</b> conventionally fractionated EBRT to the prostate plus or minus the seminal vesicles delivered using standard fractionation (1.8 Gy to 2 Gy per fraction). </p> <p>EBRT could be given using intensity‐modulated radiation therapy (IMRT) (high‐precision, highly conformal RT delivered by linear accelerator, advanced arc therapy, tomotherapy or novel techniques) or conformal radiation therapy (3DCRT) (planned using computerized tomography to increase precision and conformity) or other novel RT techniques, provided that the same technique was used in each arm. The use of image‐guided radiation therapy (IGRT) (using fiducial markers or other techniques) was permitted as long as this was equally applied to each arm. The use of techniques to reduce acute and late toxicity (e.g. bladder and bowel protocols to reduce positional variability of OAR) were permitted, as long as these were equally applied to both arms. </p> <p>Concomitant interventions (such as androgen deprivation, chemotherapy or other therapies) had to be the same in both the intervention and comparator groups to establish fair comparisons. </p> <p>The dose prescribed and the prescription point or volume were to be clearly described (<a href="./references#CD011462-bbs2-0065" title="International Commission on Radiation Units and Measurements. ICRU report 62: prescribing, recording, and reporting photon beam therapy (supplement to ICRU report 50). Bethesda (MD): International Commission on Radiation Units and Measurements, 1999. ">ICRU 1999</a>). </p> <p>If a trial included multiple arms, we planned to include any arm that met the inclusion criteria in the review. </p> <p><b>Exclusion criteria:</b> we excluded studies using brachytherapy or protons. RT to the pelvic nodes was not permitted </p> <p>The minimum duration of the intervention was the length of the shortest hypofractionated RT treatment course over which the intervention was conducted. Minimum duration of follow‐up was five years for cancer‐related outcomes, one month for acute RT toxicity and three months for late RT toxicity outcomes. </p> </section> <section id="CD011462-sec-0038"> <h4 class="title">Types of outcome measures</h4> <p>We did not exclude trials because one or several of our primary or secondary outcome measures were not reported in the publication. If none of our primary or secondary outcomes were reported, we did not include this trial but provided some basic information in an additional table. </p> <section id="CD011462-sec-0039"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011462-list-0001"> <li> <p> Prostate cancer‐specific survival [PC‐SS] measured from randomization date to date of prostate cancer death. </p> </li> <li> <p>Late gastrointestinal (GI) radiation therapy toxicity (occurring or lasting more than 90 days after RT is completed) Grade II Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer (RTOG/EORTC) or greater toxicity. </p> </li> <li> <p>Late gastrointestinal (GU) radiation therapy toxicity (occurring or lasting more than 90 days after RT is completed) Grade II RTOG/EORTC RT or greater toxicity. </p> </li> </ul> </p> </section> <section id="CD011462-sec-0040"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011462-list-0002"> <li> <p>Overall survival measured from randomization date to date of death.</p> </li> <li> <p>Metastasis‐free survival measured from randomization date to date of diagnosis of metastatic disease. </p> </li> <li> <p>Biochemical relapse‐free survival (BR‐FS) assessed using the Phoenix definition of a rise of 2 ng/mL or more above the prostate‐specific antigen (PSA) nadir after EBRT with or without hormonal therapy (<a href="./references#CD011462-bbs2-0099" title="RoachM3rd , HanksG , ThamesHJr , SchellhammerP , ShipleyWU , SokolGH , et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG‐ASTRO Phoenix Consensus Conference. International Journal of Radiation Oncology, Biology, Physics2006;65(4):965‐74. ">Roach 2006</a>). </p> </li> <li> <p>Acute radiation therapy gastrointestinal toxicity. Acute effects of RT were those effects occurring during and within 90 days of starting RT. We used individual protocol‐based definitions. </p> </li> <li> <p>Acute radiation therapy genitourinary (GU) toxicity. Acute effects of RT were those effects occurring during and within 90 days of starting RT. We used individual protocol‐based definitions. </p> </li> <li> <p>Late radiation‐induced malignancy</p> </li> <li> <p>Health‐related quality of life (using trial‐specific instruments) at five years and 10 years. </p> </li> </ul> </p> <section id="CD011462-sec-0041"> <h6 class="title">Method and timing of outcome measurement</h6> <p>Inclusion criteria required a minimum of 60 months' follow‐up from baseline. If multiple measures were available for a particular outcome, we extracted the measures closest to 60 months and 120 months for cancer‐related outcomes. For late RT toxicity, we extracted the measure closest to 60 months. For acute RT toxicity, we extracted the measure closest to three months. For quality of life measures, we extracted the measure closest to 60 months. </p> </section> <section id="CD011462-sec-0042"> <h6 class="title">Outcomes for 'Summary of findings' table</h6> <p> <ul id="CD011462-list-0003"> <li> <p>PC‐SS.</p> </li> <li> <p>Late radiation therapy toxicity (specifically late gastrointestinal toxicity).</p> </li> <li> <p>Overall survival.</p> </li> <li> <p>Metastasis‐free survival.</p> </li> <li> <p>Biochemical relapse‐free survival.</p> </li> <li> <p>Acute radiation therapy GU toxicity.</p> </li> <li> <p>Health‐related quality of life.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD011462-sec-0043"> <h3 class="title">Search methods for identification of studies</h3> <p>We performed comprehensive searches from database inception and did not limit the searches by language or publication status. We reran all searches within three months prior to publication and screened the results for eligible studies. If we detected additional relevant key words during any electronic or other searches, we modified the electronic search strategies to incorporate these terms and would document the changes to the search strategy. </p> <section id="CD011462-sec-0044"> <h4 class="title">Electronic searches</h4> <p>We searched <i>the Cochrane Library</i> (see <a href="./appendices#CD011462-sec-0154">Appendix 1</a> for search strategy), which is composed of several databases including the Cochrane Central Register of Controlled Trials (CENTRAL), Database of Abstracts of Reviews of Effects (DARE) and Health Technology Assessment (HTA) database to 2 April 2018. We conducted a comprehensive search of MEDLINE (Ovid; see <a href="./appendices#CD011462-sec-0155">Appendix 2</a> for search strategy) from 1974 to 15 March 2019, and Embase (Ovid; see <a href="./appendices#CD011462-sec-0156">Appendix 3</a> for search strategy) from 1946 to 15 March 2019. </p> <p>We searched the PubMed database (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>) using the MEDLINE search strategy; however, we limited the search to non‐MEDLINE records (by adding NOT MEDLINE[sb] to the search line). We searched the Latin American and Caribbean Health Sciences Literature Database (LILACS; <a href="http://lilacs.bvsalud.org/en/" target="_blank">lilacs.bvsalud.org/en/</a>) using the search strategy described in <a href="./appendices#CD011462-sec-0157">Appendix 4</a> (search date 15 March 2019). We searched several grey literature databases (<a href="http://www.opengrey.eu" target="_blank">www.opengrey.eu/</a>; <a href="http://www.greylit.org/" target="_blank">www.greylit.org/</a>; <a href="http://www.oclc.org/oaister.en.html" target="_blank">www.oclc.org/oaister.en.html</a>) using terms based on the MEDLINE search strategy. </p> <p>We searched the following trials registries.</p> <p> <ul id="CD011462-list-0004"> <li> <p>International Standard Randomized Controlled Trial Number (ISRCTN) Register to 15 March 2019 (<a href="http://www.controlled-trials.com/isrctn/" target="_blank">www.controlled‐trials.com/isrctn/</a>; see <a href="./appendices#CD011462-sec-0158">Appendix 5</a> for search strategy). </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) search portal to 15 March 2019 (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>; see <a href="./appendices#CD011462-sec-0159">Appendix 6</a> for search strategy). </p> </li> <li> <p>EORTC to 15 March 2019 (<a href="http://www.eortc.be" target="_blank">www.eortc.be</a>; see <a href="./appendices#CD011462-sec-0160">Appendix 7</a> for search strategy). </p> </li> <li> <p>National Cancer Institute (NCI) Clinical Trials Search Form to 15 March 2019 (<a href="http://www.cancer.gov/clinicaltrials/search" target="_blank">www.cancer.gov/clinicaltrials/search</a>; see <a href="./appendices#CD011462-sec-0161">Appendix 8</a> for search strategy). </p> </li> <li> <p>Australian New Zealand Clinical Trials Registry to 15 March 2019 (ANZCTR; <a href="http://www.anzctr.org.au/" target="_blank">www.anzctr.org.au/</a>; see <a href="./appendices#CD011462-sec-0162">Appendix 9</a> for search strategy). </p> </li> </ul> </p> <p>We also searched the National Guideline Clearinghouse (<a href="http://www.guideline.gov" target="_blank">www.guideline.gov</a>; see <a href="./appendices#CD011462-sec-0163">Appendix 10</a> for search strategy) to 3 April 2018. </p> </section> <section id="CD011462-sec-0045"> <h4 class="title">Searching other resources</h4> <section id="CD011462-sec-0046"> <h5 class="title">Handsearching</h5> <p>We searched conference proceedings to identify eligible trials from:</p> <p> <ul id="CD011462-list-0005"> <li> <p>European Society for Radiotherapy and Oncology (ESTRO) (<a href="http://www-clinicalkey-com-au.ezproxy.library.uq.edu.au/#!/browse/journal/01678140/latest" target="_blank">www‐clinicalkey‐com‐au.ezproxy.library.uq.edu.au/#!/browse/journal/01678140/latest</a>) (searched to 2018); </p> </li> <li> <p>American Urological Association (AUA) (<a href="https://www-clinicalkey-com-au.ezproxy.library.uq.edu.au/#!/browse/journal/00225347/latest" target="_blank">www‐clinicalkey‐com‐au.ezproxy.library.uq.edu.au/#!/browse/journal/00225347/latest</a>); </p> </li> <li> <p>European Association of Urology (EAU).</p> </li> </ul> </p> <p>We handsearched from 2008 to 2018.</p> <p>We tried to identify other potentially eligible trials or ancillary publications by searching the reference lists of included trials, systematic reviews, meta‐analyses and health technology assessment reports. We contacted authors of included trials to identify additional information on the retrieved trials and trials that we may have missed. </p> </section> </section> </section> <section id="CD011462-sec-0047"> <h3 class="title" id="CD011462-sec-0047">Data collection and analysis</h3> <section id="CD011462-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MLJ, BH) independently scanned the abstract, title, or both, of every record we retrieved in the literature searches, to determine which trials to assess further. We obtained the full‐text of all potentially relevant records (we removed duplicate studies using <a href="./references#CD011462-bbs2-0038" title="Veritas Health Innovation. Covidence. Version accessed 6 June 2017. Melbourne, Australia: Veritas Health Innovation. ">Covidence</a>). We resolved any disagreements through consensus or by recourse to a third review author (MJ). If we could not resolve a disagreement, we planned to categorize the trial as a 'study awaiting classification' and contact the trial authors for clarification. The <a href="./references#CD011462-sec-0174" title="">Characteristics of excluded studies</a> table documented reasons for the exclusion of studies which might have reasonably be expected to be included. We presented an adapted PRISMA flow diagram to show the process of trial selection (<a href="./references#CD011462-bbs2-0073" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic and meta‐analyses of studies that evaluate interventions: explanation and elaboration. PLoS Medicine2009;6(7):1‐28. ">Liberati 2009</a>). </p> </section> <section id="CD011462-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>For trials that fulfilled our inclusion criteria, two review authors (MLJ, BH) independently extracted key participant and intervention characteristics. We resolved any disagreements by discussion or, if required, by consultation with a third review author (MJ). </p> <p>We provide information about potentially relevant ongoing trials, including the trial identifier in the <a href="./references#CD011462-sec-0176" title="">Characteristics of ongoing studies</a> table. </p> <p>We requested the protocol for each included trial and reported primary, secondary and other outcomes in comparison with data in publications in a joint appendix if it was received. </p> <section id="CD011462-sec-0050"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents or multiple reports of a primary trial, we maximized the information yield by collating all available data and used the most complete data set aggregated across all known publications. We listed duplicate publications, companion documents, multiple reports of a primary trial and trial documents of included trials (such as trial registry information) as secondary references under the study ID of the included trial. Furthermore, we listed duplicate publications, companion documents, multiple reports of a trial and trial documents of excluded trials (such as trial registry information) as secondary references under the study ID of the excluded trial. </p> </section> <section id="CD011462-sec-0051"> <h5 class="title">Data from clinical trial registers</h5> <p>In case data of included trials are available as study results in clinical trial registers such as <a href="http://ClinicalTrials.gov" target="_blank">ClinicalTrials.gov</a> or similar sources, we made full use of this information and extracted data. If there was also a full publication of the trial, we collated and critically appraised all available data. If an included trial was marked as a completed study in a clinical trial register but no additional information was available, we would have added this trial to the <a href="./references#CD011462-sec-0175" title="">Characteristics of studies awaiting classification</a> table. </p> <p>We constructed and piloted a data extraction form for two studies. Three review authors (MJ, BH, FS) independently performed data extraction, with disagreements resolved by discussion. We entered data into Review Manager 5 for analysis (<a href="./references#CD011462-bbs2-0097" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). Where data were limited, we requested further information from the authors of the original studies. For each study, we aimed to collect and report the following details in the <a href="./references#CD011462-sec-0173" title="">Characteristics of included studies</a> table: </p> <p> <ul id="CD011462-list-0006"> <li> <p>study design;</p> </li> <li> <p>inclusion and exclusion criteria for the study;</p> </li> <li> <p>setting;</p> </li> <li> <p>accrual dates;</p> </li> <li> <p>number of participants in each study and in each intervention/comparator group;</p> </li> <li> <p>median age and range;</p> </li> <li> <p>stage;</p> </li> <li> <p>radiation dose;</p> </li> <li> <p>dose per fraction;</p> </li> <li> <p>number of fractions;</p> </li> <li> <p>QA procedures performed (to investigate the quality of radiation delivered);</p> </li> <li> <p>type of image guidance used;</p> </li> <li> <p>use of androgen deprivation;</p> </li> <li> <p>details of outcomes relevant to this review that were assessed in the study, including how measured, the times at which they were measured and any subgroups relevant to this review that were assessed for the outcomes; </p> </li> <li> <p>study funding sources;</p> </li> <li> <p>declarations of interest for study authors.</p> </li> </ul> </p> <p>We converted the radiation doses to the equivalent dose in 2 Gy fractions (EQD<sup>2</sup>) (<a href="./references#CD011462-bbs2-0075" title="MaciejewskiB , TaylorJM , WithersHR . Alpha/beta value and the importance of size of dose per fraction for late complications of the supraglottic larynx. Radiotherapy and Oncology1986;7:323‐6. ">Maciejewski 1986</a>; <a href="./references#CD011462-bbs2-0115" title="WithersHR , ThamesHDJr , PetersLJ . A new isoeffect curve for change in dose per fraction. Radiotherapy and Oncology1983;1(2):187‐91. ">Withers 1983</a>), using the formula: EQD<sup>2</sup> = D (d + (α/β)/(2 + α/β), where D = total dose, d = dose per fraction and α/β = Gy (<a href="./references#CD011462-bbs2-0066" title="JoinerMC , Van derKogelAJ . The linear‐quadratic approach to fractionation and calculation of isoeffect relationships. Basic Clinical Radiobiology. 1st Edition. New York (NY): Oxford University Press, 1997:106‐12. ">Joiner 1997</a>). This was to facilitate comparison of radiation doses given at a different dose per fraction. No time correction factor was used. </p> <p>Two studies reported data for biochemical relapse as first event data, which meant we were unable to report these outcomes (<a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>; <a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a>). One study reported data for distant metastases as first event data, which meant we were unable to report these outcomes (<a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a>). </p> <p>We used the methods according to a spreadsheet developed by Matthew Sydes (<a href="./references#CD011462-bbs2-0087" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>; <a href="./references#CD011462-bbs2-0108" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>) to derive log HR and standard error (SE) where necessary. </p> <p> <ul id="CD011462-list-0007"> <li> <p>We used method three (where HR and 95% CI available)(<a href="./references#CD011462-bbs2-0108" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>) to derive Log HR and SE: </p> </li> </ul> <ul class="plain" id="CD011462-list-0008"> <li> <ul id="CD011462-list-0009"> <li> <p>metastasis‐free survival (<a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>). </p> </li> </ul> </li> </ul> <ul id="CD011462-list-0010"> <li> <p>We used method four (where HR number of events in each arm are available and randomization is 1:1)(<a href="./references#CD011462-bbs2-0108" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>) to derive log HR and SE for: </p> </li> </ul> <ul class="plain" id="CD011462-list-0011"> <li> <ul id="CD011462-list-0012"> <li> <p>overall survival (<a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a>); </p> </li> <li> <p>PC‐SS (<a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a>); </p> </li> <li> <p>metastasis‐free survival (<a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>). </p> </li> </ul> </li> </ul> <ul id="CD011462-list-0013"> <li> <p>We used method 11 (where data for curve with numbers at risk are available) (<a href="./references#CD011462-bbs2-0114" title="WilliamsonPR , SmithCT , HuttonJL , MarsonAG . Aggregate data meta‐analysis with time‐to‐event outcomes. Statistics in Medicine2002;21(22):3337‐51. ">Williamson 2002</a>) to derive log HR and SE for: </p> </li> </ul> <ul class="plain" id="CD011462-list-0014"> <li> <ul id="CD011462-list-0015"> <li> <p>overall survival (<a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>; <a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a>); </p> </li> <li> <p>PC‐SS (<a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>). </p> </li> </ul> </li> </ul> <ul id="CD011462-list-0016"> <li> <p>We derived log HR and SE by using the Review Manager 5 calculator for (<a href="./references#CD011462-bbs2-0097" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>): </p> </li> </ul> <ul class="plain" id="CD011462-list-0017"> <li> <ul id="CD011462-list-0018"> <li> <p>overall survival (<a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>; <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>; <a href="./references#CD011462-bbs2-0008" title="NorkusD , MillerA , KurtinaitisJ , HaverkampU , PopovS , ProttFJ . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional external‐beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlentherapie Onkologie2009;185(11):715‐21. [DOI: 10.1007/s00066‐009‐1982‐z] NorkusD , MillerA , PlieskieneA , JanulionisE , ValukaKV . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional conformal external beam radiotherapy for localized prostate adenocarcinoma: a report on the first‐year biochemical response. Medicina (Kaunas)2009;45(6):469‐75. NorkusD , ValuckasKP , MillerA , PlieskienėA , KurtinaitisJ . Safety investigation of hypofractionated prostate gland radiotherapy [Neišplitusio priešinės liaukos vėžio hipofrakcionuoto spindulinio gydymo saugumo tyrimas]. Medicina2005;41(12):1035. ">Norkus 2009</a>); </p> </li> <li> <p>BR‐FS (<a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a>); </p> </li> <li> <p>distant metastasis‐free survival (<a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>); </p> </li> <li> <p>PC‐SS (<a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>). </p> </li> </ul> </li> </ul> <ul id="CD011462-list-0019"> <li> <p>We used method 9 (where P value, total number of events and number randomized were available)(<a href="./references#CD011462-bbs2-0108" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>) to derive Log HR and SE for: </p> </li> </ul> <ul class="plain" id="CD011462-list-0020"> <li> <ul id="CD011462-list-0021"> <li> <p>overall survival (<a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>); </p> </li> <li> <p>BR‐FS (<a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>). </p> </li> </ul> </li> </ul> </p> <p>Information about potentially relevant studies (including the study identifier) is provided in the <a href="./references#CD011462-sec-0176" title="">Characteristics of ongoing studies</a> table. </p> </section> </section> <section id="CD011462-sec-0052"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MJ, BH) independently assessed the risk of bias of each included trial. We resolved any disagreements by consensus or by consultation with a third review author (ML). In case of disagreement, we consulted the rest of the group and made a judgment based on consensus. If adequate information was not available from trial authors, trial protocols or both, we contacted trial authors for missing data on risk of bias items. </p> <p>We used the Cochrane 'Risk of bias' assessment tool and judged 'Risk of bias' criteria as having low, high or unclear risk (<a href="./references#CD011462-bbs2-0062" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> according to the criteria and associated categorizations contained therein (<a href="./references#CD011462-bbs2-0062" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>We assessed the following domains for risk of bias.</p> <section id="CD011462-sec-0053"> <h5 class="title">Random sequence generation (selection bias)</h5> <p>For each included trial we described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p> <ul id="CD011462-list-0022"> <li> <p>Low risk of bias: the trial authors achieved sequence generation using computer‐generated random numbers or a random numbers table. Drawing of lots, tossing a coin, shuffling cards or envelopes, and throwing dice were deemed adequate if an independent person performed this who was not otherwise involved in the trial. We considered the use of the minimization technique as equivalent to being random. </p> </li> <li> <p>Unclear risk of bias: insufficient information about the sequence generation process.</p> </li> <li> <p>High risk of bias: the sequence generation method was non‐random or quasi‐random (e.g. sequence generated by odd or even date of birth; sequence generated by some rule based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number; allocation by judgment of the clinician; allocation by preference of the participant; allocation based on the results of a laboratory test or a series of tests; or allocation by availability of the intervention). </p> </li> </ul> </p> </section> <section id="CD011462-sec-0054"> <h5 class="title">Allocation concealment (selection bias due to inadequate concealment of allocation prior to assignment) </h5> <p>We described for each included trial the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of or during recruitment, or changed after assignment. </p> <p> <ul id="CD011462-list-0023"> <li> <p>Low risk of bias: central allocation (including telephone, interactive voice‐recorder, web‐based and pharmacy‐controlled randomization); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes. </p> </li> <li> <p>Unclear risk of bias: insufficient information about the allocation concealment.</p> </li> <li> <p>High risk of bias: using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards; alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure. </p> </li> </ul> </p> <p>We also evaluated trial baseline data to incorporate assessment of baseline imbalance into the risk of bias judgment for selection bias (<a href="./references#CD011462-bbs2-0037" title="CorbettMS , HigginsJP , WoolacottNF . Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool. Research Synthesis Methods2014;5:79‐85. ">Corbett 2014</a>). Chance imbalances may also affect judgments on the risk of attrition bias. In case of unadjusted analyses, we distinguished between studies we rated as at low risk of bias on the basis of both randomization methods and baseline similarity, and studies we rated at low risk of bias on the basis of baseline similarity alone (<a href="./references#CD011462-bbs2-0037" title="CorbettMS , HigginsJP , WoolacottNF . Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool. Research Synthesis Methods2014;5:79‐85. ">Corbett 2014</a>). We reclassified judgments of unclear, low or high risk of selection bias as specified in <a href="./appendices#CD011462-sec-0155">Appendix 2</a>. </p> </section> <section id="CD011462-sec-0055"> <h5 class="title">Blinding of participants and personnel (performance bias due to knowledge of the allocated interventions by participants and personnel during the trial) (for subjective and objective outcomes) </h5> <p>We evaluated the risk of detection bias separately for each outcome (<a href="./references#CD011462-bbs2-0064" title="HróbjartssonA , ThomsenAS , EmanuelssonF , TendalB , HildenJ , BoutronI , et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal2013;185(4):E201‐11. ">Hróbjartsson 2013</a>). We noted whether endpoints were self‐reported, investigator‐assessed or adjudicated outcome measures (see below). </p> <p> <ul id="CD011462-list-0024"> <li> <p>Low risk of bias: blinding of participants and key study personnel was ensured, and it was unlikely that the blinding could have been broken; no blinding or incomplete blinding, but we judged that the outcome was unlikely to have been influenced by lack of blinding. </p> </li> <li> <p>Unclear risk of bias: insufficient information about the blinding of participants and study personnel; the trial does not address this outcome. </p> </li> <li> <p>High risk of bias: no blinding or incomplete blinding, and the outcome was likely to have been influenced by lack of blinding; blinding of trial participants and key personnel attempted, but likely that the blinding could have been broken, and the outcome was likely to be influenced by lack of blinding. </p> </li> </ul> </p> </section> <section id="CD011462-sec-0056"> <h5 class="title">Risk of performance bias by outcome</h5> <p>PC‐SS: this investigator‐assessed outcome was not at risk of performance bias in the absence of blinding. </p> <p>Late GI RT and GU RT toxicity: these self‐assessed or investigator‐assessed outcomes were at risk of performance bias if, for example, trial participants were seen more frequently (in the knowledge that they were having experimental treatment), bias could have been introduced in the absence of blinding. </p> <p>Overall survival: we felt this investigator‐assessed outcome was not at risk of performance bias. </p> <p>Distant metastases‐free survival (DM‐FS): this outcome was at risk of performance bias, for example, if trial participants had more frequent investigations (in the knowledge that they were having experimental treatment), bias could have been introduced in the absence of blinding. </p> <p>BR‐FS: this investigator‐assessed outcome was at risk of performance bias, for example, if trial participants had more frequent investigations (in the knowledge that they were having experimental treatment), bias could have been introduced in the absence of blinding. </p> <p>Acute GI RT and GU RT toxicity: these self‐assessed or investigator‐assessed outcomes were at risk of performance bias if, for example, trial participants were seen more frequently (in the knowledge that they were having experimental treatment), bias could have been introduced in the absence of blinding. </p> <p>Second malignancy: this investigator‐assessed outcome was not felt to be at risk of performance bias because it was an objective outcome and likely to have been assessed by clinicians other than the investigators after a long time delay (e.g. 10 to 15 years). </p> <p>Quality of life: this investigator‐assessed or self‐assessed outcome was at risk of performance bias. </p> <p>We judged the following outcomes to be similarly susceptible to performance bias and rated them in one group. </p> <p> <ul id="CD011462-list-0025"> <li> <p>Late GI RT toxicity.</p> </li> <li> <p>Late GU RT toxicity.</p> </li> <li> <p>Metastasis‐free survival.</p> </li> <li> <p>Biochemical recurrence‐free survival.</p> </li> <li> <p>Quality of life.</p> </li> </ul> </p> <p>We judged the following outcomes as not susceptible to performance bias and rated them in one group. </p> <p> <ul id="CD011462-list-0026"> <li> <p>PC‐SS.</p> </li> <li> <p>Overall survival.</p> </li> <li> <p>Secondary malignancy.</p> </li> </ul> </p> </section> <section id="CD011462-sec-0057"> <h5 class="title">Blinding of outcome assessment (detection bias due to knowledge of the allocated interventions by outcome assessment) (for subjective and objective outcomes) </h5> <p>We evaluated the risk of detection bias separately for each outcome (<a href="./references#CD011462-bbs2-0064" title="HróbjartssonA , ThomsenAS , EmanuelssonF , TendalB , HildenJ , BoutronI , et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal2013;185(4):E201‐11. ">Hróbjartsson 2013</a>). We noted whether endpoints were self‐reported, investigator‐assessed or adjudicated outcome measures (see below). </p> <p> <ul id="CD011462-list-0027"> <li> <p>Low risk of bias: blinding of outcome assessment was ensured, and it was unlikely that the blinding could have been broken; no blinding of outcome assessment, but we judged that the outcome measurement was unlikely to have been influenced by lack of blinding. </p> </li> <li> <p>Unclear risk of bias: insufficient information about the blinding of outcome assessors; the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: no blinding of outcome assessment, and the outcome measurement was likely to have been influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement was likely to be influenced by lack of blinding. </p> </li> </ul> </p> <p>We judged the following outcomes to be susceptible to detection bias, thereby making blinding of outcome assessors important. </p> <p> <ul id="CD011462-list-0028"> <li> <p>PC‐SS.</p> </li> <li> <p>Late GI RT toxicity and late GU RT toxicity.</p> </li> <li> <p>Metastasis‐free survival.</p> </li> <li> <p>Biochemical recurrence‐free survival.</p> </li> <li> <p>Quality of life.</p> </li> </ul> </p> <p>Given that risk of judgments for these outcomes were the same, we reported them in one group. </p> <p>We judged the following outcomes as not to susceptible to detection bias.</p> <p> <ul id="CD011462-list-0029"> <li> <p>Overall survival.</p> </li> <li> <p>Secondary malignancy.</p> </li> </ul> </p> </section> <section id="CD011462-sec-0058"> <h5 class="title">Incomplete outcome data (attrition bias due to amount, nature or handling of incomplete outcome data) </h5> <p>For each included trial and or each outcome, we described the completeness of data, including attrition and exclusions from the analyses. We stated whether the trial reported attrition and exclusions, and the number of participants included in the analysis at each stage (compared with the number of randomized participants per intervention/comparator groups). We noted if the trial reported the reasons for attrition or exclusion and whether missing data were balanced across groups or were related to outcomes. We considered the implications of missing outcome data per outcome such as high dropout rates (e.g. above 15%) or disparate attrition rates (e.g. difference of 10% or more between trial arms) where it was applicable. </p> <p> <ul id="CD011462-list-0030"> <li> <p>Low risk of bias: no missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to introduce bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk is not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (mean difference [MD] or standardized mean difference [SMD]) among missing outcomes was not enough to have a clinically relevant impact on observed effect size; appropriate methods, such as multiple imputation, were used to handle missing data. </p> </li> <li> <p>Unclear risk of bias: insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias; the trial did not address this outcome. </p> </li> <li> <p>High risk of bias: reason for missing outcome data were likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (MD or SMD) among missing outcomes enough to induce clinically relevant bias in observed effect size; 'as‐treated' or similar analysis done with substantial departure of the intervention received from that assigned at randomization; potentially inappropriate application of simple imputation. </p> </li> </ul> </p> </section> <section id="CD011462-sec-0059"> <h5 class="title">Selective reporting (reporting bias due to selective outcome reporting)</h5> <p>We assessed outcome reporting bias by integrating the results of the appendix 'Matrix of trial endpoints (publications and trial documents)' (<a href="./references#CD011462-bbs2-0032" title="BoutronI , AltmanDG , HopewellS , Vera‐BadilloF , TannockI , RavaudP . Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial. Journal of Clinical Oncology2014;32:4120‐6. ">Boutron 2014</a>; <a href="./references#CD011462-bbs2-0067" title="JonesCW , KeilLG , HollandWC , CaugheyMC , Platts‐MillsTF . Comparison of registered and published outcomes in randomized controlled trials: a systematic review. BMC Medicine2015;13:282. ">Jones 2015</a>; <a href="./references#CD011462-bbs2-0077" title="MathieuS , BoutronI , MoherD , AltmanDG , RavaudP . Comparison of registered and published primary outcomes in randomized controlled trials. JAMA2009;302:977‐84. ">Mattieu 2009</a>), with those of the appendix 'High risk of outcome reporting bias according to ORBIT classification' (<a href="./references#CD011462-bbs2-0068" title="KirkhamJJ , DwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:c365. ">Kirkham 2010</a>). This analysis formed the basis for the judgment of selective reporting. </p> <p> <ul id="CD011462-list-0031"> <li> <p>Low risk of bias: the trial protocol was available and all of the trial's prespecified (primary and secondary) outcomes that were of interest in the review were reported in the prespecified way; the study protocol was unavailable, but it was clear that the published reports included all expected outcomes (ORBIT classification). </p> </li> <li> <p>Unclear risk of bias: insufficient information about selective reporting.</p> </li> <li> <p>High risk of bias: not all of the trial's prespecified primary outcomes were reported; one or more primary outcomes were reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not prespecified; one or more reported primary outcomes were not prespecified (unless clear justification for their reporting was provided, such as an unexpected adverse effect); one or more outcomes of interest in the Cochrane Review were reported incompletely so that we could not enter them in a meta‐analysis; the trial report failed to include results for a key outcome that we would expect to have been reported for such a trial (ORBIT classification). </p> </li> </ul> </p> </section> <section id="CD011462-sec-0060"> <h5 class="title">Other sources of bias</h5> <p> <ul id="CD011462-list-0032"> <li> <p>Low risk of bias: the trial appeared free of other sources of bias.</p> </li> <li> <p>Unclear risk of bias: there was insufficient information to assess whether an important risk of bias existed; insufficient rationale or evidence that an identified problem introduced bias. </p> </li> <li> <p>High risk of bias: the trial had a potential source of bias related to the specific trial design used; the trial has been claimed to have been fraudulent or the trial had some other serious problem. </p> </li> </ul> </p> </section> <section id="CD011462-sec-0061"> <h5 class="title">Summary assessment of risk of bias</h5> <p><b>Risk of bias for a trial across outcomes</b>: some risk of bias domains such as selection bias (sequence generation and allocation sequence concealment), affect the risk of bias across all outcome measures in a trial. In case of high risk of selection bias, all endpoints investigated in the associated trial would be marked as high risk. Otherwise, we would not have performed a summary assessment of the risk of bias across all outcomes for a trial. </p> <p><b>Risk of bias for an outcome within a trial and across domains</b>: we assessed the risk of bias for an outcome measure by including all entries relevant to that outcome (i.e. both trial‐level entries and outcome‐specific entries). We considered low risk of bias to denote a low risk of bias for all key domains, unclear risk to denote an unclear risk of bias for one or more key domains and high risk to denote a high risk of bias for one or more key domains. </p> <p><b>Risk of bias for an outcome across trials and across domains</b>: these were our main summary assessments that we incorporated into our judgments about the certainty of evidence in the 'Summary of finding' table. We defined outcomes as low risk of bias when most information came from trials at low risk of bias, unclear risk when most information came from trials at low or unclear risk of bias and high risk when a sufficient proportion of information came from trials at high risk of bias. </p> <p>We present a 'Risk of bias' summary figure (<a href="#CD011462-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011462-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD011462-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> </div> <p>We distinguished between self‐reported, investigator‐assessed and adjudicated outcome measures. </p> <p>We accepted the following outcomes as self‐reported:</p> <p> <ul id="CD011462-list-0033"> <li> <p>health‐related quality of life as reported by participants.</p> </li> </ul> </p> <p>We accepted the following outcomes as investigator‐assessed:</p> <p> <ul id="CD011462-list-0034"> <li> <p>PC‐SS, overall survival, metastasis‐free survival and BR‐FS as measured by trial personnel;</p> </li> <li> <p>adverse events: acute and late GU and GI toxicity as measured by study personnel.</p> </li> </ul> </p> </section> </section> <section id="CD011462-sec-0062"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011462-sec-0063"> <h5 class="title">Dichotomous data</h5> <p>When at least two included trials were available for a comparison and a given outcome, we tried to express dichotomous data as a risk ratio (RR) with 95% confidence interval (CI) (<a href="./references#CD011462-bbs2-0047" title="DeeksJJ . Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomes. Statistics in Medicine2002;21(11):1575‐600. ">Deeks 2002</a>). </p> </section> <section id="CD011462-sec-0064"> <h5 class="title">Continuous data</h5> <p>For continuous outcomes measured on the same scale (e.g. weight loss in kilograms), we estimated the intervention effect using the MD with 95% CI. For continuous outcomes measuring the same underlying concept (e.g. health‐related quality of life) but using different measurement scales, we calculated the SMD with 95% CI (<a href="./references#CD011462-bbs2-0047" title="DeeksJJ . Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomes. Statistics in Medicine2002;21(11):1575‐600. ">Deeks 2002</a>). </p> </section> <section id="CD011462-sec-0065"> <h5 class="title">Time‐to‐event data</h5> <p>We expressed time‐to‐event data as hazard ratio (HR) with 95% CI (<a href="./references#CD011462-bbs2-0039" title="CoxDR . Regression models and life‐tables. Journal of the Royal Statistical Society. Series B, Statistical Methodology1972;34(2):187‐220. ">Cox 1972</a>; <a href="./references#CD011462-bbs2-0042" title="CoxDR , OakesD . Analysis of Survival Data. London (UK): Chapman and Hall, 2001. ">Cox 2001</a>). If time‐to‐event data were not available in, or possible to derive from, study reports, and were not available after consultation with study authors, we planned to present the RR with 95% CI as discussed above (at 10 years). </p> <p>Individual participant data analysis was not performed.</p> </section> </section> <section id="CD011462-sec-0066"> <h4 class="title">Unit of analysis issues</h4> <p>We explicitly excluded cluster‐randomized and cross‐over trials so the unit of analysis was the individual man. If more than one comparison from the same trial was eligible for inclusion in the same meta‐analysis, we combined groups to create a single pair‐wise comparison. </p> </section> <section id="CD011462-sec-0067"> <h4 class="title">Dealing with missing data</h4> <p>We performed an intention‐to‐treat analysis. When data were missing, we attempted to obtain these data by contacting the study authors. We did not impute missing data. </p> </section> <section id="CD011462-sec-0068"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of substantial clinical or methodologic heterogeneity, we planned not to report trial results as the pooled effect estimate in a meta‐analysis. </p> <p>We identified heterogeneity (inconsistency) by visually inspecting the forest plots and by using a standard Chi² test with a significance level of α = 0.1. In view of the low power of this test, we also considered the I² statistic (<a href="./references#CD011462-bbs2-0059" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21(11):1539‐58. ">Higgins 2002</a>; <a href="./references#CD011462-bbs2-0060" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ (Clinical Research Ed.)2003;327(7414):557‐60. ">Higgins 2003</a>), which quantifies inconsistency across trials to assess the impact of heterogeneity on the meta‐analysis. An I² statistic of 75% or greater indicated a considerable level of heterogeneity (<a href="./references#CD011462-bbs2-0062" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>Where we did identify heterogeneity, we rechecked our data, considered whether meta‐analysis was appropriate and attempted to explore the reasons for it by examining individual trial and subgroup characteristics. BR‐FS was a compound endpoint, with different events contributing data in different studies (see <a href="#CD011462-tbl-0002">Table 1</a>), we explored this by (post‐hoc) excluding those studies where PSA failure was the only event contributing to that outcome (<a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a>). </p> <div class="table" id="CD011462-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute RT toxicity scale used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Late RT toxicity scale used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PSA failure definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events contributing to biochemical relapse endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐reported outcomes (PRO)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sexual function</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up (median)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. "><b>Arcangeli 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG/EORTC<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LENT‐SOMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phoenix<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA rise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. "><b>CHHiP 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG/EORTC<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG/EORTC<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phoenix</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA failure, LR, DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRO<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UCLA‐PCI, EPIC<sup>e</sup>, FACT‐P </p> <p>EPIC‐50 was used for bowel and urinary domains</p> <p>EPIC‐26 for sexual and hormonal domains. For all quality of life instruments, scores range from 0 to 100, and higher was better </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.4 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. "><b>Fox Chase 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4‐point scale, detailed, but not referenced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LENT‐SOMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phoenix<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA rise, LR, DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐reported: EPIC<sup>e</sup>, IPSS<sup>f</sup>, EQ5D<sup>g</sup> assessed at baseline, and 12, 24, 36, 48 and 60 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. "><b>HYPRO Dutch 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG/EORTC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG/EORTC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phoenix<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA rise<sup>h</sup>, LR, DM, salvage AD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRO<sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IIIEF<sup>j</sup> used at baseline, and 6, 12, 24 and 36 months. EORTC ‐QLQ‐PR25<sup>k</sup> used </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. "><b>Lee 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCI CTCAE Maximum toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG/EORTC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phoenix<sup>c</sup> </p> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death without recurrence, PSA rise, salvage AD, DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EPIC<sup>e</sup> was used, with assessments at baseline, 6 months and 12 months after randomization </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). "><b>Lukka NCIC 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCIC Grade III‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCIC Grade III‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ASTRO<sup>l</sup> </p> <p>BCDF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA rise, LR, DM, salvage AD, PC death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. "><b>MDACC 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified EORTC/RTOG<sup>m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phoenix</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA rise, salvage AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRO<sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urinary, sexual and bowel function assessed at baseline, 2, 3, 4 and 5 years<sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0008" title="NorkusD , MillerA , KurtinaitisJ , HaverkampU , PopovS , ProttFJ . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional external‐beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlentherapie Onkologie2009;185(11):715‐21. [DOI: 10.1007/s00066‐009‐1982‐z] NorkusD , MillerA , PlieskieneA , JanulionisE , ValukaKV . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional conformal external beam radiotherapy for localized prostate adenocarcinoma: a report on the first‐year biochemical response. Medicina (Kaunas)2009;45(6):469‐75. NorkusD , ValuckasKP , MillerA , PlieskienėA , KurtinaitisJ . Safety investigation of hypofractionated prostate gland radiotherapy [Neišplitusio priešinės liaukos vėžio hipofrakcionuoto spindulinio gydymo saugumo tyrimas]. Medicina2005;41(12):1035. "><b>Norkus 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scale not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scale not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ASTRO<sup>l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA rise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). "><b>PROFIT 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG/EORTC<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG/EORTC<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ASTRO<sup>l</sup> </p> <p>Phoenix<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA rise, LR, DM, salvage AD, death any cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EPIC<sup>e</sup>, AUA at baseline, and 24 and 48 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. "><b>Yeoh 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified LENT‐SOMA<sup>o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phoenix<sup>b</sup> </p> <p>ASTRO<sup>l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA rise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EORTC<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 months<sup>p</sup> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AD: androgen deprivation; ASTRO: American Society for Radiation Oncology; AUA: American Urological Association; BCDF: biochemical or clinical disease failure, or both; DFS: disease‐free survival; DM: distant metastases; EORTC: European Organisation for Research and Treatment of Cancer; EPIC: Expanded Prostate Cancer Index Composite; EQ5D: EuroQoL 5‐dimension; FACT‐P: Functional Assessment of Cancer Therapy – Prostate (<a href="./references#CD011462-bbs2-0051" title="EsperP , MoF , ChodakG , SinnerM , CellaD , PientaKJ . Measuring quality of life in men with prostate cancer using the functional assessment of cancer‐therapy‐prostate instrument. Urology1997;50:920‐8. ">Esper 1997</a>); IIIEF: International Index of Erectile Function; IPSS: International Prostate Symptom Score; LENT‐SOMA: Late Effects Normal Tissue Task Force‐Subjective, Objective, Management, Analytic system (<a href="./references#CD011462-bbs2-0089" title="PavyJJ , DenekampJ , LetschertJ , LittbrandB , MornexF , BernierJ , et al. Late effects toxicity scoring: the SOMA scale. International Journal of Radiation Oncology, Biology, Physics1995;31(5):1043‐7. ">Pavy 1995</a>); LR: local recurrence; NCI CTCAE: National Cancer Institute Common Toxicity Criteria for Adverse Events version 3 (<a href="#CD011462-tbl-0010">Table 8</a>); NCIC: National Institute of Cancer Canada toxicity 5‐point scale; PC: prostate cancer; PRO: participant‐reported outcome; PSA: prostate‐specific antigen; QLQ‐PR25: Quality of Life Questionnaire – Prostate Cancer Module; RT: radiation therapy; RTOG: Radiation Therapy Oncology Group; UCLA‐PCI: University of California, Los Angeles Prostate Cancer Index (<a href="./references#CD011462-bbs2-0074" title="LitwinMS , HaysRD , FinkA , Ganz PA LeakeB , BrookeRH . The UCLA Prostate Cancer Index: development, reliability, and validity of a health‐related quality of life measure. Medical Care1998;36:1002‐12. ">Litwin 1998</a>).<br/> <sup>a</sup>RTOG/EORTC RT toxicity scoring scale (<a href="./references#CD011462-bbs2-0040" title="CoxJD , StatzJ , PajakTF . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology, Biology, Physics1995;31:1341‐6. ">Cox 1995</a>).<br/> <sup>b</sup>Phoenix definition of biochemical failure: PSA nadir plus 2 (<a href="./references#CD011462-bbs2-0099" title="RoachM3rd , HanksG , ThamesHJr , SchellhammerP , ShipleyWU , SokolGH , et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG‐ASTRO Phoenix Consensus Conference. International Journal of Radiation Oncology, Biology, Physics2006;65(4):965‐74. ">Roach 2006</a>). PSA measured at three monthly follow‐up visits for first two years, six monthly for years three to five, then annually to 10 years.<br/> <sup>c</sup>Assessed weekly during RT; weeks 10, 12 and 18 for acute toxicity; then at 26 weeks and every six months for five years for late toxicity.<br/> <sup>d</sup>In <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>, the question: "Overall, how much of a problem have your bowels been for you in the last 4/52?" was asked. A seven‐item bowel bother was assessed. The bowel domain summary (5‐point scale) is reported, those with small, moderate or severe bowel bother (Grade II or more) (<a href="#CD011462-tbl-0003">Table 10</a>). <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>: quality of life scales changed during the study, because better instruments became available. Initially, UCLA‐PCI was used from trial initiation to early 2009 (<a href="./references#CD011462-bbs2-0074" title="LitwinMS , HaysRD , FinkA , Ganz PA LeakeB , BrookeRH . The UCLA Prostate Cancer Index: development, reliability, and validity of a health‐related quality of life measure. Medical Care1998;36:1002‐12. ">Litwin 1998</a>). The UCLA‐PCI included 36‐item Short Form (SF‐36) and FACT‐P (<a href="./references#CD011462-bbs2-0051" title="EsperP , MoF , ChodakG , SinnerM , CellaD , PientaKJ . Measuring quality of life in men with prostate cancer using the functional assessment of cancer‐therapy‐prostate instrument. Urology1997;50:920‐8. ">Esper 1997</a>). From March 2009, the EPIC and SF‐12 (<a href="./references#CD011462-bbs2-0112" title="WareJ , KosinskiM , KellerSD . A 12‐item short‐form health survey: construction of scales and preliminary tests of reliability and validity. Medical Care1996;34:220‐33. ">Ware 1996</a>) replaced UCLA‐PCI. EPIC‐50 was used for bowel and urinary domains and EPIC‐26 for sexual and hormonal domains.<br/> <sup>e</sup>EPIC and 12‐item Short Form 12 (<a href="./references#CD011462-bbs2-0112" title="WareJ , KosinskiM , KellerSD . A 12‐item short‐form health survey: construction of scales and preliminary tests of reliability and validity. Medical Care1996;34:220‐33. ">Ware 1996</a>). The tool is scored from 0 to 100 (with higher scores being better, a significant change is 0.5 standard deviations and four domains are assessed: bowel, urinary, sexual and hormonal.<br/> <sup>f</sup>IPSS measures urinary obstructive symptoms: 0 = no symptoms, 35 = maximum (<a href="./references#CD011462-bbs2-0030" title="BarryMH , FowlerFJJr , O'LearyMP , BruskewitzRC , HoltgreweHL , MebustWK , et al. The American Urological Association index for benign prostatic hyperplasia: the measurement committee of the American Urological Association. Journal of Urology1992;148(5):1549‐57. ">Barry 1992</a>). It also incorporates a 1 to 6 visual analogue scale: 0 = 'delighted' with current state of urinary symptoms.<br/> <sup>g</sup>EuroQoL 5‐dimension (EQD5) questionnaire covers five dimensions (mobility, self‐care, usual activities, pain/discomfort, anxiety/depression), also incorporates visual analog scale: the two scores are transformed into a utility score where 0 = 'worst health state' and 1 = 'best health state'.<br/> <sup>h</sup>PSA failure was reported as "first event" data, so we could not include it (<a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>).<br/> <sup>i</sup>Late RTOG/EORTC gastrointestinal and genitourinary toxicity events were counted if noted in clinical record, participant self‐assessments or both (<a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>).<br/> <sup>j</sup>IIEF although not formally validated in men who have RT or radical prostatectomy for PC, is the most commonly used validated tool for assessment of erectile function (<a href="./references#CD011462-bbs2-0100" title="RosenRC , RileyA , WagnerG , OsterlohIH , KirkpatrickJ , MishraA . The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology1997;49:822‐30. ">Rosen 1997</a>). <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a> used it to assess the following sexual domains in 671/820 men enrolled: erectile function (in hormone‐naive men), orgasmic function, sexual desire, intercourse and overall satisfaction. The minimally important clinical difference for erectile function was 4. In <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>, 322/820 men completed the IIEF at baseline and at least one other time‐point enrolled .<br/> <sup>k</sup>EORTC scale measures toxicity and functional subscales (<a href="./references#CD011462-bbs2-0110" title="vanAndelG , BottomleyA , FossaSD . An international field study of the health‐related quality of life of patients with prostate cancer. European Journal of Cancer2008;44:2418‐24. ">van Andel 2008</a>). For all quality of life instruments, scores range from 0 to 100, and higher score is better for functional outcomes and lower is better for toxicity outcomes. Quality of life was assessed at baseline, and six, 12, 24, 36, 48 and 60 months. Change from baseline of five points was considered relevant clinically. Non‐inferiority was set at 8%, i.e. the incidence of clinically relevant deterioration in the hypofractionation group will be no worse than 8% more than the incidence in the conventional arm.<br/> <sup>l</sup>ASTRO definition of biochemical failure: three consecutive PSA rises (<a href="./references#CD011462-bbs2-0041" title="CoxJ , GrignonD , KaplanR , ParsonsJT , SchelhammerPF . Concensus statement: guidelines for PSA following radiation therapy. International Journal of Radiation Oncology, Biology, Physics1997;37(5):1035‐41. ">Cox 1997</a>).<br/> <sup>m</sup>Modified RTOG/EORTC scoring system (see <a href="#CD011462-tbl-0009">Table 7</a>) (<a href="./references#CD011462-bbs2-0040" title="CoxJD , StatzJ , PajakTF . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology, Biology, Physics1995;31:1341‐6. ">Cox 1995</a>).<br/> <sup>n</sup>185 men in <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a> were eligible for PROs, they did not differ from the remainder of men randomized in the study, and completion of the PRO questionnaire was similar at each time‐point. Self‐reported urinary, bowel and sexual function were assessed at baseline (<a href="http://links.lww.com/AJCO/A138" target="_blank">links.lww.com/AJCO/A138</a>) and at two, three, four and five years (<a href="http://links.lww.com/AJCO/A140" target="_blank">links.lww.com/AJCO/A140</a>).<br/> <sup>o</sup>Modified LENT‐SOMA (see <a href="#CD011462-tbl-0011">Table 9</a>).<br/> <sup>p</sup> Participants reviewed at first month after RT, three‐month intervals for two years, then six‐month intervals for three years, then annually thereafter. </p> </div> </div> <div class="table" id="CD011462-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Bowel 'bother'</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Description</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No bother</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>I</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very small bother</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>II</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small bother</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>III</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate bother</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Big bother</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD011462-sec-0069"> <h4 class="title">Assessment of reporting biases</h4> <p>Where we included 10 or more trials that investigated a particular outcome, we used funnel plots to assess small‐trial effects. Several explanations may have accounted for funnel plot asymmetry, including true heterogeneity of effect with respect to trial size, poor methodologic design (and hence bias of small trials) and publication bias. Therefore, we interpreted results carefully (<a href="./references#CD011462-bbs2-0106" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ2011;343:d4002. ">Sterne 2011</a>). We attempted to obtain the study protocols, in order to assess for selective outcome reporting bias. </p> </section> <section id="CD011462-sec-0070"> <h4 class="title">Data synthesis</h4> <p>We used Mantel‐Haenszel (M‐H) methods to calculate pooled data for dichotomous data (if participants, interventions, comparisons and outcomes were judged to be sufficiently similar to ensure an answer that was clinically meaningful). Unless good evidence showed homogeneous effects across trials, we primarily summarized low risk of bias data using a random‐effects model (<a href="./references#CD011462-bbs2-0117" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601‐5. ">Wood 2008</a>). We interpreted random‐effects meta‐analyses with due consideration to the whole distribution of effects, ideally by presenting a prediction interval (<a href="./references#CD011462-bbs2-0061" title="HigginsJP , ThompsonSG , SpiegelhalterDJ . A re‐evaluation of random‐effects meta‐analysis. Journal of the Royal Statistical Society. Series A, (Statistics in Society)2009;172(1):137‐59. ">Higgins 2009</a>). A prediction interval specifies a predicted range for the true treatment effect in an individual trial (<a href="./references#CD011462-bbs2-0098" title="RileyRD , HigginsJP , DeeksJJ . Interpretation of random effects meta‐analyses. BMJ2011;342:d549. ">Riley 2011</a>). For rare events such as event rates below 1%, we planned to use Peto's odds ratio (OR) method, provided that there was no substantial imbalance between intervention and comparator group sizes and intervention effects were not exceptionally large. In addition, we performed statistical analyses according to the statistical guidelines presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011462-bbs2-0062" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a> from the University College, Cork protocol) (<a href="./references#CD011462-bbs2-0057" title="GreenlandS , RobinsJM . Estimation of a common effect parameter from sparse follow‐up data. Biometrics1985;41(1):55‐68. ">Greenland 1985</a>; <a href="./references#CD011462-bbs2-0076" title="MantelN , HaenszelW . Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute1959;22(4):719‐48. ">Mantel 1959</a>). </p> <p>Where time‐to‐event data were available, we calculated the log rank statistic (O‐E) and its variance using an Excel spreadsheet developed by Matthew Sydes (Cancer Division) in collaboration with the Meta‐analysis Group of the Medical Research Council Clinical Trials Unit, London (<a href="./references#CD011462-bbs2-0108" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>). We derived the log HR and used the Peto fixed‐effect model in Review Manager 5 to pool the data, when appropriate (<a href="./references#CD011462-bbs2-0048" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>; <a href="./references#CD011462-bbs2-0097" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> <section id="CD011462-sec-0071"> <h5 class="title">Certainty of the evidence</h5> <p>We presented the overall certainty of the evidence for each outcome according to the GRADE approach, which takes into account issues related to internal validity (risk of bias, inconsistency, imprecision, publication bias) and external validity (directness of results)<i>.</i> Two review authors (MJ, BH) independently rated the certainty of evidence for each outcome. We present a summary of the evidence in <a href="./full#CD011462-tbl-0001">summary of findings Table for the main comparison</a>. This provides key information about the best estimate of the magnitude of the effect, in relative terms and as absolute differences, for each relevant comparison of alternative management strategies, numbers of participants and trials addressing each important outcome, and rating of overall confidence in effect estimates for each outcome. We created the 'Summary of findings' table based on the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> by means of Review Manager 5's table editor (<a href="./references#CD011462-bbs2-0097" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We used the GRADEpro Guideline Development Tool (GDT) software (<a href="./references#CD011462-bbs2-0056" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 12 May 2016. Hamilton (ON): McMaster University (developed by Evidence Prime). ">GRADEpro GDT</a>). We presented results for the outcomes as described in the <a href="#CD011462-sec-0038">Types of outcome measures</a> section. If meta‐analysis was not possible, we presented the results in a narrative format in the 'Summary of findings' table. We justified all decisions to downgrade the certainty of studies using footnotes, and we made comments to aid the reader's understanding of the Cochrane Review where necessary. </p> </section> </section> <section id="CD011462-sec-0072"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to introduce clinical heterogeneity, and we planned to carry out the following subgroup analyses including investigation of interactions. </p> <p> <ul id="CD011462-list-0035"> <li> <p>Risk stratification of primary disease (based on clinical stage, Gleason score and PSA; where possible examining the effect of the intervention in each of the relevant risk categories: very low, low, intermediate, high, very high). Category definitions were as follows: low risk: clinical stage T1c or T2a, PSA 10 ng/mL and Gleason score 6 or less; intermediate risk: clinical stage T2b, PSA 10 ng/mL to 20 ng/mL or Gleason score 7; high risk: clinical stage T2c, PSA 20 ng/mL or Gleason score 8 to 10 (<a href="./references#CD011462-bbs2-0043" title="D'AmicoAV , WhittingtonR , MalkowiczSB , SchultzD , BlankK , BroderickGA , et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA1998;280:969. ">D'Amico 1998</a>), although this was not possible. </p> </li> <li> <p>RT dose, according to:</p> <ul id="CD011462-list-0036"> <li> <p>EQD<sup>2</sup> 74 Gy or greater in conventional arm (which reflects current practice); </p> </li> <li> <p>EQD<sup>2</sup> less than 74 Gy in conventional arm (<a href="#CD011462-tbl-0004">Table 2</a>). </p> </li> </ul> </li> <li> <p>Difference in EQD<sup>2</sup> between the RT doses delivered in the two study arms (which allowed us to distinguish the effect of hypofractionation from dose escalation, given that we expected that the studies we found may have had an element of dose escalation in addition to hypofractionation), according to: </p> </li> </ul> </p> <div class="table" id="CD011462-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">EQD2 dose comparison (α/β 1.93)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypofractionation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose per fraction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQD2</b> </p> <p><b>(α/β = 1.93 prostate cancer)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conventional</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose per fraction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQD2</b> </p> <p><b>(α/β = 1.93 prostate cancer)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. "><b>Arcangeli 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 Gy/40 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. "><b>CHHiP 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 Gy/20 fractions</p> <p>57 Gy/19 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.38</p> <p>71.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 Gy/37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. "><b>Fox Chase 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.2 Gy/26 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 Gy/38 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. "><b>HYPRO Dutch 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.6 Gy/19 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 Gy/39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. "><b>Lee 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy/28 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.8 Gy/41 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). "><b>Lukka NCIC 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.5 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66 Gy/33 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. "><b>MDACC 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 Gy/30 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.6 Gy/42 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0008" title="NorkusD , MillerA , KurtinaitisJ , HaverkampU , PopovS , ProttFJ . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional external‐beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlentherapie Onkologie2009;185(11):715‐21. [DOI: 10.1007/s00066‐009‐1982‐z] NorkusD , MillerA , PlieskieneA , JanulionisE , ValukaKV . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional conformal external beam radiotherapy for localized prostate adenocarcinoma: a report on the first‐year biochemical response. Medicina (Kaunas)2009;45(6):469‐75. NorkusD , ValuckasKP , MillerA , PlieskienėA , KurtinaitisJ . Safety investigation of hypofractionated prostate gland radiotherapy [Neišplitusio priešinės liaukos vėžio hipofrakcionuoto spindulinio gydymo saugumo tyrimas]. Medicina2005;41(12):1035. "><b>Norkus 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 Gy/17 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 Gy/37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). "><b>PROFIT 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 Gy/39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. "><b>Yeoh 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 Gy/32 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>EQD<sup>2</sup>: equivalent dose in 2 Gy fractions. </p> </div> </div> <p> <ul class="plain" id="CD011462-list-0037"> <li> <ul id="CD011462-list-0038"> <li> <p>difference in EQD<sup>2</sup> greater than 4 Gy (which represents dose escalation in addition to hypofractionation); </p> </li> <li> <p>difference in EQD<sup>2</sup> 4 Gy or less (which represents hypofractionation without dose escalation). </p> </li> </ul> </li> </ul> <ul id="CD011462-list-0039"> <li> <p>Quality of delivered radiation (based on performance of QA of delivered radiation, i.e. using performance of QA as a surrogate for the quality of the RT delivered), according to: </p> </li> </ul> <ul class="plain" id="CD011462-list-0040"> <li> <ul id="CD011462-list-0041"> <li> <p>performance of QA;</p> </li> <li> <p>lack of performance of QA.</p> </li> </ul> </li> </ul> <ul id="CD011462-list-0042"> <li> <p>RT technique: highly conformal RT techniques allow both dose escalation and reduce dose to OARs. Reduction in dose to normal tissues reduces both acute and late radiation toxicity, according to: </p> </li> </ul> <ul class="plain" id="CD011462-list-0043"> <li> <ul id="CD011462-list-0044"> <li> <p>use of 3DCRT;</p> </li> <li> <p>highly conformal RT (IMRT or volumetric modulated arc therapy [VMAT]).</p> </li> </ul> </li> </ul> <ul id="CD011462-list-0045"> <li> <p>Androgen deprivation: post‐hoc analysis performed in response to peer reviewer input)</p> <ul id="CD011462-list-0046"> <li> <p>use of androgen deprivation</p> </li> <li> <p>no androgen deprivation.</p> </li> </ul> </li> </ul> </p> </section> <section id="CD011462-sec-0073"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses to explore the influence of the following factors on effect sizes by restricting analysis to the following. </p> <p> <ul id="CD011462-list-0047"> <li> <p>Study age (excluding those studies that commenced accrual prior to 2002).</p> </li> <li> <p>Study quality (excluding studies at high risk of bias for that outcome).</p> </li> <li> <p>Duration of follow‐up (excluding studies with follow‐up of less than 10 years, measured from time of randomization to outcome assessment). </p> </li> </ul> </p> <p>For the calculation of EQD<sup>2</sup>, we used an α/β ratio for prostate cancer of 1.93 Gy (<a href="./references#CD011462-bbs2-0111" title="VogeliusIR , BentzenSM . Meta‐analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?. International Journal of Radiation Oncology, Biology, Physics2013;85(1):89‐94. ">Vogelius 2013</a>), in the assumption that a shorter total treatment time would impact on tumor control. We also performed sensitivity analysis based on an α/β value of 0.58 Gy (see <a href="#CD011462-tbl-0005">Table 3</a>), and 4.14 Gy (see <a href="#CD011462-tbl-0006">Table 4</a>), selected based on the 95% CI of estimated α/β derived from four randomized phase III studies and one non‐randomized study on hypofractionated prostate RT (<a href="./references#CD011462-bbs2-0111" title="VogeliusIR , BentzenSM . Meta‐analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?. International Journal of Radiation Oncology, Biology, Physics2013;85(1):89‐94. ">Vogelius 2013</a>). </p> <div class="table" id="CD011462-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">EQD2 (α/β 0.58)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypofractionation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose per fraction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQD<sup>2</sup> </b> </p> <p><b>(α/β = 0.58 prostate cancer)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conventional</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose per fraction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQD<sup>2</sup> </b> </p> <p><b>α/β = 0.58 prostate cancer</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. "><b>Arcangeli 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 Gy/40 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. "><b>CHHiP 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 Gy/20 fractions</p> <p>57 Gy/19 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.08</p> <p>78.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 Gy/37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. "><b>Fox Chase 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.2 Gy/26 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 Gy/38 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. "><b>HYPRO Dutch 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.6 Gy/19 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 Gy/39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. "><b>Lee 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy/28 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.8 Gy/41 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). "><b>Lukka NCIC 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.5 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66 Gy/33 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. "><b>MDACC 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 Gy/30 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.6 Gy/42 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0008" title="NorkusD , MillerA , KurtinaitisJ , HaverkampU , PopovS , ProttFJ . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional external‐beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlentherapie Onkologie2009;185(11):715‐21. [DOI: 10.1007/s00066‐009‐1982‐z] NorkusD , MillerA , PlieskieneA , JanulionisE , ValukaKV . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional conformal external beam radiotherapy for localized prostate adenocarcinoma: a report on the first‐year biochemical response. Medicina (Kaunas)2009;45(6):469‐75. NorkusD , ValuckasKP , MillerA , PlieskienėA , KurtinaitisJ . Safety investigation of hypofractionated prostate gland radiotherapy [Neišplitusio priešinės liaukos vėžio hipofrakcionuoto spindulinio gydymo saugumo tyrimas]. Medicina2005;41(12):1035. "><b>Norkus 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 Gy/17 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 Gy/37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). "><b>PROFIT 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 Gy/39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. "><b>Yeoh 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 Gy/32 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>EQD<sup>2</sup>: equivalent dose in 2 Gy fractions. </p> </div> </div> <div class="table" id="CD011462-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">EQD2 (α/β 4.14)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypofractionation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose per</b> </p> <p><b>fraction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQD<sup>2</sup> </b> </p> <p><b>(α/β = 4.14 prostate cancer)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conventional</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose per</b> </p> <p><b>fraction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQD<sup>2</sup> </b> </p> <p><b>α/β = 4.14 prostate cancer</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. "><b>Arcangeli 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 Gy/40 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. "><b>CHHiP 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 Gy/20 fractions</p> <p>57 Gy/19 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.84</p> <p>66.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 Gy/37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. "><b>HYPRO Dutch 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.6 Gy/19 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78 Gy/39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. "><b>Fox Chase 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.2 Gy/26 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 Gy/38 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. "><b>Lee 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 Gy/28 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.8 Gy/41 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). "><b>Lukka NCIC 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.5 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 Gy/33 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. "><b>MDACC 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 Gy/30 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.6 Gy/42 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0008" title="NorkusD , MillerA , KurtinaitisJ , HaverkampU , PopovS , ProttFJ . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional external‐beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlentherapie Onkologie2009;185(11):715‐21. [DOI: 10.1007/s00066‐009‐1982‐z] NorkusD , MillerA , PlieskieneA , JanulionisE , ValukaKV . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional conformal external beam radiotherapy for localized prostate adenocarcinoma: a report on the first‐year biochemical response. Medicina (Kaunas)2009;45(6):469‐75. NorkusD , ValuckasKP , MillerA , PlieskienėA , KurtinaitisJ . Safety investigation of hypofractionated prostate gland radiotherapy [Neišplitusio priešinės liaukos vėžio hipofrakcionuoto spindulinio gydymo saugumo tyrimas]. Medicina2005;41(12):1035. "><b>Norkus 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 Gy/17 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 Gy/37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). "><b>PROFIT 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78 Gy/39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. "><b>Yeoh 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 Gy/32 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>EQD<sup>2</sup>: equivalent dose in 2 Gy fractions. </p> </div> </div> <p>We tested the robustness of results by repeating the analyses using different measures of effect size (RR, OR, etc.) and different statistical models (fixed‐effect and random‐effects models). </p> <section id="CD011462-sec-0074"> <h5 class="title">'Summary of findings' table</h5> <p>We used <a href="./references#CD011462-bbs2-0056" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 12 May 2016. Hamilton (ON): McMaster University (developed by Evidence Prime). ">GRADEpro GDT</a> to create a 'Summary of findings' table following the Cochrane methods and recommendations in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011462-bbs2-0102" title="SchünnemanHJ , OxmanAD , VistGE , HigginsJP , DeeksJT , GlaziouP , et al. Interpretation of results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünneman 2011</a>). We used the GRADE approach to evaluate the certainty of the evidence (<a href="./references#CD011462-bbs2-0055" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.)2004;328:1490. ">GRADE Working Group 2004</a>). One author (BH) initially applied the GRADE system and then two authors (BH and MJ) jointly agreed on the decisions made with respect to downgrading in the 'Summary of findings' table, with discussion of the decisions to reach consensus. Our decisions were informed by (but not limited to) the following principles. If a study contributing more than 30% of weight to an outcome was at high risk of bias for domains relevant to that outcome, we downgraded. If there was evidence of unexplained heterogeneity (P less than 0.1 and I<sup>2</sup> greater than 30%), we downgraded for inconsistency. If studies did not directly evaluate the intervention, we downgraded for indirectness. We downgraded for imprecision if there were fewer than 300 events, if optimum information size (OIS) was not met or if the 95% CI did not exclude 0.75 to 1.25 (this did not exclude clinically insignificant benefits or harms) (<a href="./references#CD011462-bbs2-0101" title="RyanR , SynnotA , HillS . Describing results: Cochrane Consumers and Communication Group, 2016. cccrg.cochrane.org/author‐resources. Version 1.0 (accessed prior to 7 July 2019). ">Ryan 2016</a>). Because we believed our search had identified all potentially relevant studies, we did not downgrade for publication bias. The assumed control risk used in <a href="./full#CD011462-tbl-0001">summary of findings Table for the main comparison</a> was the median control risk in the studies contributing to the comparison. </p> <p>The review only included RCTs, and we reported four evidence certainty levels: high, moderate, low and very low, with our rationale detailed in the 'Summary of findings' table. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011462-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011462-sec-0075"></div> <section id="CD011462-sec-0076"> <h3 class="title">Description of studies</h3> <section id="CD011462-sec-0077"> <h4 class="title">Results of the search</h4> <p>We screened 12,115 records and removed 3106 duplicate publications. We screened the titles and abstracts of 9009 and excluded irrelevant 8880 publications. We examined 129 full‐text articles and excluded six studies (seven reports) with reasons (<a href="./references#CD011462-sec-0174" title="">Characteristics of excluded studies</a> table). This version of the review included 10 studies (104 reports). Four studies await classification (<a href="./references#CD011462-sec-0175" title="">Characteristics of studies awaiting classification</a> table). Four reports referred to four ongoing studies (<a href="./references#CD011462-sec-0176" title="">Characteristics of ongoing studies</a> table; <a href="#CD011462-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD011462-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011462-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011462-sec-0078"> <h4 class="title">Included studies</h4> <section id="CD011462-sec-0079"> <h5 class="title">Study population</h5> <p>We studied 8278 men (ages 64 years or greater) enrolled in 10 studies. All men had localized prostate cancer and median follow‐up ranged from 12 months to 120 months (see <a href="#CD011462-tbl-0007">Table 5</a> and <a href="./references#CD011462-sec-0173" title="">Characteristics of included studies</a> table for details). </p> <div class="table" id="CD011462-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Participants</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NCCN risk classification</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PSA (ng/mL)<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gleason score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. "><b>Arcangeli 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate 42%</p> <p>High risk 15%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 6–7: 97%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5–7: 75%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. "><b>CHHiP 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Intermediate (73%) and high risk" (12%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median PSA 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5–7: 96%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. "><b>Fox Chase 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Intermediate (66%) and high risk" (33–35%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10: 64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6–7: 81%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. "><b>HYPRO Dutch 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Intermediate (26–27%) and high risk" (74–74%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7–9: 68%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. "><b>Lee 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84% 60 + years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4–9: 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5–6: 99.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). "><b>Lukka NCIC 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5–7: 82%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. "><b>MDACC 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk 28%</p> <p>Intermediate risk 71%</p> <p>High risk 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 10: 90%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7: 65%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0008" title="NorkusD , MillerA , KurtinaitisJ , HaverkampU , PopovS , ProttFJ . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional external‐beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlentherapie Onkologie2009;185(11):715‐21. [DOI: 10.1007/s00066‐009‐1982‐z] NorkusD , MillerA , PlieskieneA , JanulionisE , ValukaKV . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional conformal external beam radiotherapy for localized prostate adenocarcinoma: a report on the first‐year biochemical response. Medicina (Kaunas)2009;45(6):469‐75. NorkusD , ValuckasKP , MillerA , PlieskienėA , KurtinaitisJ . Safety investigation of hypofractionated prostate gland radiotherapy [Neišplitusio priešinės liaukos vėžio hipofrakcionuoto spindulinio gydymo saugumo tyrimas]. Medicina2005;41(12):1035. "><b>Norkus 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10: 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 6: 97%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). "><b>PROFIT 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 10: 68%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7: 90.6%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. "><b>Yeoh 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study predates risk stratification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>n: number of participants; PSA: prostate‐specific antigen.</p> </div> </div> </section> <section id="CD011462-sec-0080"> <h5 class="title">Interventions</h5> <p>Seven studies used highly conformal radiation therapy, six used IGRT and two reported some form of motion management. Four studies described normal QA to evaluate delivered RT. EQD2 was within plus or minus 5% in both study arms in six studies. There was an element of dose escalation in addition to hypofractionation in six studies and five studies delivered RT doses less than 78 Gy. Five studies used androgen deprivation. Studies using fraction sizes greater than 2 Gy were eligible, the included studies used fraction sizes ranging between 2.35 Gy and 3.4 Gy (see <a href="#CD011462-tbl-0008">Table 6</a> and <a href="./references#CD011462-sec-0173" title="">Characteristics of included studies</a> table for details). </p> <div class="table" id="CD011462-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Technique</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IGRT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Motion control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RT QA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Androgen deprivation (in both study arms)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RT volume</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CTV to PTV margins</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. "><b>Arcangeli 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3DCRT and IMRT (center dependent)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/3 centers used either ultrasound or fiducial markers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EQD2 ± 5% in both study arms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CTV = prostate + seminal vesicles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0 isotropically (0.6 cm posteriorly)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. "><b>CHHiP 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permitted, but not required</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>National QA program</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EQD2 ± 5% in both study arms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostate + seminal vesicles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5–10 mm (depending on OARs)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. "><b>Fox Chase 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ultrasound</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Empty rectum, moderately full bladder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose escalation in hypofractionated arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk adapted<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypofractionated arm: 7 mm with 3 mm posteriorly</p> <p>conventional fractionation: 8 mm with 5 mm posteriorly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. "><b>HYPRO Dutch 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMRT 95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose escalation in hypofractionated arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk adapted<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CTV + 3–10 mm = PTV. Boost margins 0 mm towards the posteriorly, 3–5 mm in other directions<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. "><b>Lee 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMRT 79%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (fiducial markers, ultrasound, cone beam CT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central QA described<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose escalation in hypofractionated arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4–10 mm margin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). "><b>Lukka NCIC 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3DCRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Real‐time QA for first 30 participants from each center, if OK, then random spot checks on 20% of plans </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose hypofractionated arm &lt; conventional arm</p> <p>Dose in both arms &lt; 78 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mm margin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. "><b>MDACC 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fiducial markers or ultrasound</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Full bladder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose escalation in hypofractionated arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostate + seminal vesicles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10–15 mm all dimensions except 4–8 mm posteriorly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0008" title="NorkusD , MillerA , KurtinaitisJ , HaverkampU , PopovS , ProttFJ . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional external‐beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlentherapie Onkologie2009;185(11):715‐21. [DOI: 10.1007/s00066‐009‐1982‐z] NorkusD , MillerA , PlieskieneA , JanulionisE , ValukaKV . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional conformal external beam radiotherapy for localized prostate adenocarcinoma: a report on the first‐year biochemical response. Medicina (Kaunas)2009;45(6):469‐75. NorkusD , ValuckasKP , MillerA , PlieskienėA , KurtinaitisJ . Safety investigation of hypofractionated prostate gland radiotherapy [Neišplitusio priešinės liaukos vėžio hipofrakcionuoto spindulinio gydymo saugumo tyrimas]. Medicina2005;41(12):1035. "><b>Norkus 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3DCRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin marks, weekly portal images</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose escalation in hypofractionated arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostate + base of seminal vesicles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8–10 mm all dimensions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). "><b>PROFIT 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMRT (3DCRT permitted if OAR constraints met)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily image guidance (fiducial markers, cone beam CT or ultrasound)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Real‐time central QA for all cases prior to fraction 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EQD2 ± 5% in both study arms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk adapted<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mm with 7 mm posteriorly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. "><b>Yeoh 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156/217 (72%) 2DRT</p> <p>61/217 (28%) 3DCRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EQD2 ± 5% in both study arms</p> <p>Dose in both arms &lt; 78 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mm margin</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>2DRT: two‐dimensional radiation therapy; 3DCRT: three‐dimensional radiation therapy; CT: computer tomography; CTV: clinical target volume; EQD2: equivalent dose in 2 Gy fractions; IMRT: intensity‐modulated radiation therapy; OAR: organs at risk: planning target volume; QA: quality assurance; RT: radiation therapy.<br/> <sup>a</sup><a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>: CTV1 = at least 50% of the seminal vesicles (all gross disease extending to the seminal vesicles received the full dose), in addition to the prostate and any extraprostatic extension. CTV2 = distal seminal vesicles. CTV3 = pelvic lymph nodes (periprostatic, periseminal vesicle, external iliac, obturator and internal iliac lymph nodes). Pelvic nodes treated in high‐risk men (17/154) in hypofractionated arm, (32/153) in conventional arm.<br/> <sup>b</sup><a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>: prostate alone treated to 64.6 Gy in 19 fractions (hypofractionated group) or 79 Gy in 39 fractions (conventional group). Prostate + boost to seminal vesicle (35 fractions of 2 Gy up to 70 Gy) or 39 fractions of 1.85 Gy (standard fractionation group), or a dose of 16 fractions of 3.4 Gy or 19 fractions of 3.04 Gy (hypofractionation group). Prostate + seminal vesicle treated to 64.6 Gy in 19 fractions (hypofractionated group) or 79 Gy in 39 fractions (conventional group).<br/> <sup>c</sup>CTV to PTV margin depended on the setup verification and correction strategy used in each participating institute. This boost could either be delivered sequentially or simultaneously integrated depending on the institute's preference.<br/> <sup>d</sup>Quality assurance: "All RT plans were submitted as digital DICOM files to the Image guided Therapy Quality Assurance Center for central quality assurance review. CT scans, target volumes, organ‐at‐risk contours, radiation dose distributions, dose volume histograms, and dose statistics were reviewed for compliance with protocol guidelines (<a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>)".<br/> <sup>e</sup><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>: CTV = either prostate alone (if nodal involvement risk &lt; 155 according to Partin's nomogram; [<a href="./references#CD011462-bbs2-0088" title="PartinAW , KattanMW , SubongEN , WalshPC , WojnoKJ , OesterlingJE , et al. Combination of prostate‐specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multiple institutional update. JAMA1997;277:1445‐51. ">Partin 1997</a>]) or prostate + base of seminal vesicles (if nodal risk according to Partin's nomogram was 15% or greater). </p> </div> </div> </section> <section id="CD011462-sec-0081"> <h5 class="title">Outcomes</h5> <p>Median follow‐up ranged from 12 months to 120 months (see <a href="#CD011462-tbl-0002">Table 1</a> and <a href="./references#CD011462-sec-0173" title="">Characteristics of included studies</a> for details). A variety of scales were used to report both acute and late RT toxicity. Four studies reported acute RT toxicity using the RTOG/EORTC scoring system (<a href="./references#CD011462-bbs2-0040" title="CoxJD , StatzJ , PajakTF . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology, Biology, Physics1995;31:1341‐6. ">Cox 1995</a>) (<a href="#CD011462-tbl-0009">Table 7</a>), two studies used the NCI scoring system (<a href="./references#CD011462-bbs2-0085" title="National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (accessed 30 September 2016). ">NCI 2006</a>), and four studies did not describe the scoring system (<a href="#CD011462-tbl-0010">Table 8</a>). Five studies reported late RT toxicity using the RTOG/EORTC scoring system (<a href="./references#CD011462-bbs2-0040" title="CoxJD , StatzJ , PajakTF . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology, Biology, Physics1995;31:1341‐6. ">Cox 1995</a>), one study used the NCI scoring system (<a href="./references#CD011462-bbs2-0085" title="National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (accessed 30 September 2016). ">NCI 2006</a>), three studies used the Late Effects Normal Tissue Task Force‐Subjective, Objective, Management, Analytic (LENT‐SOMA) system (<a href="./references#CD011462-bbs2-0089" title="PavyJJ , DenekampJ , LetschertJ , LittbrandB , MornexF , BernierJ , et al. Late effects toxicity scoring: the SOMA scale. International Journal of Radiation Oncology, Biology, Physics1995;31(5):1043‐7. ">Pavy 1995</a>) (<a href="#CD011462-tbl-0011">Table 9</a>), and one study reported no late RT toxicity (see <a href="#CD011462-tbl-0002">Table 1</a>). </p> <div class="table" id="CD011462-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">RTOG/EORTC scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Organ tissue</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 4</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lower gastrointestinal (modified) (</b><a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). "><b>Lukka NCIC 2005</b> </a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excess bowel movements twice baseline</p> <p>Slight rectal discharge or blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 2 antidiarrheals/week</p> <p>≥ 2 coagulations for bleeding</p> <p>Occasional steroids for ulceration</p> <p>Occasional dilation</p> <p>Intermittent use of incontinence pads</p> <p>Regular non‐narcotic or occasional narcotic for pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 2 antidiarrheals/day</p> <p>≥ 1 blood transfusion or &gt; 2 coagulations for bleeding</p> <p>Steroids per enema</p> <p>Hyperbaric oxygen for ulceration</p> <p>Regular dilation</p> <p>Persistent use of incontinence pads</p> <p>Regular narcotic for pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dysfunction requiring surgery</p> <p>Perforation</p> <p>Life‐threatening bleeding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lower gastrointestinal</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild diarrhea</p> <p>Mild cramping</p> <p>Bowel movement 5 times daily</p> <p>Slight rectal discharge or bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate diarrhea and colic</p> <p>Bowel movement &gt; 5 times daily</p> <p>Excessive rectal mucus or intermittent bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Obstruction or bleeding requiring surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Necrosis/perforation</p> <p>Fistula</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urinary (modified) (</b><a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). "><b>Lukka NCIC 2005</b> </a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nocturia twice baseline</p> <p>Microscopic hematuria</p> <p>Light mucosal atrophy and minor telangiectasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate‐frequency nocturia &gt; twice baseline</p> <p>Generalized telangiectasia</p> <p>Intermittent macroscopic hematuria</p> <p>Occasional blood transfusions</p> <p>≤ 2 coagulations</p> <p>Regular non‐narcotics for pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe frequency and dysuria</p> <p>Nocturia more frequent than once every hour</p> <p>Reduction in bladder capacity (150 mL)</p> <p>Frequent hematuria</p> <p>Frequent transfusions</p> <p>&gt; 1 coagulation for hematuria</p> <p>Regular narcotic for pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe hemorrhagic cystitis</p> <p>Ulceration</p> <p>Requirement for urinary diversion or cystectomy, or both</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urinary</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Slight epithelial atrophy</p> <p>Minor telangiectasia (microscopic hematuria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate urinary frequency</p> <p>Generalized telangiectasia</p> <p>Intermittent macroscopic hematuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe urinary frequency and dysuria</p> <p>Severe generalized telangiectasia (often with petechiae)</p> <p>Frequent hematuria</p> <p>Reduction in bladder capacity (&lt; 150 mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Necrosis/contracted bladder (capacity &lt; 100 mL)</p> <p>Severe hemorrhagic cystitis</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>EORTC: European Organisation for Research and Treatment of Cancer; RTOG: Radiation Therapy Oncology Group. </p> </div> </div> <div class="table" id="CD011462-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">NCIC CTCAE Toxicity scoring</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptom</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade I</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade II</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade III</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade IV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade V</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Gastrointestinal</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anorexia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diarrhea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increase of &lt; 4 stools per day over baseline</p> <p>Increase in ostomy output</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increase of 4–6 stools per day over baseline</p> <p>Moderate increase in ostomy output compared to baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increase of 7 stools per day over baseline</p> <p>Incontinence</p> <p>Hospitalization indicated</p> <p>Severe increase in ostomy output compared to baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Life‐threatening consequences</p> <p>Urgent intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gastrointestinal bleeding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild symptoms</p> <p>Intervention not indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate symptoms</p> <p>Medical intervention or minor cauterization indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion, radiologic, endoscopic or elective operative intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Life‐threatening consequences</p> <p>Urgent intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss of appetite without alteration in eating habits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral intake decreased without significant weight loss, dehydration or malnutrition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain/cramping</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate pain</p> <p>Limiting instrumental ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe pain</p> <p>Limiting self‐care ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vomiting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1–2 episodes (separated by 5 minutes) in 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3–5 episodes (separated by 5 minutes) in 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 6 episodes (separated by 5 minutes) in 24 hours</p> <p>Tube feeding, TPN or hospitalization indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Life‐threatening consequences</p> <p>Urgent intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Bladder changes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cystitis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microscopic hematuria</p> <p>Minimal increase in frequency, urgency, dysuria or nocturia</p> <p>New‐onset incontinence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate hematuria</p> <p>Moderate increase in frequency, urgency, dysuria, nocturia or incontinence</p> <p>Urinary catheter placement or bladder irrigation indicated</p> <p>Limiting instrumental ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gross hematuria</p> <p>Transfusion, IV medications or hospitalization indicated</p> <p>Elective endoscopic, radiologic or operative intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Life‐threatening consequences</p> <p>Urgent radiologic or operative intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fistula</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive intervention indicated</p> <p>Urinary or suprapubic catheter placement indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limiting self‐care ADL</p> <p>Elective radiologic, endoscopic or operative intervention indicated</p> <p>Permanent urinary diversion indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Life‐threatening consequences</p> <p>Urgent radiologic or operative intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Genitourinary pain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate pain</p> <p>Limiting instrumental ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe pain</p> <p>Limiting self‐care ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hematuria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asymptomatic</p> <p>Clinical or diagnostic observations only</p> <p>Intervention not indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic</p> <p>Urinary catheter or bladder irrigation indicated</p> <p>Limiting instrumental ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gross hematuria</p> <p>Transfusion, IV medications or hospitalization indicated</p> <p>Elective endoscopic, radiologic or operative intervention indicated</p> <p>Limiting self‐care ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Life‐threatening consequences</p> <p>Urgent radiologic or operative intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ureteric obstruction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asymptomatic</p> <p>Clinical or diagnostic observations only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic but no hydronephrosis, sepsis or renal dysfunction</p> <p>Urethral dilation, urinary or suprapubic catheter indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic and altered organ function (e.g. hydronephrosis or renal dysfunction)</p> <p>Elective radiologic, endoscopic or operative intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Life‐threatening consequences</p> <p>Urgent intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADL: activities of daily living; IV: intravenous; NCIC CTCAE: National Cancer Information Center Common Terminology Criteria for Adverse Events; TPN: total parenteral nutrition. </p> </div> </div> <div class="table" id="CD011462-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Modified LENT‐SOMA radiation therapy late effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Toxicity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade I</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade II</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade III</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade IV</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Genitourinary</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nocturia twice baseline or non‐narcotic medication (e.g. α‐blocker) once per day increase over baseline </p> <p>Microscopic hematuria</p> <p>Light mucosal atrophy and minor telangiectasia</p> <p>Dysuria not requiring medication</p> <p>Incontinence or dribbling not requiring sanitary pad (over baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frequency ≤ every hour requiring α‐blocker &gt; once per day</p> <p>Nocturia &gt; twice baseline</p> <p>Generalized telangiectasias</p> <p>Macroscopic hematuria requiring ≤ 2 cauterization</p> <p>Dysuria requiring medication (non‐narcotic &gt; once per day or narcotic for pain ≥ 1 per day over baseline) </p> <p>≤ 2 dilations Foley or self‐catheterization for ≤ 2 weeks' incontinence requiring ≤ 2 pads (over baseline) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frequency &gt; 1 every hour or dysuria requiring narcotic &gt; once per day</p> <p>Nocturia &gt; 1 per hour</p> <p>Reduction in bladder capacity (150 cm<sup>3</sup>) ≥ 1 blood transfusions or &gt; 2 cauterizations for bleeding </p> <p>Narcotic use &gt; once per day</p> <p>Hyperbaric oxygen</p> <p>Foley or self‐catheterization &gt; 2 weeks</p> <p>TURP or &gt; 2 dilations</p> <p>Incontinence requiring &gt; 2 pads (over baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gross hematuria requiring &gt; 1 blooded transfusion</p> <p>Severe hemorrhagic cystitis or ulceration requiring urinary diversion with or without cystectomy </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>LENT‐SOMA: Late Effects Normal Tissue Task Force‐Subjective, Objective, Management, Analytic; TURP: transurethral resection of the prostate. </p> </div> </div> </section> </section> <section id="CD011462-sec-0082"> <h4 class="title">Excluded studies</h4> <p>We excluded six studies for the following reasons: use of protons (<a href="./references#CD011462-bbs2-0012" title="NCT01230866 . A phase III prospective randomized trial of standard‐fractionation vs. hypo‐fractionation with proton radiation therapy for low risk adenocarcinoma of the prostate. clinicaltrials.gov/ct2/show/NCT01230866 (first received 29 October 2010). ">NCT01230866</a>), failure to compare fraction size (<a href="./references#CD011462-bbs2-0011" title="DearnaleyDP , SydesAM , LangleyRE , GrahamJD , HuddartRA , SyndikusI , et al. The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISCTN47772397). Radiotherapy and Oncology2007;83:31‐41. DearnaleyPD , HallPD , LawrenceD , HuddartRA , EllesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92:3. ">MRC RT01</a>), use of pelvic nodal irradiation (<a href="./references#CD011462-bbs2-0013" title="NCT01444820 . Phase III study of hypofractionated, dose escalation radiotherapy for high risk adenocarcinoma of the prostate, using 3D‐CRT or intensity‐modulated radiotherapy. clinicaltrials.gov/ct2/show/NCT01444820 (first received 3 October 2011). ">NCT01444820</a>; <a href="./references#CD011462-bbs2-0016" title="NorkusD , KarklelyteA , EngelsB , VermessenH , GriskeviciusR , DeRidderM , et al. A randomized hypofractionation dose escalation trial for high risk prostate cancer patients: interim analysis of acute toxicity and quality of life in 124 patients. Radiation Oncology2013;8(206):1‐8. ">Norkus 2013</a>; <a href="./references#CD011462-bbs2-0023" title="NCT02300389 . Randomized, multi‐center clinical trial comparing hypofractionated radiotherapy boost to conventionally fractionated in a high risk group of prostate cancer patients. clinicaltrials.gov/ct2/show/NCT02300389 (first received 24 November 2014). ">NCT02300389</a>), and comparison of two different hypofractionated regimens (<a href="./references#CD011462-bbs2-0014" title="PollackA , AbramowitzM . Radiation hypofractionation via extended versus accelerated therapy (HEAT) for prostate cancer (HEAT). clinicaltrials.gov/ct2/show/NCT01794403 (first received 18 February 2013). ">NCT01794403</a>). </p> </section> </section> <section id="CD011462-sec-0083"> <h3 class="title">Risk of bias in included studies</h3> <p>See 'Risk of bias' tables for included studies and <a href="#CD011462-fig-0001">Figure 1</a>. </p> <section id="CD011462-sec-0084"> <h4 class="title">Allocation</h4> <section id="CD011462-sec-0085"> <h5 class="title">Sequence generation</h5> <p>Six studies were at low risk of bias for sequence generation and four were at unclear risk of bias. </p> </section> <section id="CD011462-sec-0086"> <h5 class="title">Allocation concealment</h5> <p>Six studies were at low risk of bias for allocation concealment and four were at unclear risk of bias. </p> </section> </section> <section id="CD011462-sec-0087"> <h4 class="title">Blinding</h4> <section id="CD011462-sec-0088"> <h5 class="title">Blinding of participants and personnel</h5> <section id="CD011462-sec-0089"> <h6 class="title">Subjective outcomes</h6> <p>Seven studies were at unclear risk of bias for lack of blinding and three were at high risk of bias. </p> </section> <section id="CD011462-sec-0090"> <h6 class="title">Objective outcomes</h6> <p>Ten studies were at low risk of bias for objective outcomes.</p> </section> </section> <section id="CD011462-sec-0091"> <h5 class="title">Blinding of outcome assessment</h5> <section id="CD011462-sec-0092"> <h6 class="title">Subjective outcomes</h6> <p>Two studies were at low risk for assessment of subjective outcomes, five were at unclear risk of bias and three were at high risk of bias. </p> </section> <section id="CD011462-sec-0093"> <h6 class="title">Objective outcomes</h6> <p>Ten studies were at low risk of bias for assessment of objective outcomes.</p> </section> </section> </section> <section id="CD011462-sec-0094"> <h4 class="title">Incomplete outcome data</h4> <p>One study was at high risk of bias for incomplete outcome data, eight were at low risk of bias and one was at unclear risk of bias. </p> </section> <section id="CD011462-sec-0095"> <h4 class="title">Selective reporting</h4> <p>Four studies were at low risk of reporting bias and six at unclear risk of bias.</p> </section> <section id="CD011462-sec-0096"> <h4 class="title">Other potential sources of bias</h4> <p>The 10 included studies were at low risk of other sources of bias. One study stopped early because of a change in RT technique, "implementation of three dimensional conventional radiation therapy" (<a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a>). Two studies changed the primary endpoint (<a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>; <a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a>). In <a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>, early stopping occurred on the basis of prespecified interim analyses, so this was at low risk of bias. <a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a> changed the primary outcome measure prior to unblinding as the Study Safety Monitoring Board requested changing the definition of PSA failure from American Society of Therapeutic Radiation Oncology to Phoenix; we deemed this domain at low risk of bias. </p> <section id="CD011462-sec-0097"> <h5 class="title">Risk of bias summarized for each outcome</h5> <p>See 'Risk of bias' tables for included studies and <a href="#CD011462-fig-0001">Figure 1</a>. </p> <section id="CD011462-sec-0098"> <h6 class="title">Time to death from prostate cancer</h6> <p>Eight studies contributed data for this outcome (<a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>; <a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>; <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>; <a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>; <a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a>; <a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>; <a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a>). </p> <p>Performance bias: <a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>; and <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a> were at risk of performance bias, given the lack of blinding participants and personnel to the intervention, but both <a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a> and <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a> blinded outcome assessors for cause of death. The single study unblinded for this outcome accounted for 20% of the weight (<a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>). The remaining studies were at unclear risk of bias for lack of information (<a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>; <a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>; <a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a>; <a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>; <a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a>). No study reported the details of on‐study care and permissible cointerventions participants received. </p> <p>Detection bias: in two studies, masked investigators ascertained cause of death, so this domain was at low risk of bias (<a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>). In <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>, there was no blinding, so this outcome was at high risk of detection bias. Two studies (<a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>; <a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a>) were deemed at low risk of detection bias. The remaining studies did not mention blinding, so were at unclear risk of bias. Attrition bias was not considered at high risk of bias for this outcome. </p> </section> <section id="CD011462-sec-0099"> <h6 class="title">Late toxicity</h6> <section id="CD011462-sec-0100"> <p><b>Late RTOG radiation therapy gastrointestinal toxicity</b></p> <p>Four studies contributed data for late RTOG GI RT toxicity (<a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>; <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>; <a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>), </p> <p>Performance bias: <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a> and <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a> were at risk of performance bias, given the lack of blinding of participants and personnel to the intervention and accounted for 52% of the weight. The other studies contributing data for this outcome were at unclear risk of bias (<a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>; <a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>). No study reported the details of on‐study care and permissible cointerventions participants received. </p> <p>Detection bias: two studies were at high risk of bias for lack of blinding for this subjective outcome (<a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>; <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>). <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a> was at high risk of attrition bias for late RTOG GI RT toxicity. The other studies were at unclear risk of bias. </p> </section> <section id="CD011462-sec-0101"> <p><b>Late RTOG radiation therapy genitourinary toxicity</b></p> <p>Four studies contributed data for late RTOG GU RT toxicity (<a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>; <a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>), </p> <p>Performance bias: <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a> and <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a> were at risk of performance bias, given the lack of blinding participants and personnel to the intervention and accounted for 52% of the weight. The other studies contributing data for this outcome were at unclear risk of bias (<a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>; <a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>). No study reported the details of on‐study care and permissible cointerventions participants received. </p> <p>Detection bias: two studies were at high risk of bias for lack of blinding for this subjective outcome (<a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>; <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>). </p> <p>Attrition bias: risk of attrition bias was high for <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a> and low for the other four studies. </p> </section> </section> <section id="CD011462-sec-0102"> <h6 class="title">Time to death from any cause</h6> <p>Performance bias: <a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>; and <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a> were at risk of performance bias, and for lack of blinding participants and personnel to the intervention. The other studies contributing data for this outcome were at unclear risk of bias (<a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>; <a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>; <a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a>; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>; <a href="./references#CD011462-bbs2-0008" title="NorkusD , MillerA , KurtinaitisJ , HaverkampU , PopovS , ProttFJ . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional external‐beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlentherapie Onkologie2009;185(11):715‐21. [DOI: 10.1007/s00066‐009‐1982‐z] NorkusD , MillerA , PlieskieneA , JanulionisE , ValukaKV . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional conformal external beam radiotherapy for localized prostate adenocarcinoma: a report on the first‐year biochemical response. Medicina (Kaunas)2009;45(6):469‐75. NorkusD , ValuckasKP , MillerA , PlieskienėA , KurtinaitisJ . Safety investigation of hypofractionated prostate gland radiotherapy [Neišplitusio priešinės liaukos vėžio hipofrakcionuoto spindulinio gydymo saugumo tyrimas]. Medicina2005;41(12):1035. ">Norkus 2009</a>; <a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>; <a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a>). No study reported the details of on‐study care and permissible cointerventions participants received. </p> <p>Detection bias: all 10 studies that contributed data for this objective outcome were at low or unclear risk of bias for sequence generation and allocation concealment. Risk of attrition bias was low in eight studies contributing data for this outcome, unclear in one study and the single study at high risk of attrition bias contributed 5.5% to the study weight (<a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a>). </p> </section> <section id="CD011462-sec-0103"> <h6 class="title">Time to metastasis</h6> <p>Performance bias: <a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a> and <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a> were at risk of performance bias, given the lack of blinding participants and personnel to the intervention. The other studies contributing data for this outcome were at unclear risk of bias (<a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>; <a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>). No study reported the details of on‐study care and permissible cointerventions participants received. </p> <p>Detection bias: two of the five (<a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>; <a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>; <a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>) studies that contributed data for time to metastasis were at high risk of bias for lack of blinding for this subjective outcome and accounted for 77% of study weight (<a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>). Risk of detection bias was unclear for two studies (<a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>). All studies contributing to this outcome reported on 100% of participants, so risk of attrition bias was low. </p> </section> <section id="CD011462-sec-0104"> <h6 class="title">Time to biochemical relapse</h6> <p>Performance bias: <a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a> was at risk of performance bias for lack of blinding participants and personnel to the intervention and accounted for 15% of study weight. <a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>; and <a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a> were at unclear risk of bias. <a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a>, which accounted for 23% of study weight was at high risk of attrition bias. No study reported the details of on‐study care and permissible cointerventions participants received. </p> <p>Detection bias: in two of the five studies contributing data to this outcome BR‐FS was not a compound endpoint, only PSA failure events contributed and PSA failure was assessed with a prespecified protocol, so this domain was at low risk of bias (see <a href="./references#CD011462-sec-0173" title="">Characteristics of included studies</a> table). It was unclear whether there was blinding in the other studies (<a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>; <a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>). <a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a> was at high risk of attrition bias for this outcome, and accounted for 23% of study weight. </p> </section> <section id="CD011462-sec-0105"> <h6 class="title">Acute toxicity EORTC/RTOG gastrointestinal and gastrointestinal toxicity</h6> <p>Performance bias: <a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>; and <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a> were at risk of performance bias for lack of blinding participants and personnel to the intervention. The other study contributing data for this outcome was at unclear risk of bias (<a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>). No study reported the details of on‐study care and permissible cointerventions participants received. </p> <p>Detection bias: three of the four studies contributing data to this subjective outcome were at high risk of bias because of a lack of blinding (<a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>; <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>); the other was at unclear risk of bias for lack of information (<a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>). The studies contributing to this outcome were at low risk of attrition bias. </p> </section> <section id="CD011462-sec-0106"> <h6 class="title">Quality of life</h6> <p>Performance bias: <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a> was at risk of performance bias for lack of blinding participants and personnel to the intervention. The other studies contributing data for this outcome were at unclear risk of bias (<a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>; <a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>). No study reported the details of on‐study care and permissible cointerventions participants received. </p> <p>Detection bias: one study did not mask the participants and personnel (<a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>), so was at high risk of bias and two studies were at unclear risk of bias for lack of information (<a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>; <a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>). </p> </section> </section> </section> </section> <section id="CD011462-sec-0107"> <h3 class="title" id="CD011462-sec-0107">Effects of interventions</h3> <p>See: <a href="./full#CD011462-tbl-0001"><b>Summary of findings for the main comparison</b> Altered fraction schedules compared to conventional fractionation for clinically localized prostate cancer</a> </p> <section id="CD011462-sec-0108"> <h4 class="title">Primary outcomes</h4> <section id="CD011462-sec-0109"> <h5 class="title">PC‐SS</h5> <p>Hypofractionation may result in little or no difference in PC‐SS (HR 1.00, 95% CI 0.72 to 1.39; studies = 8, participants = 7946; median follow‐up 72 months; low‐certainty evidence; <a href="./references#CD011462-fig-0003" title="">Analysis 1.1</a>). For men in the intermediate‐risk group undergoing conventional fractionation this corresponds to 976 per 1000 men alive after 6 years and 0 more (44 fewer to 18 more) alive per 1000 men undergoing hypofractionation (<a href="./full#CD011462-tbl-0001">summary of findings Table for the main comparison</a>). We downgraded the certainty of evidence by one level for study limitations (lack of blinding with concerns over performance and detection bias) and imprecision, </p> </section> <section id="CD011462-sec-0110"> <h5 class="title">Late gastrointestinal radiation therapy toxicity</h5> <p>We are uncertain about the effect of hypofractionation on late EORTC/RTOG (<a href="./references#CD011462-bbs2-0040" title="CoxJD , StatzJ , PajakTF . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology, Biology, Physics1995;31:1341‐6. ">Cox 1995</a>) GI toxicity at 60 months (RR 1.10, 95% CI 0.68 to 1.78; studies = 4; participants = 3843; very low‐certainty evidence; <a href="./references#CD011462-fig-0009" title="">Analysis 1.7</a>). There was evidence of heterogeneity (P = 0.008; I<sup>2</sup> = 75%). When a fixed‐effect model was used the HR was 0.97 (95% CI 0.8 to 1.17). This corresponds to 109 toxicity events per 1000 participants and 11 more (35 fewer to 85 more), with hypofractionation compared with conventional fractionation at median follow‐up of 72 months in an intermediate‐risk population (<a href="./full#CD011462-tbl-0001">summary of findings Table for the main comparison</a>). We downgraded the certainty of the evidence by three levels for inconsistency, lack of blinding and imprecision. </p> </section> <section id="CD011462-sec-0111"> <h5 class="title">Late genitourinary radiation therapy toxicity</h5> <p>Hypofractionation probably results in little to no difference in late GU toxicity at 60 months (RR 1.05, 95% CI 0.93 to 1.18; studies = 4; participants = 3843; moderate‐certainty evidence; <a href="./references#CD011462-fig-0013" title="">Analysis 1.11</a>). This corresponds to 262 toxicity events per 1000 participants and 13 more (18 fewer to 47 more) with hypofractionation compared with conventional fractionation (<a href="./full#CD011462-tbl-0001">summary of findings Table for the main comparison</a>). We downgraded the certainty of the evidence by one level for study limitations (lack of blinding with risk of performance of detection bias) and attrition bias. </p> </section> </section> <section id="CD011462-sec-0112"> <h4 class="title">Secondary outcomes</h4> <section id="CD011462-sec-0113"> <h5 class="title">Overall survival</h5> <p>Hypofractionation results in little or no difference in overall survival (HR 0.94, 95% CI 0.83 to 1.07; studies = 10, participants = 8243; high‐certainty evidence; <a href="./references#CD011462-fig-0017" title="">Analysis 1.15</a>). For men in the intermediate‐risk group undergoing conventional fractionation this corresponds to 869 per 1000 men alive after six years and 17 fewer (54 fewer to 17 more) alive per 1000 men when undergoing hypofractionation (<a href="./full#CD011462-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD011462-sec-0114"> <h5 class="title">Metastasis‐free survival</h5> <p>Hypofractionation may result in little to no difference to metastasis‐free survival (HR 1.07, 95% CI 0.65 to 1.76; studies = 5, participants = 4985; median follow‐up 62.4 months to 96.5 months; low‐certainty evidence; <a href="./references#CD011462-fig-0018" title="">Analysis 1.16</a>). This corresponds to 19 metastatic events per 1000 participants and five more (58 fewer to 19 more) with hypofractionation compared to conventional fractionation. We downgraded the certainty of the evidence by two levels for imprecision and detection bias. </p> </section> <section id="CD011462-sec-0115"> <h5 class="title">Biochemical relapse‐free survival</h5> <p>Hypofractionation likely results in a small possibly unimportant reduction in BR‐FS based on Phoenix criteria (HR 0.88, 95% CI 0.68 to 1.13; studies = 5, participants = 2889; median follow‐up 90 months to 108 months; moderate‐certainty evidence; <a href="./references#CD011462-fig-0019" title="">Analysis 1.17</a>). In men of the intermediate‐risk group, this corresponds to 804 biochemical‐recurrence free per 1000 participants at six years with conventional fractionation and 42 fewer (134 fewer to 37 more) recurrence‐free per 1000 participants with hypofractionation (<a href="./full#CD011462-tbl-0001">summary of findings Table for the main comparison</a>). We downgraded the certainty of the evidence by one level for study limitations and imprecision. </p> <p>There was moderate heterogeneity (P = 0.14; I<sup>2</sup> = 43%). When the studies where PSA failure was the only event contributing to the outcome were excluded (<a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a>), the HR was 0.90 (95% CI 0.75 to 1.08); this appeared to explain the source of heterogeneity (P = 0.53; I<sup>2</sup> = 0%). </p> </section> <section id="CD011462-sec-0116"> <h5 class="title">Acute radiation therapy gastrointestinal toxicity (Grade II acute RTOG/EORTC or greater)</h5> <p>Hypofractionation probably increases acute GI RT toxicity slightly (RR 1.45, 95% CI 1.19 to 1.75; studies = 4; participants = 4174; at 12 weeks' to 18 weeks' follow‐up; moderate‐certainty evidence; <a href="./references#CD011462-fig-0020" title="">Analysis 1.18</a>). We found there may be some heterogeneity (P = 0.17; I<sup>2</sup> = 41%). This corresponds to 306 episodes of toxicity per 1000 participants with hypofractionation and 47 more (20 more to 87 more) compared with conventional fractionation in an intermediate‐risk population at median follow‐up of 72 months. We downgraded the certainty of the evidence by one level for lack of blinding and imprecision. </p> </section> <section id="CD011462-sec-0117"> <h5 class="title">Acute radiation therapy genitourinary toxicity (Grade II acute RTOG/EORTC or greater)</h5> <p>Hypofractionation likely results in little or no difference to acute GU RT toxicity (RR 1.03, 95% CI 0.95 to 1.11; studies = 4; participants = 4174; at 12 weeks' to 18 weeks' follow‐up; moderate‐certainty evidence; <a href="./references#CD011462-fig-0021" title="">Analysis 1.19</a>). This corresponds to 360 episodes of toxicity per 1000 participants and 11 more (18 fewer to 40 more) with hypofractionation compared with conventional fractionation. We downgraded the certainty of the evidence by one level for risk of bias. </p> </section> <section id="CD011462-sec-0118"> <h5 class="title">Late radiation‐induced malignancy</h5> <p>We found no data with respect to second malignancy.</p> </section> <section id="CD011462-sec-0119"> <h5 class="title">Health‐related quality of life</h5> <section id="CD011462-sec-0120"> <h6 class="title">Global quality of life</h6> <p>EuroQoL 5‐dimension (EQ5D) (303 assessable men in one study) did not differ between treatment arms in <a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a> (see <a href="#CD011462-tbl-0002">Table 1</a>). </p> </section> <section id="CD011462-sec-0121"> <h6 class="title">Self‐reported bowel quality of life</h6> <p>Self‐reported bowel function (185 participants, one study) did not differ between the two study arms at baseline or five years (P &lt; 0.01; figure from text; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>) (see <a href="#CD011462-tbl-0002">Table 1</a>). </p> </section> <section id="CD011462-sec-0122"> <h6 class="title">Self‐reported bowel 'bother'</h6> <p>We were able to report on 1258 men in one study (<a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>). In <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>, 2100/2163 men participated in the quality of life substudy. These included 1404 men in the hypofractionation arm (698 received 60 Gy, 706 received 57 Gy) and 696 in the conventional arm. One thousand four hundred forty‐four men provided data at 24 months post‐RT. Hypofractionation probably results in little or no difference in self‐reported bowel‐related quality of life (RR 1.14, 95% CI 0.84 to 1.56; studies = 1, participants = 1258; <a href="./references#CD011462-fig-0023" title="">Analysis 1.21</a>). The 95% CI included clinically insignificant benefits and clinically meaningful harms (<a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>). The evidence certainty for this outcome was low, being downgraded for imprecision and attrition bias. In <a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>, there was no difference in questionnaire completion rates between study arms. Both Expanded Prostate Cancer Index Composite (EPIC) and 12‐item Short Form (SF‐12) had statistically significant decline over time, but no difference between arms (no P value reported). AUA Symptom Index was stable over time, with no difference between study arms. There was no difference in EPIC Bowel Score between treatment arms in <a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>. </p> <p>At three years, the MD in GI symptoms was 2.03% in favor of conventional fractionation (90% CI –6.18% to 10.23%) (<a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>), so non‐inferiority could not be demonstrated for hypofractionation. To demonstrate non‐inferiority required the incidence of clinically relevant deterioration in the hypofractionation group to be no worse than 8% more than the incidence in the conventional arm (figures from text) (<a href="#CD011462-tbl-0002">Table 1</a>). </p> </section> <section id="CD011462-sec-0123"> <h6 class="title">Sexual quality of life</h6> <p>We were able to report on the 962/1092 men who participated in the quality of life substudy (<a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>). At six months, there were no differences in EPIC scoring, and at 12 months the men in the hypofractionated arm had a larger (but not clinically significant) decline in bowel score. There was no difference between EPIC sexual scores by treatment arm in <a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>. </p> </section> <section id="CD011462-sec-0124"> <h6 class="title">Self‐reported sexual function</h6> <p>Self‐reported sexual function (studies = 1, participants = 185) did not differ between the two study arms at baseline or five years (P &lt; 0.01; figure from text; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>) (see <a href="#CD011462-tbl-0002">Table 1</a>). Erectile dysfunction (assessed in hormone‐naive men who had full or partial erectile function at baseline) was "comparable in both study arms" (quotation from study text) (RR 0.88, 95% CI 0.55 to 1.40; studies = 1, participants = 120; <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>; see <a href="#CD011462-tbl-0002">Table 1</a>). Orgasmic function was higher in the hypofractionated arm at 36 months (P = 0.043; figure from text; <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>). </p> <p>Sexual function was non‐inferior at three years (MD –10.48%, 90% CI –24.88% to –3.91%; <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>). To demonstrate non‐inferiority required the incidence of clinically relevant deterioration in the hypofractionation group to be no worse than 8% more than the incidence in the conventional arm (figures from text) (<a href="#CD011462-tbl-0002">Table 1</a>). </p> </section> <section id="CD011462-sec-0125"> <h6 class="title">Self‐reported sexual 'bother' at 60 months</h6> <p>We studied 1084 men in one study (<a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>). We found that hypofractionation probably makes little or no difference to self‐reported sexual 'bother', although we could not exclude either clinically insignificant benefits or clinically insignificant harms (RR 1.00, 95% CI 0.88 to 1.12). Evidence certainty for this outcome was moderate, being downgraded for attrition bias. </p> </section> <section id="CD011462-sec-0126"> <h6 class="title">Doctor‐reported sexual 'bother'</h6> <p>We studied 1416 men in one study (<a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>). We found hypofractionation makes little or no difference to doctor‐reported sexual 'bother', and excluded clinically significant benefits and harms (RR 0.97, 95% CI 0.90 to 1.05). </p> </section> <section id="CD011462-sec-0127"> <h6 class="title">Self‐reported bladder quality of life</h6> <p>Self‐reported bladder function (studies = 1, participants = 185) did not differ between the two study arms at baseline or five years (P &lt; 0.01; figure from text; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>) (see <a href="#CD011462-tbl-0002">Table 1</a>). </p> <p>At three years, the MD in GU symptoms was 0.49% in favor of conventional fractionation (90% CI –7.20% to 8.18%; <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>), so non‐inferiority could not be demonstrated for hypofractionation. To demonstrate non‐inferiority required the incidence of clinically relevant deterioration in the hypofractionation group to be no worse than 8% more than the incidence in the conventional arm (figures from text) (<a href="#CD011462-tbl-0002">Table 1</a>). </p> </section> <section id="CD011462-sec-0128"> <h6 class="title">Self‐reported late bladder 'bother'</h6> <p>Grade II or greater bladder 'bother' at five years was not different between the study arms in <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a> (9.6% [60 Gy regimen] and 7.9% [57 Gy regimen] in the hypofractionated arms and 6.5% in the conventional arm) (P = 0.74 [60 Gy regimen] and P = 0.83 ][57 Gy regimen]). There was no difference between EPIC Urinary scores (irritative/obstructive or incontinence) by treatment arm in <a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>. International Prostate Symptom Score (IPSS) score and IPSS Quality of Life (<a href="./references#CD011462-bbs2-0030" title="BarryMH , FowlerFJJr , O'LearyMP , BruskewitzRC , HoltgreweHL , MebustWK , et al. The American Urological Association index for benign prostatic hyperplasia: the measurement committee of the American Urological Association. Journal of Urology1992;148(5):1549‐57. ">Barry 1992</a>) did not differ between treatment arms in <a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a> (see <a href="#CD011462-tbl-0002">Table 1</a>). </p> </section> </section> </section> <section id="CD011462-sec-0129"> <h4 class="title">Subgroup analyses</h4> <section id="CD011462-sec-0130"> <h5 class="title">Risk stratification</h5> <p>We were not able to do subgroup analyses according to risk group stratification as planned </p> </section> <section id="CD011462-sec-0131"> <h5 class="title">Radiation therapy dose 74 Gy or greater versus less than 74 Gy in conventional arm (which reflects current practice) </h5> <p>Using α/β = 1.93, for prostate‐specific survival, there was no evidence of a subgroup effect with hypofractionation when the two subgroups were formally compared (Chi<sup>2</sup> = 2.17, P = 0.14, I<sup>2</sup> = 54%; <a href="./references#CD011462-fig-0005" title="">Analysis 1.3</a>). PC‐SS with dose 74 Gy or greater had an HR of 1.17 (95% CI 0.79 to 1.73) and with a dose less than 74 Gy had an HR of 0.67 (95% CI 0.36 to 1.25). </p> <p>For late GI RT toxicity (Grade II EORTC/RTOG or greater), no studies included in the comparison had a dose less than 74 Gy in the conventional arm. </p> <p>For late GU RT toxicity (Grade II EORTC/RTOG or greater), no studies included in the comparison had a dose less than 74 Gy in the conventional arm. </p> </section> <section id="CD011462-sec-0132"> <h5 class="title">Difference in EQD<sup>2</sup> between the radiation therapy doses delivered in the two study arms (EQD<sup>2</sup> difference less than 4 Gy versus 4 Gy or greater) chosen to explore any effect of dose escalation </h5> <p>For prostate‐specific survival, there was no evidence of a subgroup effect when the two subgroups were formally compared (Chi<sup>2</sup> = 0.36, P = 0.55, I<sup>2</sup> = 0%; <a href="./references#CD011462-fig-0006" title="">Analysis 1.4</a>). Dose difference less than 4 Gy had an HR of 1.11 (95% CI 0.66 to 1.87) and 4 Gy or greater had an HR of 0.90 (95% CI 0.56 to 1.43). </p> <p>For late GI RT toxicity (Grade II RTOG/EORTC or greater), there was no evidence of a subgroup effect when the two groups were formally compared (Chi<sup>2</sup> = 0.36, P = 0.55, I<sup>2</sup> = 0%; <a href="./references#CD011462-fig-0010" title="">Analysis 1.8</a>). Dose difference less than 4 Gy had an HR of 0.94 (95% CI 0.38 to 2.34) and 4 Gy or greater had an HR of 1.30 (95% CI 0.79 to 2.14). </p> <p>For late GU RT toxicity (Grade II RTOG/EORTC or greater), there was no evidence of a subgroup effect when the two groups were formally compared (Chi<sup>2</sup> = 0.24, P = 0.63, I<sup>2</sup> = 0%; <a href="./references#CD011462-fig-0014" title="">Analysis 1.12</a>). Dose difference less than 4 Gy had an HR 1.24 (95% CI 0.71 to 2.18) and 4 Gy or greater had an HR of 1.08 (95% CI 0.93 to 1.25). </p> </section> <section id="CD011462-sec-0133"> <h5 class="title">Quality of delivered radiation</h5> <p>For PC‐SS, there was no evidence of a subgroup effect with hypofractionation when the two subgroups were formally compared (Chi<sup>2</sup> = 0.89, P = 0.35, I<sup>2</sup> = 0%; <a href="./references#CD011462-fig-0008" title="">Analysis 1.6</a>). RT QA process had an HR of 0.88 (95% CI 0.57 to 1.34) and no RT QA process had an HR of 1.22 (95% CI 0.72 to 2.07). </p> <p>For late GI RTOG/EORTC RT toxicity, there was no evidence of a subgroup effect when the two groups were formally compared (Chi<sup>2</sup> = 1.44, P = 0.23, I<sup>2</sup> = 30.5%; <a href="./references#CD011462-fig-0012" title="">Analysis 1.10</a>). RT QA process had an HR of 0.94 (95% CI 0.38 to 2.34) and no RT QA process had an HR of 2.18 (95% CI 0.78 to 6.05). </p> <p>For late GU RTOG/EORTC RT toxicity, there was no evidence of a subgroup effect when the two groups were formally compared (Chi<sup>2</sup> = 0.66, P = 0.42, I<sup>2</sup> = 0%; <a href="./references#CD011462-fig-0016" title="">Analysis 1.14</a>). RT QA process had an HR of 1.00 (95% CI 0.82 to 1.23) and no RT QA process had an HR of 1.7 (95% CI 0.48 to 6.04). </p> </section> <section id="CD011462-sec-0134"> <h5 class="title">Radiation therapy technique (highly conformal radiation therapy versus 3DCRT)</h5> <p>There was no evidence of a subgroup effect on PC‐SS with hypofractionation when the two subgroups were formally compared (test for subgroup interaction: Chi<sup>2</sup> = 0.01, P = 0.93, I<sup>2</sup> = 0%; <a href="./references#CD011462-fig-0004" title="">Analysis 1.2</a>). PC‐SS with highly conformal radiation therapy use had an HR of 1.03 (95% CI 0.69 to 1.50) versus with 3DCRT use had an HR of 0.99 (95% CI 0.42 to 2.32). </p> <p>For late GI RT toxicity (Grade II EORTC/RTOG or greater), all studies included in the comparison used highly conformal radiation therapy. </p> <p>For late GU RT toxicity (Grade II EORTC/RTOG or greater), all studies included in the comparison used highly conformal radiation therapy. </p> </section> <section id="CD011462-sec-0135"> <h5 class="title">Androgen deprivation in more than 50% of participants in both study arms (for efficacy outcomes only) </h5> <p>For prostate‐specific survival, there was no evidence of a subgroup effect with hypofractionation when the two subgroups were formally compared (Chi<sup>2</sup> = 2.4, P = 0.12, I<sup>2</sup> = 58.3%; <a href="./references#CD011462-fig-0007" title="">Analysis 1.5</a>). Use of androgen deprivation had an HR of 1.29 (95% CI 0.81 to 2.04) and no androgen deprivation had an HR of 0.76 (95% CI 0.47 to 1.23). </p> <p>For late GI RT toxicity (Grade II RTOG/EORTC or greater), there was evidence of a subgroup effect when the two groups were formally compared (Chi<sup>2</sup> = 9.95, P = 0.002, I<sup>2</sup> = 89%; <a href="./references#CD011462-fig-0011" title="">Analysis 1.9</a>). Androgen deprivation had an RR of 1.22 (95% CI 0.96 to 1.56) and no androgen deprivation had an RR of 0.64 (95% CI 0.46 to 0.88). </p> <p>For late GU RT toxicity (Grade II RTOG/EORTC or greater), there was no evidence of a subgroup effect when the two groups were formally compared (Chi<sup>2</sup> = 0.50, P = 0.48, I<sup>2</sup> = 0%; <a href="./references#CD011462-fig-0015" title="">Analysis 1.13</a>). Androgen deprivation had an RR of 1.14 (95% CI 0.85 to 1.52) and no androgen deprivation had an RR of 1.00 (95% CI 0.81 to 1.23). </p> </section> </section> <section id="CD011462-sec-0136"> <h4 class="title">Sensitivity analysis</h4> <section id="CD011462-sec-0137"> <h5 class="title">Study age (excluding studies that commenced accrual before 2002)</h5> <p>For the outcome of prostate‐specific survival: our findings were robust to this sensitivity analysis when the one study that commenced accrual before 2002 was excluded (<a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a>) (HR 1.09, 95% CI 0.75 to 1.59), there was no evidence of heterogeneity (P = 0.66, I<sup>2</sup> = 0%). </p> <p>For the outcome Grade II late RTOG/EORTC or greater GI toxicity at 60 months, no studies met the criteria for this sensitivity analysis. </p> <p>For the outcome Grade II late RTOG/EORTC or greater GU toxicity at 60 months, no studies met the criteria for this sensitivity analysis. </p> </section> <section id="CD011462-sec-0138"> <h5 class="title">Study quality (excluding studies at high risk of bias for that outcome)</h5> <p>No study contributing to this outcome met the criteria for this sensitivity analysis.</p> </section> <section id="CD011462-sec-0139"> <h5 class="title">Duration of follow‐up (excluding studies with follow‐up of less than 10 years, measured from time of randomization to outcome assessment) </h5> <p>All included studies had fewer than 10 years' follow‐up.</p> </section> <section id="CD011462-sec-0140"> <h5 class="title">By altering the α/β ratio for the subgroup analysis dose 74 Gy or greater versus less than 74 Gy in conventional arm (chosen to reflect current practice) </h5> <p>Using α/β = 4.14 for PC‐SS, there was no evidence of an effect with hypofractionation when the two subgroups were formally compared (Chi<sup>2</sup> = 2.17, P = 0.14, I<sup>2</sup> = 54%). PC‐SS with dose 74 Gy or greater had an HR of 1.17 (95% CI 0.79 to 1.73) and dose less than 74 Gy had an HR of 0.67 (95% CI 0.36 to 1.25). </p> <p>Using α/β = 0.58 for PC‐SS, there was no evidence of an effect with hypofractionation when the two subgroups were formally compared (Chi<sup>2</sup> = 2.17, P = 0.14, I<sup>2</sup> = 54%). PC‐SS with dose 74 Gy or greater had an HR of 1.17 (95% CI 0.79 to 1.73) and dose less than 74 Gy had an HR of 0.67 (95% CI 0.36 to 1.25). </p> </section> <section id="CD011462-sec-0141"> <h5 class="title">By altering the α/β ratio for the subgroup analysis difference in EQD<sup>2</sup> between the radiation therapy doses delivered in the two study arms (EQD<sup>2</sup> difference less than 4 Gy versus 4 Gy or greater) chosen to explore any effect of dose escalation </h5> <p>Using α/β = 4.14 for PC‐SS, there was no evidence of an effect with hypofractionation when the two subgroups were formally compared (Chi<sup>2</sup> = 0.00, P = 0.97, I<sup>2</sup> = 0%). PC‐SS with dose 74 Gy or greater had an HR of 0.99 (95% CI 0.66 to 1.49) and dose less than 74 Gy had an HR of 1.01 (95% CI 0.55 to 1.84). </p> <p>Using α/β = 0.58 for PC‐SS, there was no evidence of an effect with hypofractionation when the two subgroups were formally compared (Chi<sup>2</sup> = 1.2, P = 0.27, I<sup>2</sup> = 16.8%). PC‐SS with dose 74 Gy or greater had an HR of 1.14 (95% CI 0.77 to 1.68) and dose less than 74 Gy had an HR of 0.73 (95% CI 0.36 to 1.47). </p> <p>We tested how robust our findings were by using both random‐effects and fixed‐effect models to analyze outcomes other than time‐to‐event data. For the outcome of late GI RT toxicity (Grade II EORTC/RTOG or greater), there was an effect (HR 0.97, 95% CI 0.8 to 1.17). Changing the model did not affect other outcomes. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011462-sec-0142" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011462-sec-0142"></div> <section id="CD011462-sec-0143"> <h3 class="title" id="CD011462-sec-0143">Summary of main results</h3> <p>With hypofractionation for localized prostate cancer we found: low‐certainty evidence that PC‐SS is similar, very low‐certainty evidence that late GI RT toxicity is probably similar, moderate‐certainty evidence that late GU RT toxicity is similar, high‐certainty evidence that overall survival is similar and low‐certainty evidence that metastasis‐free survival is similar. We found moderate‐certainty evidence that BR‐FS is probably slightly increased with hypofractionation. We found moderate‐certainty evidence that hypofractionation probably increases acute GU RT toxicity slightly while it likely results in little to no difference in acute GI toxicity. Hypofractionation probably results in little to no difference in quality of life. </p> </section> <section id="CD011462-sec-0144"> <h3 class="title" id="CD011462-sec-0144">Overall completeness and applicability of evidence</h3> <p>We found no evidence of indirectness; the studies included all directly evaluated our review question. </p> <p>The participants included reflected those seen in the clinic. The studies included a mixture of men with low‐, intermediate‐ and high‐risk disease (<a href="./references#CD011462-bbs2-0083" title="National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®): prostate cancer. Version 1.2015. www.nccn.org (accessed 23 November 2014). ">NCCN 2014</a>), with the exception of <a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>, which was limited to low‐risk men (see <a href="#CD011462-tbl-0007">Table 5</a>). We were unable to report the time‐to‐event outcomes by risk subgroup. </p> <p>Most (73.6%) men studied received highly conformal radiation therapy, which is the standard of care for men treated radically with RT for prostate cancer. highly conformal radiation therapy (paired with image guidance) allows safe dose escalation, while minimizing both acute and late GI RT and GU RT toxicity (<a href="./references#CD011462-bbs2-0046" title="DearnaleyDP , JovicG , SyndikusI , KhooV , CowanRA , GrahamJD , et al. Escalated‐dose versus control‐dose conformal radiotherapy for prostate cancer: long‐term results from the MRC RT01 randomised controlled trial. Lancet Oncology2014;15(4):464‐73. ">Dearnaley 2014</a>; <a href="./references#CD011462-bbs2-0063" title="HouZ , LiG , BaiS . High dose versus conventional dose in external‐beam radiotherapy of prostate cancer: a meta‐analysis of long‐term follow‐up. Journal of Cancer Research Clinical Oncology2015;141:1063‐71. ">Hou 2015</a>; <a href="./references#CD011462-bbs2-0090" title="PeetersST , HeemsbergenWD , vanPuttenWL , SlotA , TabakH , MensJW , et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy of radiotherapy with 78 Gy. International Journal of Radiation Oncology, Biology, Physics2005;61(4):1019‐34. ">Peeters 2005</a>; <a href="./references#CD011462-bbs2-0091" title="PeetersST , HeemsbergenWD , KoperPC , vanPuttenWL , SlotA , DielwartMF , et al. Dose‐response in radiotherapy for localised prostate cancer treated with 3D conformal radiotherapy. Journal of Clinical Oncology2006;24:1990‐6. ">Peeters 2006</a>). </p> <p>BR‐FS was a compound outcome in some studies (see <a href="#CD011462-tbl-0002">Table 1</a>); contributing events included PSA failure, deaths and initiation of androgen deprivation. <a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a> reported a compound endpoint which included clinical and biochemical failure, <a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a> reported disease‐free survival (which included local progression, distant metastases, biochemical relapse or death any cause) and <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a> reported relapse‐free survival (events comprised clinical or biochemical progression, distant metastases or commencement of androgen deprivation). </p> <p>Some studies reported cumulative toxicity of a certain grade, while others reported maximum toxicity reported, which did not allow combination of the results. Some studies used the <a href="./references#CD011462-bbs2-0028" title="American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. International Journal of Radiation Oncology, Biology, Physics1997;37:1035‐41. ">ASTRO 1997</a> definition to report biochemical failure, but we chose to use the Phoenix definition of biochemical failure because it is a better predictor for distant metastases, PC‐SS and overall survival (<a href="./references#CD011462-bbs2-0025" title="AbramowitzMC , LiT , BuyyounouskiMK , RossE , UzzoRG , PollackA , et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer2008;12(1):55‐60. ">Abramowitz 2008</a>). </p> <p>The long natural history of prostate cancer necessitates prolonged observation to observe events. Competing causes of death in older men make PC‐SS important to evaluate the effectiveness of prostate cancer therapies. The relatively short duration of follow‐up in the included studies (median 69 months) may have contributed to imprecision for the CIs around the point estimates for PC‐SS and DM‐FS. Biochemical relapse can precede clinical manifestations of prostate cancer relapse after dose‐escalated RT for localized prostate cancer by more than 10 years (<a href="./references#CD011462-bbs2-0119" title="ZumstegZS , SprattDE , RomesserPB , PeiZ , ZhangZ , PolkinghornW , et al. The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy. European Urology2015;67(6):1009. ">Zumsteg 2015</a>). Late RT toxicity can increase with time, so rates may increase with longer follow‐up duration. With longer follow‐up duration, we may see more precision for these outcomes in updates of this review. More effective salvage therapies may postpone or reduce prostate cancer deaths. </p> <p>Dose‐escalated RT (74 Gy or more) with or without androgen deprivation is the standard of care for external beam treatment of localized intermediate‐ and high‐risk prostate cancer. Most (6/8) studies contributing to cancer outcomes used dose‐escalated RT. Two studies used doses less than 74 Gy, so do not represent current practice (<a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a>; <a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a>). Dose escalation improves BR‐FS, but not PC‐SS or OS (<a href="./references#CD011462-bbs2-0079" title="MichalskiJM , YanY , Watkins‐BrunerD , CoschWR , WinterK , GalvinJM , et al. Preliminary toxicity analysis of 3‐dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high‐dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. International Journal of Radiation Oncology, Biology, Physics2013;87(5):932‐8. ">Michalski 2013</a>). The doses used in the included studies in this review were isoeffective between study arms, so demonstration of equivalent safety and toxicity (both acute and late) was required. The assumption of isoeffectiveness is based on radiobiologic modeling of the α/β ratio for prostate cancer. </p> <p>Studies using more than 2 Gy per fraction were eligible for inclusion in this review. Fraction size in included studies ranged from 2.35 Gy to 3.4 Gy, this could be considered moderate hypofractionation. The conclusions are not valid for fraction sizes larger than 3.4 Gy. </p> <p>A QA process decreased late RTOG/ERTC GI toxicity (<a href="./references#CD011462-fig-0012" title="">Analysis 1.10</a>). Dose escalation without a careful QA process can be associated with increased late GI RT toxicity. </p> </section> <section id="CD011462-sec-0145"> <h3 class="title" id="CD011462-sec-0145">Quality of the evidence</h3> <p>The certainty of evidence ranged from high (overall survival) to very low (late GI toxicity). We frequently downgraded for study limitations due to lack of blinding and the risk of performance and detection bias and imprecision related to study size, event rate and potentially insufficient length of follow‐up. This lack of precision may be addressed in updates of this review. We also downgraded for unexplained inconsistency. </p> </section> <section id="CD011462-sec-0146"> <h3 class="title" id="CD011462-sec-0146">Potential biases in the review process</h3> <p>We believe we have identified all the relevant studies for inclusion in this analysis; despite our best efforts, we may have missed studies in particular foreign language and unpublished studies. </p> <p>For the elderly men in 5/10 included studies treated with androgen deprivation, the presence of prolonged testosterone suppression might have biased the outcome of biochemical relapse if assessed prematurely. We performed a post‐hoc subgroup analysis of the effect of androgen deprivation (based on editorial advice), considering it a potential effect‐modifier but found no suggestion of a subgroup effect. </p> <p>We explored the heterogeneity we detected for the outcome of acute RT toxicity (Grade II EORTC/RTOG or greater) by excluding <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>, and we recognize that this post‐hoc analysis may be a potential source of bias. However, it is a biologically plausible explanation for the potential heterogeneity. </p> <p>Studies contributing data for the outcome of BR‐FS had different events contributing data for the outcome (see <a href="#CD011462-tbl-0002">Table 1</a>). We included all studies in the analysis, but detected what we thought was meaningful heterogeneity, which we explained by excluding the two studies which only contributed PSA failure events to their endpoint of biochemical relapse. This decision was post‐hoc, and done to explain our findings, but may be a potential source of bias. </p> </section> <section id="CD011462-sec-0147"> <h3 class="title" id="CD011462-sec-0147">Agreements and disagreements with other studies or reviews</h3> <p>We found five systematic reviews addressing the topic.</p> <p><a href="./references#CD011462-bbs2-0029" title="BannuruRR , DvorakT , ObadanN , YuWW , PatelK , ChungM , et al. Comparative evaluation of radiation treatments for clinically localized prostate cancer: an updated systematic review. Annals of Internal Medicine2011;155(3):171‐8. ">Bannuru 2011</a> (search date 2007 to 2011) included only English language studies, and included <a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>; <a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a>; <a href="./references#CD011462-bbs2-0008" title="NorkusD , MillerA , KurtinaitisJ , HaverkampU , PopovS , ProttFJ . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional external‐beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlentherapie Onkologie2009;185(11):715‐21. [DOI: 10.1007/s00066‐009‐1982‐z] NorkusD , MillerA , PlieskieneA , JanulionisE , ValukaKV . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional conformal external beam radiotherapy for localized prostate adenocarcinoma: a report on the first‐year biochemical response. Medicina (Kaunas)2009;45(6):469‐75. NorkusD , ValuckasKP , MillerA , PlieskienėA , KurtinaitisJ . Safety investigation of hypofractionated prostate gland radiotherapy [Neišplitusio priešinės liaukos vėžio hipofrakcionuoto spindulinio gydymo saugumo tyrimas]. Medicina2005;41(12):1035. ">Norkus 2009</a>; and <a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a>. The evidence was not systematically reviewed, so the search was not comprehensive. The search date was not recent (2001). No evidence quality assessment was performed. They reported "no significant difference" in overall survival, freedom from biochemical relapse, GI toxicity and GU toxicity for the comparison of hypofractionation versus conventional fractionation of RT for prostate cancer. </p> <p><a href="./references#CD011462-bbs2-0069" title="KoontzBF , BossiA , CozzariniC , WiegelT , D'AmicoA . A systematic review of hypofractionation for primary management of prostate cancer. European Urology2015;68:683‐91. ">Koontz 2015</a> (search date January 1990 to June 2014) included English language studies and performed a systematic search. They included <a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>; <a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>; <a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a>; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>; and <a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a>. They concluded that there was evidence to support the safety of the technique of hypofractionated RT for localized prostate cancer, but that efficacy data were lacking, because follow‐up duration was inadequate. </p> <p><a href="./references#CD011462-bbs2-0118" title="ZaorskyNG , OhriN , ShowalterTN , DickerAP , DenRB . Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treatment Reviews2013;39(7):728‐36. ">Zaorsky 2013</a> (search date 1970 to 2012) searched MEDLINE, PubMed and conference proceedings, but excluded non‐English language studies. The search date was not recent. They included five RCTs (<a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>; <a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a>; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>; <a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a>). They concluded that there was no clear evidence that hypofractionated RT for localized PC was not associated with either improved outcomes or reduced toxicity, and that its use be limited to clinical trials. </p> <p><a href="./references#CD011462-bbs2-0107" title="SunL , ZhuS , ZhaoY , ZhangH , ShangZ , JiangN , et al. Who benefits from hypofractionated radiotherapy for clinically localized prostate cancer: evidence from meta‐analysis. Tumor Biology2014;35:9911‐8. ">Sun 2014</a> (search date 2014) systematically searched and reviewed the literature, they included six RCTs (<a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>; <a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a>; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>; <a href="./references#CD011462-bbs2-0008" title="NorkusD , MillerA , KurtinaitisJ , HaverkampU , PopovS , ProttFJ . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional external‐beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlentherapie Onkologie2009;185(11):715‐21. [DOI: 10.1007/s00066‐009‐1982‐z] NorkusD , MillerA , PlieskieneA , JanulionisE , ValukaKV . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional conformal external beam radiotherapy for localized prostate adenocarcinoma: a report on the first‐year biochemical response. Medicina (Kaunas)2009;45(6):469‐75. NorkusD , ValuckasKP , MillerA , PlieskienėA , KurtinaitisJ . Safety investigation of hypofractionated prostate gland radiotherapy [Neišplitusio priešinės liaukos vėžio hipofrakcionuoto spindulinio gydymo saugumo tyrimas]. Medicina2005;41(12):1035. ">Norkus 2009</a>; <a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a>), three cohort studies and three retrospective case controlled studies. They included non‐randomized data. They reported that hypofractionation improved BR‐FS in localized prostate cancer. </p> <p><a href="./references#CD011462-bbs2-0044" title="DattaNR , StutzE , RogersS , BodisS . Conventional versus hypofractionated radiation therapy for localized or locally advanced prostate cancer: a systematic review and meta‐analysis along with therapeutic implications. International Journal of Radiation Oncology, Biology, Physics2017;99(3):573‐89. ">Datta 2017</a> (search date not stated to 30 March 2017) included English language studies with five years' follow‐up. The authors included nine studies (<a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>; <a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>; <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>; <a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>; <a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a>; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>; <a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>; <a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a>). The evidence was systematically reviewed and the search was systematic. The authors reported to Grade II or greater acute and late RT toxicity, amalgamating data reported using different scoring systems (RTOG/EORTC, LENT‐SOMA and NCI) without explaining how this was accounted for. They concluded they found "non‐significant" differences for PC‐SS, PS and biochemical failure (reported graphically in text, no effect size measures or 95% CI reported). Acute GI RT toxicity was increased with hypofractionation (OR 1.68, CI not reported). For acute GI RT toxicity, and late GI and GU RT toxicity differences were "non‐significant" (no effect sizes or CI reported). They concluded that "hypofractionation provides similar therapeutic outcomes to conventional fractionation except for a significantly greater risk of acute GI toxicity". </p> <p><a href="./references#CD011462-bbs2-0027" title="ArcangeliG , ArcangeliS , PinzicV , BenassidM , BenassieM , StrigarieL . Optimal scheduling of hypofractionated radiotherapy for localized prostate cancer: a systematic review and metaanalysis of randomized clinical trials. Cancer Treatment Reviews2018;70:22‐9. ">Arcangeli 2018</a> (search date not stated to 30 December 2017) included English language studies reporting biochemical failure and greater than Grade II toxicity with five years' follow‐up. The review included nine studies (<a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>; <a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>; <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>; <a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>; <a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). ">Lukka NCIC 2005</a>; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>; <a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>; <a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. ">Yeoh 2011</a>). They did not perform quality assessment. They amalgamated data reported using different scoring systems (RTOG/EORTC, LENT‐SOMA and NCI) without explaining how this was accounted for. They concluded that moderate hypofractionation was associated with equivalent results in freedom from biochemical relapse (risk difference (RD) 0.93, 95% CI 0.84 to1.04), late GI toxicity (RD 0.96, 95% CI 0.77 to 1.25) and late GU toxicity (RD 1.06, 95% CI 0.90 to 1.26). </p> <p>These reviews were conducted with less methodologic rigor than the Cochrane methodology we used, no systematic review assessed evidence certainty on a per outcome basis, the search dates were not current and two limited their search to studies published in English (<a href="./references#CD011462-bbs2-0029" title="BannuruRR , DvorakT , ObadanN , YuWW , PatelK , ChungM , et al. Comparative evaluation of radiation treatments for clinically localized prostate cancer: an updated systematic review. Annals of Internal Medicine2011;155(3):171‐8. ">Bannuru 2011</a>; <a href="./references#CD011462-bbs2-0118" title="ZaorskyNG , OhriN , ShowalterTN , DickerAP , DenRB . Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treatment Reviews2013;39(7):728‐36. ">Zaorsky 2013</a>). One review included non‐randomized data (<a href="./references#CD011462-bbs2-0107" title="SunL , ZhuS , ZhaoY , ZhangH , ShangZ , JiangN , et al. Who benefits from hypofractionated radiotherapy for clinically localized prostate cancer: evidence from meta‐analysis. Tumor Biology2014;35:9911‐8. ">Sun 2014</a>). No other systematic review defined what effect size was considered clinically meaningful for these outcomes and presented no absolute effects. Since publication of these reviews, new studies (<a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>; <a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>; <a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>) and updated results (<a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. ">Arcangeli 2010</a>; <a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>; <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a>) have become available to contribute to the evidence with respect to this question. </p> <p>Joint guidelines produced by American Society of Clinical Oncology (ASCO) and American Society for Therapeutic Radiation Oncology (ASTRO) support the use of hypofractionation for prostate cancer stating that "moderately hypofractionated radiation therapy should be offered to patients who choose EBRT for treatment of prostate cancer" and "hypofractionated radiation therapy provides important potential advantages in cost and convenience for patients" (<a href="./references#CD011462-bbs2-0081" title="MorganSC , HoffmanK , LoblawA , BuyyounouskiMK , Caroline PattonS , BarocasD , et al. Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence‐based guideline, 2018. Practical Radiation Oncology2018; Vol. 8, issue 6:354‐60. ">Morgan 2018</a>). Guidelines from the European Association of Urology (EAU), ESTRO and International Society of Geriatric Oncology (SIOG) support the use of moderate hypofractionation as safe and effective, but note that long‐term data are still lacking (<a href="./references#CD011462-bbs2-0082" title="MottettN , BellmuntJ , BollaM , BriersE , CumberbatchMG , DeSantosM , et al. EAU‐ESTRO‐SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. European Urology2017;71(4):618‐29. ">Mottett 2017</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011462-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgments about each risk of bias item for each included study." data-id="CD011462-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgments about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011462-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 1 Prostate cancer‐specific survival (PC‐SS)." data-id="CD011462-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 1 Prostate cancer‐specific survival (PC‐SS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 2 PC‐SS 3‐dimensional conformal radiation therapy (3DCRT) vs intensity‐modulated radiation therapy (IMRT)." data-id="CD011462-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 2 PC‐SS 3‐dimensional conformal radiation therapy (3DCRT) vs intensity‐modulated radiation therapy (IMRT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 3 PC‐SS subgroup analysis (SGA) by dose 74 Gy or greater control arm." data-id="CD011462-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 3 PC‐SS subgroup analysis (SGA) by dose 74 Gy or greater control arm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 4 PC‐SS &lt; 4 Gy equivalent dose in 2 Gy fractions (EQD2) vs ≥ 4 Gy." data-id="CD011462-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 4 PC‐SS &lt; 4 Gy equivalent dose in 2 Gy fractions (EQD<sup>2</sup>) vs ≥ 4 Gy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 5 PC‐SS androgen deprivation (AD) versus no AD." data-id="CD011462-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 5 PC‐SS androgen deprivation (AD) versus no AD. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 6 PC‐SS quality assurance (QA) versus no QA." data-id="CD011462-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 6 PC‐SS quality assurance (QA) versus no QA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 7 ≥ Grade II late gastrointestinal (GI) Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer (RTOG/EORTC) toxicity at 60 months." data-id="CD011462-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 7 ≥ Grade II late gastrointestinal (GI) Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer (RTOG/EORTC) toxicity at 60 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 8 Late GI RT toxicity by dose ≥ 4 Gy difference between arms." data-id="CD011462-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 8 Late GI RT toxicity by dose ≥ 4 Gy difference between arms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 9 SGA ≥ Grade II late GI RTOG/EORTC toxicity AD vs no AD." data-id="CD011462-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 9 SGA ≥ Grade II late GI RTOG/EORTC toxicity AD vs no AD. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 10 Late GI RT toxicity by QA vs no QA." data-id="CD011462-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 10 Late GI RT toxicity by QA vs no QA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 11 Late genitourinary (GU) ≥ Grade II RTOG/EORTC toxicity at 60 months." data-id="CD011462-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 11 Late genitourinary (GU) ≥ Grade II RTOG/EORTC toxicity at 60 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 12 Late GU RT toxicity by dose ≥ 4 Gy difference between arms." data-id="CD011462-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 12 Late GU RT toxicity by dose ≥ 4 Gy difference between arms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 13 SGA late GU ≥ Grade II RTOG/EORTC toxicity: AD vs no AD." data-id="CD011462-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 13 SGA late GU ≥ Grade II RTOG/EORTC toxicity: AD vs no AD. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 14 Late GU RT toxicity by QA vs no QA." data-id="CD011462-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 14 Late GU RT toxicity by QA vs no QA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 15 Overall survival." data-id="CD011462-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 15 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 16 Metastasis‐free survival." data-id="CD011462-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 16 Metastasis‐free survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 17 Biochemical relapse‐free survival Phoenix." data-id="CD011462-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 17 Biochemical relapse‐free survival Phoenix. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 18 Acute GI ≥ Grade II RTOG/EORTC." data-id="CD011462-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 18 Acute GI ≥ Grade II RTOG/EORTC. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 19 Acute GU ≥ Grade II RTOG/EORTC toxicity." data-id="CD011462-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 19 Acute GU ≥ Grade II RTOG/EORTC toxicity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 20 Health‐related quality of life (HRQoL): ≥ Grade II sexual 'bother' (participant reported) at 60 months." data-id="CD011462-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 20 Health‐related quality of life (HRQoL): ≥ Grade II sexual 'bother' (participant reported) at 60 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 21 HRQoL: ≥ bowel 'bother'." data-id="CD011462-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 21 HRQoL: ≥ bowel 'bother'. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 22 HRQoL: ≥ Grade II sexual 'bother' (doctor reported) at 60 months." data-id="CD011462-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 22 HRQoL: ≥ Grade II sexual 'bother' (doctor reported) at 60 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 23 HRQoL: erectile function." data-id="CD011462-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 23 HRQoL: erectile function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 24 PC‐SS sensitivity analysis (SA) dose ≥ 74 Gy conventional (α/β 4.14)." data-id="CD011462-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 24 PC‐SS sensitivity analysis (SA) dose ≥ 74 Gy conventional (α/β 4.14). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 25 PC‐SS SA dose control arm ≥ 74 Gy (α/β 0.58)." data-id="CD011462-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 25 PC‐SS SA dose control arm ≥ 74 Gy (α/β 0.58). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 26 PC‐SS SA &lt; 4 Gy EQD2 vs ≥ 4 Gy (α/β 4.14) to 4 Gy." data-id="CD011462-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 26 PC‐SS SA &lt; 4 Gy EQD<sup>2</sup> vs ≥ 4 Gy (α/β 4.14) to 4 Gy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011462-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/urn:x-wiley:14651858:media:CD011462:CD011462-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_t/tCD011462-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Hypofraction versus conventional fractionation, Outcome 27 PC‐SS SA EQD2 &lt; 4 Gy vs ≥ 4 Gy (α/β 0.58))." data-id="CD011462-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 Hypofraction versus conventional fractionation, Outcome 27 PC‐SS SA EQD<sup>2</sup> &lt; 4 Gy vs ≥ 4 Gy (α/β 0.58)). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/media/CDSR/CD011462/image_n/nCD011462-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011462-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Altered fraction schedules compared to conventional fractionation for clinically localized prostate cancer</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Altered fraction schedules compared to conventional fractionation for clinically localized prostate cancer</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b> : clinically localized prostate cancer<br/> <b>Setting</b> :<b>h</b> ospitals and cancer centers<br/> <b>Intervention</b> : altered fraction schedules<br/> <b>Comparison</b>: conventional fractionation </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with conventional fractionation</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with altered fraction schedules</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Prostate cancer‐specific survival</b> </p> <p>Follow‐up: median 60–108 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="6" valign="top"> <p>7946<br/> (8 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 1.00</b><br/> (0.72 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>996 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 more per 1000<br/> (15 fewer to 4 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Intermediate<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>976 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 more per 1000<br/> (44 fewer to 18 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>962 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 more per 1000<br/> (57 fewer to 27 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Late gastrointestinal RT toxicity</b><br/> ≥ Grade II RTOG/EORTC </p> <p>Follow‐up: median 60 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3843<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1a,f,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.10</b><br/> (0.68 to 1.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109 per 1000<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 more per 1000<br/> (35 fewer to 85 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Late genitourinary RT toxicity</b><br/> ≥ Grade II RTOG/EORTC </p> <p>Follow‐up: median 60 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>3843<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.05</b><br/> (0.93 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262 per 1000<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 more per 1000<br/> (13 fewer to 47 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Overall survival</b> </p> <p>Follow‐up: median 12–108 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="6" valign="top"> <p>8243<br/> (10 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>HR 0.94</b><br/> (0.83 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>905 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 fewer per 1000<br/> (47 fewer to 14 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Intermediate<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>869 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 fewer per 1000<br/> (54 fewer to 17 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>High<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>851 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 fewer per 1000<br/> (57 fewer to 19 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Metastasis‐free survival</b> </p> <p>Follow‐up: median 68.4–100.5 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4985<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>HR 1.07</b><br/> (0.65 to 1.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>j</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>981 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 more per 1000<br/> (58 fewer to 19 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Biochemical relapse‐free survival</b> </p> <p>Follow‐up: median 90–108 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>2889<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a,k,l</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>HR 0.88</b><br/> (0.68 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Low<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>907 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 fewer per 1000<br/> (106 fewer to 25 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Intermediate<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>804 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 fewer per 1000<br/> (134 fewer to 37 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute GU RT toxicity</b><br/> assessed with: ≥ Grade II RTOG/EORTC </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>4174<br/> (4 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.03</b><br/> (0.95 to 1.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>h</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 more per 1000<br/> (15 fewer to 34 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>EORTIC:</b> European Organisation for Research and Treatment of Cancer; <b>HR:</b> hazard ratio; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio; <b>RT:</b> radiation therapy; <b>RTOG:</b> Radiation Therapy Oncology Group. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for study limitations (lack of blinding with risk of performance of detection bias).<br/> <sup>b</sup>Downgraded one level for imprecision because there were fewer than 300 events.<br/> <sup>c</sup><a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a> was used for control event rate: a contemporary study that used highly conformal radiation therapy with image guidance in a low‐risk population.<br/> <sup>d</sup><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a> was used for control event rate: a contemporary study that used highly conformal radiation therapy with image guidance in an intermediate‐risk population.<br/> <sup>e</sup><a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a> was used for control event rate: a contemporary study that used highly conformal radiation therapy with image guidance in a population that had 74% of participants with high‐risk prostate cancer.<br/> <sup>f</sup>Downgraded one level because there may have been moderate heterogeneity (I<sup>2</sup> = 76%).<br/> <sup>g</sup>Downgraded one level for imprecision; although it met optimum information size, the 95% confidence interval included both clinically meaningful and clinically insignificant harms.<br/> <sup>h</sup><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a> was used for control event rate: a contemporary source of prospectively collected toxicity data that used highly conformal radiation therapy with image guidance in an intermediate‐risk population.<br/> <sup>i</sup>Downgraded one level for study limitations (lack of blinding with risk of performance of detection bias) and attrition bias.<br/> <sup>j</sup>Control event rate was derived from the included studies for this outcome.<br/> <sup>k</sup>Although there may have been meaningful heterogeneity (P = 0.09, I<sup>2</sup> = 55%), this could be explained by excluding the two studies for which biochemical relapse‐free survival was not a compound endpoint (P = 0.36, I<sup>2</sup> = 0%). For the other studies, biochemical relapse‐free survival was a compound endpoint, incorporating prostate‐specific antigen failure, deaths and salvage therapy.<br/> <sup>l</sup>Downgraded for study limitations (attrition bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Altered fraction schedules compared to conventional fractionation for clinically localized prostate cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011462-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcomes</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acute RT toxicity scale used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Late RT toxicity scale used</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PSA failure definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events contributing to biochemical relapse endpoint</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Self‐reported outcomes (PRO)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sexual function</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Follow‐up (median)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. "><b>Arcangeli 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG/EORTC<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LENT‐SOMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phoenix<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA rise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. "><b>CHHiP 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG/EORTC<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG/EORTC<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phoenix</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA failure, LR, DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRO<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UCLA‐PCI, EPIC<sup>e</sup>, FACT‐P </p> <p>EPIC‐50 was used for bowel and urinary domains</p> <p>EPIC‐26 for sexual and hormonal domains. For all quality of life instruments, scores range from 0 to 100, and higher was better </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.4 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. "><b>Fox Chase 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4‐point scale, detailed, but not referenced</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LENT‐SOMA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phoenix<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA rise, LR, DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Self‐reported: EPIC<sup>e</sup>, IPSS<sup>f</sup>, EQ5D<sup>g</sup> assessed at baseline, and 12, 24, 36, 48 and 60 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. "><b>HYPRO Dutch 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG/EORTC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG/EORTC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phoenix<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA rise<sup>h</sup>, LR, DM, salvage AD </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRO<sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IIIEF<sup>j</sup> used at baseline, and 6, 12, 24 and 36 months. EORTC ‐QLQ‐PR25<sup>k</sup> used </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. "><b>Lee 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCI CTCAE Maximum toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG/EORTC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phoenix<sup>c</sup> </p> <p>DFS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death without recurrence, PSA rise, salvage AD, DM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EPIC<sup>e</sup> was used, with assessments at baseline, 6 months and 12 months after randomization </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). "><b>Lukka NCIC 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCIC Grade III‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NCIC Grade III‐IV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ASTRO<sup>l</sup> </p> <p>BCDF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA rise, LR, DM, salvage AD, PC death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. "><b>MDACC 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified EORTC/RTOG<sup>m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phoenix</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA rise, salvage AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRO<sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Urinary, sexual and bowel function assessed at baseline, 2, 3, 4 and 5 years<sup>n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0008" title="NorkusD , MillerA , KurtinaitisJ , HaverkampU , PopovS , ProttFJ . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional external‐beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlentherapie Onkologie2009;185(11):715‐21. [DOI: 10.1007/s00066‐009‐1982‐z] NorkusD , MillerA , PlieskieneA , JanulionisE , ValukaKV . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional conformal external beam radiotherapy for localized prostate adenocarcinoma: a report on the first‐year biochemical response. Medicina (Kaunas)2009;45(6):469‐75. NorkusD , ValuckasKP , MillerA , PlieskienėA , KurtinaitisJ . Safety investigation of hypofractionated prostate gland radiotherapy [Neišplitusio priešinės liaukos vėžio hipofrakcionuoto spindulinio gydymo saugumo tyrimas]. Medicina2005;41(12):1035. "><b>Norkus 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scale not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scale not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ASTRO<sup>l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA rise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). "><b>PROFIT 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG/EORTC<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RTOG/EORTC<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ASTRO<sup>l</sup> </p> <p>Phoenix<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA rise, LR, DM, salvage AD, death any cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PRO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EPIC<sup>e</sup>, AUA at baseline, and 24 and 48 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. "><b>Yeoh 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Modified LENT‐SOMA<sup>o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phoenix<sup>b</sup> </p> <p>ASTRO<sup>l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PSA rise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EORTC<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90 months<sup>p</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>AD: androgen deprivation; ASTRO: American Society for Radiation Oncology; AUA: American Urological Association; BCDF: biochemical or clinical disease failure, or both; DFS: disease‐free survival; DM: distant metastases; EORTC: European Organisation for Research and Treatment of Cancer; EPIC: Expanded Prostate Cancer Index Composite; EQ5D: EuroQoL 5‐dimension; FACT‐P: Functional Assessment of Cancer Therapy – Prostate (<a href="./references#CD011462-bbs2-0051" title="EsperP , MoF , ChodakG , SinnerM , CellaD , PientaKJ . Measuring quality of life in men with prostate cancer using the functional assessment of cancer‐therapy‐prostate instrument. Urology1997;50:920‐8. ">Esper 1997</a>); IIIEF: International Index of Erectile Function; IPSS: International Prostate Symptom Score; LENT‐SOMA: Late Effects Normal Tissue Task Force‐Subjective, Objective, Management, Analytic system (<a href="./references#CD011462-bbs2-0089" title="PavyJJ , DenekampJ , LetschertJ , LittbrandB , MornexF , BernierJ , et al. Late effects toxicity scoring: the SOMA scale. International Journal of Radiation Oncology, Biology, Physics1995;31(5):1043‐7. ">Pavy 1995</a>); LR: local recurrence; NCI CTCAE: National Cancer Institute Common Toxicity Criteria for Adverse Events version 3 (<a href="#CD011462-tbl-0010">Table 8</a>); NCIC: National Institute of Cancer Canada toxicity 5‐point scale; PC: prostate cancer; PRO: participant‐reported outcome; PSA: prostate‐specific antigen; QLQ‐PR25: Quality of Life Questionnaire – Prostate Cancer Module; RT: radiation therapy; RTOG: Radiation Therapy Oncology Group; UCLA‐PCI: University of California, Los Angeles Prostate Cancer Index (<a href="./references#CD011462-bbs2-0074" title="LitwinMS , HaysRD , FinkA , Ganz PA LeakeB , BrookeRH . The UCLA Prostate Cancer Index: development, reliability, and validity of a health‐related quality of life measure. Medical Care1998;36:1002‐12. ">Litwin 1998</a>).<br/> <sup>a</sup>RTOG/EORTC RT toxicity scoring scale (<a href="./references#CD011462-bbs2-0040" title="CoxJD , StatzJ , PajakTF . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology, Biology, Physics1995;31:1341‐6. ">Cox 1995</a>).<br/> <sup>b</sup>Phoenix definition of biochemical failure: PSA nadir plus 2 (<a href="./references#CD011462-bbs2-0099" title="RoachM3rd , HanksG , ThamesHJr , SchellhammerP , ShipleyWU , SokolGH , et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG‐ASTRO Phoenix Consensus Conference. International Journal of Radiation Oncology, Biology, Physics2006;65(4):965‐74. ">Roach 2006</a>). PSA measured at three monthly follow‐up visits for first two years, six monthly for years three to five, then annually to 10 years.<br/> <sup>c</sup>Assessed weekly during RT; weeks 10, 12 and 18 for acute toxicity; then at 26 weeks and every six months for five years for late toxicity.<br/> <sup>d</sup>In <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>, the question: "Overall, how much of a problem have your bowels been for you in the last 4/52?" was asked. A seven‐item bowel bother was assessed. The bowel domain summary (5‐point scale) is reported, those with small, moderate or severe bowel bother (Grade II or more) (<a href="#CD011462-tbl-0003">Table 10</a>). <a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. ">CHHiP 2016</a>: quality of life scales changed during the study, because better instruments became available. Initially, UCLA‐PCI was used from trial initiation to early 2009 (<a href="./references#CD011462-bbs2-0074" title="LitwinMS , HaysRD , FinkA , Ganz PA LeakeB , BrookeRH . The UCLA Prostate Cancer Index: development, reliability, and validity of a health‐related quality of life measure. Medical Care1998;36:1002‐12. ">Litwin 1998</a>). The UCLA‐PCI included 36‐item Short Form (SF‐36) and FACT‐P (<a href="./references#CD011462-bbs2-0051" title="EsperP , MoF , ChodakG , SinnerM , CellaD , PientaKJ . Measuring quality of life in men with prostate cancer using the functional assessment of cancer‐therapy‐prostate instrument. Urology1997;50:920‐8. ">Esper 1997</a>). From March 2009, the EPIC and SF‐12 (<a href="./references#CD011462-bbs2-0112" title="WareJ , KosinskiM , KellerSD . A 12‐item short‐form health survey: construction of scales and preliminary tests of reliability and validity. Medical Care1996;34:220‐33. ">Ware 1996</a>) replaced UCLA‐PCI. EPIC‐50 was used for bowel and urinary domains and EPIC‐26 for sexual and hormonal domains.<br/> <sup>e</sup>EPIC and 12‐item Short Form 12 (<a href="./references#CD011462-bbs2-0112" title="WareJ , KosinskiM , KellerSD . A 12‐item short‐form health survey: construction of scales and preliminary tests of reliability and validity. Medical Care1996;34:220‐33. ">Ware 1996</a>). The tool is scored from 0 to 100 (with higher scores being better, a significant change is 0.5 standard deviations and four domains are assessed: bowel, urinary, sexual and hormonal.<br/> <sup>f</sup>IPSS measures urinary obstructive symptoms: 0 = no symptoms, 35 = maximum (<a href="./references#CD011462-bbs2-0030" title="BarryMH , FowlerFJJr , O'LearyMP , BruskewitzRC , HoltgreweHL , MebustWK , et al. The American Urological Association index for benign prostatic hyperplasia: the measurement committee of the American Urological Association. Journal of Urology1992;148(5):1549‐57. ">Barry 1992</a>). It also incorporates a 1 to 6 visual analogue scale: 0 = 'delighted' with current state of urinary symptoms.<br/> <sup>g</sup>EuroQoL 5‐dimension (EQD5) questionnaire covers five dimensions (mobility, self‐care, usual activities, pain/discomfort, anxiety/depression), also incorporates visual analog scale: the two scores are transformed into a utility score where 0 = 'worst health state' and 1 = 'best health state'.<br/> <sup>h</sup>PSA failure was reported as "first event" data, so we could not include it (<a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>).<br/> <sup>i</sup>Late RTOG/EORTC gastrointestinal and genitourinary toxicity events were counted if noted in clinical record, participant self‐assessments or both (<a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>).<br/> <sup>j</sup>IIEF although not formally validated in men who have RT or radical prostatectomy for PC, is the most commonly used validated tool for assessment of erectile function (<a href="./references#CD011462-bbs2-0100" title="RosenRC , RileyA , WagnerG , OsterlohIH , KirkpatrickJ , MishraA . The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology1997;49:822‐30. ">Rosen 1997</a>). <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a> used it to assess the following sexual domains in 671/820 men enrolled: erectile function (in hormone‐naive men), orgasmic function, sexual desire, intercourse and overall satisfaction. The minimally important clinical difference for erectile function was 4. In <a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>, 322/820 men completed the IIEF at baseline and at least one other time‐point enrolled .<br/> <sup>k</sup>EORTC scale measures toxicity and functional subscales (<a href="./references#CD011462-bbs2-0110" title="vanAndelG , BottomleyA , FossaSD . An international field study of the health‐related quality of life of patients with prostate cancer. European Journal of Cancer2008;44:2418‐24. ">van Andel 2008</a>). For all quality of life instruments, scores range from 0 to 100, and higher score is better for functional outcomes and lower is better for toxicity outcomes. Quality of life was assessed at baseline, and six, 12, 24, 36, 48 and 60 months. Change from baseline of five points was considered relevant clinically. Non‐inferiority was set at 8%, i.e. the incidence of clinically relevant deterioration in the hypofractionation group will be no worse than 8% more than the incidence in the conventional arm.<br/> <sup>l</sup>ASTRO definition of biochemical failure: three consecutive PSA rises (<a href="./references#CD011462-bbs2-0041" title="CoxJ , GrignonD , KaplanR , ParsonsJT , SchelhammerPF . Concensus statement: guidelines for PSA following radiation therapy. International Journal of Radiation Oncology, Biology, Physics1997;37(5):1035‐41. ">Cox 1997</a>).<br/> <sup>m</sup>Modified RTOG/EORTC scoring system (see <a href="#CD011462-tbl-0009">Table 7</a>) (<a href="./references#CD011462-bbs2-0040" title="CoxJD , StatzJ , PajakTF . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology, Biology, Physics1995;31:1341‐6. ">Cox 1995</a>).<br/> <sup>n</sup>185 men in <a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. ">MDACC 2014</a> were eligible for PROs, they did not differ from the remainder of men randomized in the study, and completion of the PRO questionnaire was similar at each time‐point. Self‐reported urinary, bowel and sexual function were assessed at baseline (<a href="http://links.lww.com/AJCO/A138" target="_blank">links.lww.com/AJCO/A138</a>) and at two, three, four and five years (<a href="http://links.lww.com/AJCO/A140" target="_blank">links.lww.com/AJCO/A140</a>).<br/> <sup>o</sup>Modified LENT‐SOMA (see <a href="#CD011462-tbl-0011">Table 9</a>).<br/> <sup>p</sup> Participants reviewed at first month after RT, three‐month intervals for two years, then six‐month intervals for three years, then annually thereafter. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011462-tbl-0003"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Bowel 'bother'</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Description</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No bother</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>I</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Very small bother</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>II</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Small bother</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>III</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate bother</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Big bother</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Bowel 'bother'</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011462-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">EQD2 dose comparison (α/β 1.93)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypofractionation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose per fraction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQD2</b> </p> <p><b>(α/β = 1.93 prostate cancer)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conventional</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose per fraction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQD2</b> </p> <p><b>(α/β = 1.93 prostate cancer)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. "><b>Arcangeli 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 Gy/40 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. "><b>CHHiP 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 Gy/20 fractions</p> <p>57 Gy/19 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.38</p> <p>71.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 Gy/37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. "><b>Fox Chase 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.2 Gy/26 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 Gy/38 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. "><b>HYPRO Dutch 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.6 Gy/19 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 Gy/39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. "><b>Lee 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy/28 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.8 Gy/41 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). "><b>Lukka NCIC 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.5 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66 Gy/33 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. "><b>MDACC 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 Gy/30 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.6 Gy/42 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71.28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0008" title="NorkusD , MillerA , KurtinaitisJ , HaverkampU , PopovS , ProttFJ . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional external‐beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlentherapie Onkologie2009;185(11):715‐21. [DOI: 10.1007/s00066‐009‐1982‐z] NorkusD , MillerA , PlieskieneA , JanulionisE , ValukaKV . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional conformal external beam radiotherapy for localized prostate adenocarcinoma: a report on the first‐year biochemical response. Medicina (Kaunas)2009;45(6):469‐75. NorkusD , ValuckasKP , MillerA , PlieskienėA , KurtinaitisJ . Safety investigation of hypofractionated prostate gland radiotherapy [Neišplitusio priešinės liaukos vėžio hipofrakcionuoto spindulinio gydymo saugumo tyrimas]. Medicina2005;41(12):1035. "><b>Norkus 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 Gy/17 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 Gy/37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). "><b>PROFIT 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 Gy/39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. "><b>Yeoh 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 Gy/32 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>EQD<sup>2</sup>: equivalent dose in 2 Gy fractions. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">EQD2 dose comparison (α/β 1.93)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011462-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">EQD2 (α/β 0.58)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypofractionation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose per fraction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQD<sup>2</sup> </b> </p> <p><b>(α/β = 0.58 prostate cancer)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conventional</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose per fraction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQD<sup>2</sup> </b> </p> <p><b>α/β = 0.58 prostate cancer</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. "><b>Arcangeli 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 Gy/40 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. "><b>CHHiP 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 Gy/20 fractions</p> <p>57 Gy/19 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.08</p> <p>78.92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 Gy/37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. "><b>Fox Chase 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.2 Gy/26 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 Gy/38 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. "><b>HYPRO Dutch 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.6 Gy/19 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 Gy/39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. "><b>Lee 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70 Gy/28 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.8 Gy/41 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). "><b>Lukka NCIC 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.5 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66 Gy/33 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. "><b>MDACC 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72 Gy/30 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.6 Gy/42 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0008" title="NorkusD , MillerA , KurtinaitisJ , HaverkampU , PopovS , ProttFJ . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional external‐beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlentherapie Onkologie2009;185(11):715‐21. [DOI: 10.1007/s00066‐009‐1982‐z] NorkusD , MillerA , PlieskieneA , JanulionisE , ValukaKV . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional conformal external beam radiotherapy for localized prostate adenocarcinoma: a report on the first‐year biochemical response. Medicina (Kaunas)2009;45(6):469‐75. NorkusD , ValuckasKP , MillerA , PlieskienėA , KurtinaitisJ . Safety investigation of hypofractionated prostate gland radiotherapy [Neišplitusio priešinės liaukos vėžio hipofrakcionuoto spindulinio gydymo saugumo tyrimas]. Medicina2005;41(12):1035. "><b>Norkus 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 Gy/17 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74 Gy/37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). "><b>PROFIT 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 Gy/39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. "><b>Yeoh 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 Gy/32 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>EQD<sup>2</sup>: equivalent dose in 2 Gy fractions. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">EQD2 (α/β 0.58)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011462-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">EQD2 (α/β 4.14)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hypofractionation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose per</b> </p> <p><b>fraction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQD<sup>2</sup> </b> </p> <p><b>(α/β = 4.14 prostate cancer)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Conventional</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose per</b> </p> <p><b>fraction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EQD<sup>2</sup> </b> </p> <p><b>α/β = 4.14 prostate cancer</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. "><b>Arcangeli 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80 Gy/40 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. "><b>CHHiP 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 Gy/20 fractions</p> <p>57 Gy/19 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.84</p> <p>66.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 Gy/37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. "><b>HYPRO Dutch 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64.6 Gy/19 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78 Gy/39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. "><b>Fox Chase 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.2 Gy/26 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 Gy/38 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. "><b>Lee 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 Gy/28 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.8 Gy/41 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). "><b>Lukka NCIC 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52.5 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 Gy/33 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. "><b>MDACC 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 Gy/30 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.6 Gy/42 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73.12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0008" title="NorkusD , MillerA , KurtinaitisJ , HaverkampU , PopovS , ProttFJ . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional external‐beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlentherapie Onkologie2009;185(11):715‐21. [DOI: 10.1007/s00066‐009‐1982‐z] NorkusD , MillerA , PlieskieneA , JanulionisE , ValukaKV . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional conformal external beam radiotherapy for localized prostate adenocarcinoma: a report on the first‐year biochemical response. Medicina (Kaunas)2009;45(6):469‐75. NorkusD , ValuckasKP , MillerA , PlieskienėA , KurtinaitisJ . Safety investigation of hypofractionated prostate gland radiotherapy [Neišplitusio priešinės liaukos vėžio hipofrakcionuoto spindulinio gydymo saugumo tyrimas]. Medicina2005;41(12):1035. "><b>Norkus 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 Gy/17 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74 Gy/37 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). "><b>PROFIT 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78 Gy/39 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. "><b>Yeoh 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 Gy/20 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 Gy/32 fractions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>EQD<sup>2</sup>: equivalent dose in 2 Gy fractions. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">EQD2 (α/β 4.14)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011462-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Participants</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NCCN risk classification</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PSA (ng/mL)<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Gleason score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. "><b>Arcangeli 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate 42%</p> <p>High risk 15%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 6–7: 97%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5–7: 75%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. "><b>CHHiP 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Intermediate (73%) and high risk" (12%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median PSA 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5–7: 96%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. "><b>Fox Chase 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Intermediate (66%) and high risk" (33–35%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10: 64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6–7: 81%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. "><b>HYPRO Dutch 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Intermediate (26–27%) and high risk" (74–74%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>median 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7–9: 68%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. "><b>Lee 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84% 60 + years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4–9: 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5–6: 99.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). "><b>Lukka NCIC 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5–7: 82%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. "><b>MDACC 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk 28%</p> <p>Intermediate risk 71%</p> <p>High risk 1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 10: 90%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7: 65%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0008" title="NorkusD , MillerA , KurtinaitisJ , HaverkampU , PopovS , ProttFJ . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional external‐beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlentherapie Onkologie2009;185(11):715‐21. [DOI: 10.1007/s00066‐009‐1982‐z] NorkusD , MillerA , PlieskieneA , JanulionisE , ValukaKV . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional conformal external beam radiotherapy for localized prostate adenocarcinoma: a report on the first‐year biochemical response. Medicina (Kaunas)2009;45(6):469‐75. NorkusD , ValuckasKP , MillerA , PlieskienėA , KurtinaitisJ . Safety investigation of hypofractionated prostate gland radiotherapy [Neišplitusio priešinės liaukos vėžio hipofrakcionuoto spindulinio gydymo saugumo tyrimas]. Medicina2005;41(12):1035. "><b>Norkus 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 10: 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 6: 97%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). "><b>PROFIT 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intermediate risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 10: 68%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7: 90.6%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. "><b>Yeoh 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study predates risk stratification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>n: number of participants; PSA: prostate‐specific antigen.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Participants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011462-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Interventions</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Technique</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>IGRT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Motion control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RT QA</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Androgen deprivation (in both study arms)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RT volume</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CTV to PTV margins</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0001" title="ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariM , et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three‐dimensional conformal radiotherapy for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;79(4):1013‐21. ArcangeliG , FowlerJ , GomelliniS , ArcangeliS , SaracinoB , PetrongariMG , et al. A phase III randomized study of high‐dose conventional versus hypofractionated radiotherapy in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S79. ArcangeliG , SaracinoB , ArcangeliS , GomelliniS , PetrongariMG , SanguinettiG , et al. Moderate hypofractionation in high‐risk, organ‐confined prostate cancer: final results of a phase III randomised controlled trial. Journal of Clinical Oncology2017;35(17):1891‐7. [DOI: 10.1200/JCO.2016.70.4189] ArcangeliG , SaracinoB , GomelliniS , PetrongariM , ArcangeliG , SentinelliS , et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2010;78(1):11‐8. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariM , PinnaroP , et al. Updated results and pattern of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S147. ArcangeliS , StrigariL , GomelliniS , SaracinoB , PetrongariMG , PinnaroP , et al. Updated results and patterns of failure in a randomized hypofractionation trial for high‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(5):1172‐8. ArcangeliS , StrigariL , SoeteG , DeMeelleerG , GomelliniS , FonteyneV , et al. Clinical and dosimetric predictors of acute toxicity after a 4‐week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. International Journal of Radiation Oncology, Biology, Physics2009;73(1):39‐45. GiordanoC , FerraroAM , SaracinoB , PetrongariMG , ArcangeliG , LandoniV , et al. Hypofractionated versus conventionally fractionated 3DCRT for high‐risk prostate cancer: updated results of a randomized trial. Anticancer Research2015;35(6):3615‐3740. LandoniV , ArcidiaconoF , SaracinoBM , FarnetiA , PetrongariMG , SanguinetiG . Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2015;93:S200. MarziS , SaracinoB , PetrongariMG , ArcangeliS , GomelliniS , ArcangeliG , et al. Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. Journal of Experimental Clinical Cancer Research2009;28(1):117. SanguinetiG , ArcidiaconoF , LandoniV , SaracinoBM , FarnetiA , ArcangeliS , et al. Macroscopic hematuria after conventional or hypofractionated radiation therapy: results from a prospective phase 3 study. International Journal of Radiation Oncology, Biology, Physics2016;96(2):304‐12. [DOI: 10.1016/j.ijrobp.2016.05.017] SaracinoB , ArcangeliG , StrigariL , PetrongariM , GomelliniS , GiordanoC . Hypo versus conventionally fractionated 3DCRT for high risk prostate cancer: updated results of a randomized trial. International Journal of Radiation Oncology, Biology. Physics2014;90(1):S53. StrigariL , ArcangeliG , ArcangeliG , BenassiM . Mathematical model for evaluating incidence of acute rectal toxicity during conventional or hypofractionated radiotherapy courses for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2009;73(5):1454‐60. "><b>Arcangeli 2010</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3DCRT and IMRT (center dependent)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/3 centers used either ultrasound or fiducial markers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EQD2 ± 5% in both study arms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CTV = prostate + seminal vesicles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0 isotropically (0.6 cm posteriorly)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0002" title="CHHiP . Correction to Lancet Oncol 2016; 17: 1055. Lancet Oncology2016;17(8):e321. CHHiP Trial Management Committee. Conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer protocol version 9.2. www.thelancet.com/cms/10.1016/S1470‐2045(11)70293‐5/attachment/69c8416a‐a567‐43a2‐ab17‐5926fc5cc8b6/mmc1.pdf (accessed 10 March 2019). DearnaleyD , GriffinCL , SyndikusI , ScraseC , ThomasS , NaismithO . IGRT for prostate cancer: results from the CHHiP IGRT phase II sub‐study. Radiotherapy and Oncology2014;19(1):S59. DearnaleyD , SyndikusE , MossopH , KhooV , BIrtleA , BloomfieldD , et al. Conventional versus hypo‐fractionated high‐dose intensity modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. [DOI: 10.2016/S1470‐2045(16)30102‐4] DearnaleyD , SyndikusI , MossopH , BirtleA , BloomfieldD , CruickshankC , et al. 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group. European Journal of Oncology2015;51:S712. DearnaleyD , SyndikusI , MossopH , KhooV , BirtleA , BloomfieldD , et al. on behalf of the CHHiP Investigators. Supplement to conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: 5‐year outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2016;17(8):1047‐60. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. (ISRCTN47772397) The early toxicity of escalated versus standard dose conformal radiotherapy with neo‐adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial. Radiotherapy and Oncology2007;83(1):31‐41. DearnaleyD , SyndikusI , SumoG , BidmeadM , BloomfieldD , ClarkC , et al. Conventional versus hypofractionated high‐dose intensity‐modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncology2012;13(1):43‐54. DearnaleyDP , HallE , LawrenceD , HuddartRA , EelesR , NuttingCM , et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. British Journal of Cancer2005;92(3):488‐98. DearnaleyDP , NaismithO , SumoG . A dosimetry comparison of forward‐ and inverse‐planned IMRT for prostate cancer in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. Dearnaley on behalf of the CHHiP Trial Management Group. CHHiP (Conventional of Hypofractionated High‐dose intensity‐modulated radiotherapy for Prostate cancer) (CRUK/06/016). International Journal of Radiation Oncology, Biology, Physics2016;96:S2. ISRCTN97182923 . A randomised phase III multi‐centre trial of Conventional or Hypofractionated High dose Intensity modulated radiotherapy for Prostate cancer. www.isrctn.com/ISRCTN97182923 (first received 9 September 2005). [DOI 10.1186/ISRCTN97182923] KhooVS , DearnaleyDP . Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer – the CHHiP trial. Clinical Oncology (Royal College of Radiologists (Great Britain))2008;20(1):12‐4. NCT00392535 . Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP. clinicaltrials.gov/ct2/show/NCT00392535 (first received 26 October 2006). NaismithO , DearnaleyDP , HallE . A survey of the benefits to RT processes and techniques of participating in the CHHiP trial. Radiotherapy and Oncology2011;99 S1:S585. StaffurthJ , HavilandJ , WilkinsA , SyndikusI , KhooV , BloomfieldD , et al. Impact of prostate cancer hypofractionation on patient reported outcomes: baseline to 5 years change in the CHHIP trial. International Journal of Radiation Oncology, Biology, Physics2018;102:S1. WilkinsA , MossopH , GriffinC , DearnaleyD , HallE , on behalf of the CHHiP Trial Management Group. Patient reported outcomes of overall bowel and urinary bother in the CHHiP trial (CRUK: 8262/A7257). Radiotherapy and Oncology2015;115:S355. WilkinsA , MossopH , SyndikusI , KhooV , BloomfieldD , ParkerC , et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate‐risk localised prostate cancer: 2‐year patient‐reported outcomes of the randomised, non‐inferiority, phase 3 CHHiP trial. Lancet Oncology2015;16(16):1605‐16. WilkinsAC , GustersonB , SzijgyartoZ , HavilandJ , GriffinC , StuttleC , et al. Ki67 is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer. www.ncbi.nlm.nih.gov/m/pubmed/29559283/ (accessed 8 April 2018). [DOI: 10.1016/j.ijrobp.2018.01.072] WilsonJM , DearnaleyDP , SyndikusI , KhooV , BirtleA , BloomfieldD , et al. The efficacy and safety of conventional and hypofractionated high‐dose radiation therapy for prostate cancer in an elderly population: a subgroup analysis of the CHHiP trial. International Journal of Radiation Oncology, Biology, Physics2018;100(5):1179‐89. "><b>CHHiP 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Permitted, but not required</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>National QA program</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EQD2 ± 5% in both study arms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostate + seminal vesicles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5–10 mm (depending on OARs)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. "><b>Fox Chase 2013</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ultrasound</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Empty rectum, moderately full bladder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose escalation in hypofractionated arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk adapted<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypofractionated arm: 7 mm with 3 mm posteriorly</p> <p>conventional fractionation: 8 mm with 5 mm posteriorly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. "><b>HYPRO Dutch 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMRT 95%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose escalation in hypofractionated arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk adapted<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CTV + 3–10 mm = PTV. Boost margins 0 mm towards the posteriorly, 3–5 mm in other directions<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. "><b>Lee 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMRT 79%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes (fiducial markers, ultrasound, cone beam CT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central QA described<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose escalation in hypofractionated arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4–10 mm margin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). "><b>Lukka NCIC 2005</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3DCRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Real‐time QA for first 30 participants from each center, if OK, then random spot checks on 20% of plans </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose hypofractionated arm &lt; conventional arm</p> <p>Dose in both arms &lt; 78 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mm margin</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0007" title="HoffmanK , VoongKR , LevyLB , PughTJ , MunsellMF , ChoiS , et al. Randomized trial of hypofractionated dose‐escalated IMRT vs conventionally fractionated IMRT for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96 2S:S32. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer results from a randomized trial. American Journal of Clinical Oncology2018;41:558‐67. HoffmanKE , SkinnerH , PughTJ , VoongKR , LevyLB , ChoiS , et al. Patient‐reported urinary, bowel, and sexual function after hypofractionated intensity‐modulated radiation therapy for prostate cancer: results from a randomized trial. journals.lww.com/amjclinicaloncology/Abstract/publishahead/Patient_reported_Urinary,_Bowel,_and_Sexual.99020.aspx (accessed 24 May 2017). [DOI: 10.1097/COC.0000000000000325] HoffmanKE , VoongKR , LevyLB , AllenPK , ChoiS , SchlembachPJ , et al. Randomized trial of hypofractionated, dose‐escalated, intensity‐modulated radiation therapy (IMRT) versus conventionally fractionated IMRT for localized prostate cancer. Journal of Clinical Oncology2018;36(29):2943‐9. HoffmanKE , VoongKR , PughTJ , SkinnerH , Levy LB TakairV , et al. Risk of late toxicity in men receiving dose‐escalated hypo‐fractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. KubanDA , LevyLB , CheungMR , LeeAK , ChoiS , FrankS , et al. Long‐term failure patterns and survival in a randomized dose‐escalation trial for prostate cancer. Who dies of disease?. International Journal of Radiation Oncology, Biology, Physics2011;79(5):1310‐7. KubanDA , Nogueras‐GonzalezGM , HamblinL , LeeAK , ChoiS , FrankSJ , et al. Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology, Biology, Physics2010;78(3):S58‐9. NCT00667888 . A phase III intensity radiation dose escalation for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00667888 (first received 28 April 2008). SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSJ , ChoiS , et al. Risk of late toxicity in men receiving dose‐escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology, Biology, Physics2014;88(5):1074‐84. SkinnerHD , HoffmanKE , LevyLB , LeeAK , FrankSK , ChoiS , et al. Toxicity and dosimetric parameters related to conventional versus dose‐escalated, hypofractionated radiation in prostate cancer. International Journal of Radiation Oncology, Biology, Physics2012;84(3S):S147. VoongKR , LalLS , KubanDA , PughTJ , SwintM , GodbyJ , et al. Long‐term economic value of hypofractionated prostate radiation: secondary analysis of a randomized trial. Advances in Radiation Oncology2017;2(3):249‐58. "><b>MDACC 2014</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fiducial markers or ultrasound</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Full bladder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose escalation in hypofractionated arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostate + seminal vesicles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10–15 mm all dimensions except 4–8 mm posteriorly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0008" title="NorkusD , MillerA , KurtinaitisJ , HaverkampU , PopovS , ProttFJ . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional external‐beam radiotherapy for localized prostate adenocarcinoma: a report on acute toxicity. Strahlentherapie Onkologie2009;185(11):715‐21. [DOI: 10.1007/s00066‐009‐1982‐z] NorkusD , MillerA , PlieskieneA , JanulionisE , ValukaKV . A randomized trial comparing hypofractionated and conventionally fractionated three‐dimensional conformal external beam radiotherapy for localized prostate adenocarcinoma: a report on the first‐year biochemical response. Medicina (Kaunas)2009;45(6):469‐75. NorkusD , ValuckasKP , MillerA , PlieskienėA , KurtinaitisJ . Safety investigation of hypofractionated prostate gland radiotherapy [Neišplitusio priešinės liaukos vėžio hipofrakcionuoto spindulinio gydymo saugumo tyrimas]. Medicina2005;41(12):1035. "><b>Norkus 2009</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3DCRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin marks, weekly portal images</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose escalation in hypofractionated arm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostate + base of seminal vesicles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8–10 mm all dimensions</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). "><b>PROFIT 2016</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IMRT (3DCRT permitted if OAR constraints met)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily image guidance (fiducial markers, cone beam CT or ultrasound)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Real‐time central QA for all cases prior to fraction 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EQD2 ± 5% in both study arms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk adapted<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 mm with 7 mm posteriorly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011462-bbs2-0010" title="YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Anorectal dysfunction increases with time following radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2004;99(2):361‐9. YeohEE , BottenRJ , ButtersJ , DiMatteoAC , HollowayRH , FowlerJ . Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1271‐8. YeohEE , FraserRJ , McGowanRE , BottenRJ , DiMatteoAC , RoosDE , et al. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2003;55(4):943‐55. YeohEE , HollowayRH , FraserRJ , BottenRJ , DiMatteoAC , ButtersJ , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics2006;66(4):1072‐83. YeohEK , HollowayRH , FraserRJ , BottenR , DiMatteoA , MooreJW . Anorectal function after three‐ versus two‐dimensional radiation therapy for carcinoma of the prostate. International Journal of Radiation Oncology, Biology, Physics2009;73(1):46‐52. "><b>Yeoh 2011</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156/217 (72%) 2DRT</p> <p>61/217 (28%) 3DCRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EQD2 ± 5% in both study arms</p> <p>Dose in both arms &lt; 78 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prostate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 mm margin</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>2DRT: two‐dimensional radiation therapy; 3DCRT: three‐dimensional radiation therapy; CT: computer tomography; CTV: clinical target volume; EQD2: equivalent dose in 2 Gy fractions; IMRT: intensity‐modulated radiation therapy; OAR: organs at risk: planning target volume; QA: quality assurance; RT: radiation therapy.<br/> <sup>a</sup><a href="./references#CD011462-bbs2-0003" title="AvkshtolV , LiT , HallmanMA , GreenbergR , PriceRA , UzzoRG , et al. 10‐year update of a randomized prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2018;102:S30. Jean‐PierreP , StoyanovaR , PenedoF , AntoniM , AbramowitzM , BuyyounouskiM , et al. Treatment‐related side effects and quality of life among prostate cancer patients treated with conventional versus hypofractionated intensity mediated radiotherapy: a phase iii hypofractionation trial. International Journal of Radiation Oncology, Biology, Physics2011;2:S667. KonskiAA , BuyyounouskiMK , StoyanovaR , MovsasB , UzzoR , HorwitzEM , et al. Quality adjusted survival comparing standard versus hypofractionated radiation therapy in the treatment of prostate cancer. International Journal of Radiation Oncology, Biology, Physics2015;93(3):S118‐9. NCT00062309 . A phase III intensity modulated radiotherapy dose escalation trial for prostate cancer using hypofractionation. clinicaltrials.gov/ct2/show/NCT00062309 (first received 6 June 2003). PollackA , BaeK , KhorLY , HammondE , Al‐SaleemT Li T , et al. Stability of tumor biomarkers in archival tissue from men treated with radiotherapy for prostate cancer: an analysis of RTOG 92‐02 and Fox Chase randomized trials. International Journal of Radiation Oncology Biology, Physics. 2006; Vol. 66 3S:S365‐S366. PollackA , BuyyounouskiTM , HorwitzE , PriceR , FeigenbergS , KonskiA , et al. Hypofractionation for prostate cancer: interim results of a randomized trial. International Journal of Radiation Oncology, Biology, Physics2009;75(3):S81. PollackA , HanlonAL , HorwitzEM , FeigenbergSJ , KonksiAA , MovsasB , et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology, Biology, Physics2006;64(2):518‐26. PollackA , WalkerG , BuyyounouskiM , HorwitzE , PriceR , FeigenbergS , et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. International Journal of Radiation Oncology, Biology, Physics2011;81(2):S1. PollackA , WalkerG , HorwitzEM , PriceR , FeigenbergS , KonskiAA , et al. Randomized trial of hypofractionated external‐beam radiotherapy for prostate cancer. Journal of Clinical Oncology2013;31(3):3860‐8. PollackH , WalkerG , HorwitzEM , PriceK , FeigenbergS , KonskiAA , et al. Reply to M.J. Brenner et al and I.R. Vogelius et al. Journal of Clinical Oncology2014; Vol. 32, issue 17:1853‐4. ShaikhT , RuthK , DevarajanK , ZaorskyNG , HallmanMA , SobczakML , et al. Dosimetric and clinical predictors of long‐term toxicity in patients undergoing hypofractionated prostate radiation therapy: results from a randomized phase 3 trial. International Journal of Radiation Oncology, Biology, Physics2016;96:S123. ShaikhT , TianyuL , HandorfEA , JohnsonME , WangLS , HallmanMA , et al. Long‐term patient‐reported outcomes from a phase 3 randomised prospective trial of conventional versus hypofractionated radiation therapy for localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2017;97(4):722‐31. StoyanovaR , WalkerG , SandlerK , KhorL , HorwitzE , BuyyounouskiM , et al. Determinants of prostate biopsy positivity 2 years after radiation therapy for men with prostate cancer treated on a randomized trial. International Journal of Radiation Oncology, Biology, Physics2012;84(3):S60. TurakaA , ZhuF , BuyyounouskiMK , HorwitzD , Watkins‐BrunerD , KonskiA , PollackA . Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. International Journal of Radiation Oncology, Biology, Physics2010;78:S62. ">Fox Chase 2013</a>: CTV1 = at least 50% of the seminal vesicles (all gross disease extending to the seminal vesicles received the full dose), in addition to the prostate and any extraprostatic extension. CTV2 = distal seminal vesicles. CTV3 = pelvic lymph nodes (periprostatic, periseminal vesicle, external iliac, obturator and internal iliac lymph nodes). Pelvic nodes treated in high‐risk men (17/154) in hypofractionated arm, (32/153) in conventional arm.<br/> <sup>b</sup><a href="./references#CD011462-bbs2-0004" title="AluwiniS , PosF , SchimmelE , KrolS , van derToornPP , deJagerH , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non‐inferiority, phase 3 trial. Lancet Oncology2016;17(4):464‐74. AluwiniS , PosF , SchimmelE , vanLinE , KrolS , van derToornPP , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non‐inferiority phase 3 trial. Lancet Oncology2015;16(3):274‐83. AluwiniS , PosF , vanLinE , SchimmelE , KrolA , van derToornP , et al. Acute toxicity of the randomized phase III Dutch Hypofractionation trial (HYPRO) for prostate cancer. Radiotherapy and Oncology2012;103:S84‐5. HeemsbergenW , IncrocciI , VensC , WitteM , AluwiniS , PosF , et al. More acute proctitis symptoms with hypofractionation (3.4Gy) than 2 Gy fractions. Radiotherapy and Oncology2016;119 S1:S155‐6. HeemsbergenW , WortelR , PosF , SmeenkR , KroS , AluwiniS , et al. Patient‐reported outcome in the prostate HYPRO trial: gastrointestinal toxicity. Radiotherapy and Oncology2017;123:S60. ISRCTN85138529 . HYpofractionated irradiation for PROstate cancer: a randomised multicentre phase III study. www.isrctn.com/ISRCTN85138529 (first received 22 November 2006). [DOI: 10.1186/ISRCTN85138529] IncrocciI , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13(11):1695‐703. IncrocciL , WortelRC , AlemayehuWG , AluwiniS , SchimmelE , KrolS , et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncology2016;17(8):1061‐9. [DOI: 10.1016/S1470‐2045(16)30070‐5] IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2016;94:1. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolAD , Van DerToornPP , et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94(1):1‐2. IncrocciL , WortelRC , AluwiniS , SchimmelE , KrolDG , Van DerToornPP . Hypofractionated versus conventionally fractionated radiation therapy for prostate cancer: five‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2015;94 S1:LBA2. PosF , IncrocciL , WortelR , Van derHeideU , LebesqueJ , AluwiniS , et al. Anal dose reduction for radiotherapy of prostate cancer does not lead to less rectal incontinence. Radiotherapy and Oncology2016;S:157. PosF , WortelRC , HeemsbergenWD , Oomen‐de HoopE , IncrocciL . Health‐related quality of life from the prostate hypofractionation (HYPRO) trial. Radiotherapy and Oncology2018;127 s1:s26‐s27. SharfoAW , DirkxML , BijmanRG , SchillemansW , BreedveldS , AluwiniS , et al. Late toxicity in HYPRO randomized trial analyzed by automated planning and intrinsic NTCP modelling. Radiotherapy and Oncology2017;123:S126. SharfoAW , MaartenLP , DirkxRG , SchilemansW , BreedveldS , AluwiniS , et al. Late toxicity in the randomized multicenter HYPRO trial for prostate cancer analyzed with automated treatment planning. Radiotherapy and Oncology2018;128(2):2349‐56. WitteM , HeemsbergenW , PosF , VensC , AluwiniS , IncrocciL . Linear‐quadratic modelling of acute rectum toxicity in a prostate hypo‐fractionation trial. Radiotherapy and Oncology2016;119 S1:S119. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;127(S1):S258. WitteM , PosF , IncrocciL , HeemsbergenW . Relating dose outside the prostate with freedom from failure in the Dutch HYPRO trial. Radiotherapy and Oncology2018;128:S258. WortelR , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results of the prospective, randomized phase 3 randomized phase 3 HYPRO trial. Journal of Urology 2016 4S;195:e626‐7. WortelR , IncrocciL , AluwiniS , SchimmelE , KrolS , van derToornP , et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‐year oncologic outcomes of the Dutch randomized phase 3 HYPRO trial. American Journal of Urology2016:e142‐e143. WortelRC , FlorisJP , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. WortelRC , HeemsbergenWD , SmeenkRJ , WitteMG , SDG , PosFJ . Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. International Journal of Radiation, Oncology, Physics2017;99(5):1243‐52. WortelRC , IncrocciL , PosFJ , SmeenkRJ , KrolAD , AluwiniS . Patient‐reported outcomes from the phase III prostate HYPRO trial: urinary toxicity. Radiotherapy and Oncology2017;123:S295. WortelRC , IncrocciL , PosFJ , van derHeideUA , LebesqueV , AluwiniS . Late side effects after image guided intensity modulated radiation therapy compared to 3D‐conformal radiation therapy for prostate cancer: results from 2 prospective cohorts. International Journal of Radiation Oncology, Biology, Physics2016;95(2):680‐99. WortelRC , Oomen‐de HoopE , HeemsbergenWD , PosFJ , IncrocciL . Moderate hypofractionation in intermediate and high‐risk, localized prostate cancer: health‐related quality of life from the randomized, phase 3 HYPRO trial. International Journal of Radiation Oncology, Biology, Physics2019;103(4):823‐33. WortelRC , PosFJ , HeemsbergenWD , IncrocciL . Sexual function after hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: results from the randomized phase III HYPRO trial. Journal of Sexual Medicine2016;13:1695‐703. ">HYPRO Dutch 2016</a>: prostate alone treated to 64.6 Gy in 19 fractions (hypofractionated group) or 79 Gy in 39 fractions (conventional group). Prostate + boost to seminal vesicle (35 fractions of 2 Gy up to 70 Gy) or 39 fractions of 1.85 Gy (standard fractionation group), or a dose of 16 fractions of 3.4 Gy or 19 fractions of 3.04 Gy (hypofractionation group). Prostate + seminal vesicle treated to 64.6 Gy in 19 fractions (hypofractionated group) or 79 Gy in 39 fractions (conventional group).<br/> <sup>c</sup>CTV to PTV margin depended on the setup verification and correction strategy used in each participating institute. This boost could either be delivered sequentially or simultaneously integrated depending on the institute's preference.<br/> <sup>d</sup>Quality assurance: "All RT plans were submitted as digital DICOM files to the Image guided Therapy Quality Assurance Center for central quality assurance review. CT scans, target volumes, organ‐at‐risk contours, radiation dose distributions, dose volume histograms, and dose statistics were reviewed for compliance with protocol guidelines (<a href="./references#CD011462-bbs2-0005" title="LeeRL , DignamJL , AminMB , BrunerDW , LowD , SwansonGP , et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low‐risk prostate cancer. Journal of Clinical Oncology2016;34(20):2325‐33. LeeRW , DignamJJ , AminMB , BrunerDW , LowD , SwansonGP , et al. NRD Oncology RTOG 0415: a randomized phase III non‐inferiority study comparing two fractionation schedules in men with low‐risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;94 1S:S3. NCT00331773 . A phase III randomized study of hypofractionated 3D‐CRT/MRT versus conventionally fractionated 3D‐CRT/MRT in patients with favorable‐risk prostate cancer. clinicaltrials.gov/ct2/show/NCT00331773 (first received 31 May 2006). Watkins BrunerD , PughSL , LeeWR , DignamJJ , LowD , SwansonGP , et al. NRG Oncology/RTOG 0415, Phase 3 noninferiority study comparing 2 fractionation schedules in patients with low‐risk prostate cancer: prostate‐specific quality of life results. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):S2‐3. ">Lee 2016</a>)".<br/> <sup>e</sup><a href="./references#CD011462-bbs2-0009" title="CattonC , on behalf of the PROFIT trial investigators. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2016;96(2S):32‐3. [Abstract #5003] CattonCN , LukkaH , GuCS , MartinJ , SupiotS , ChungPW , et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. Journal of Clinical Oncology2017;35(17):1884‐90. [DOI: 10.1200/JCO.2016.71.7397] HealyB , KronT , FrantzisJ , ThompsonK , MurryR , CattonC , et al. Multi‐centre Australian dosimetric inter‐comparison of prostate IMRT delivery for the OCOG PROFIT trial. Journal of Medical Imaging and Radiation Therapy2009;53 S1:A64. ISRCTN43853433 . A randomised trial of a shorter radiation fraction schedule for the treatment of localised prostate cancer. www.isrctn.com/ISRCTN43853433 (first received 5 November 2007). [DOI: 10.1186/ISRCTN43853433] MIddletonM , FrantzisJ , HealyB , JonesM , MurryR , KronT , et al. Successful implementation of image‐guided radiation therapy quality assurance implementation in the Trans Tasman Radiation Oncology Group 08.01 PROFIT Study. International Journal of Radiation Oncology, Biology, Physics2011;81(5):1576‐81. MartinJ , FrantzisJ , ChungP , LangahI , CraindM , CornesD , et al. Prostate radiotherapy clinical trial quality assurance: how real should real time review be? (a TROG‐OCOG intergroup project). Radiotherapy and Oncology2013;107:333‐8. MartinJ , TaiKH , TurnerS , TangC , EadeT , NasserL , et al. A randomised trial of a shorter schedule for the treatment of localised prostate cancer (PC): profit – an OCOG/TROG intergroup study. Journal of Medical Imaging and Radiation therapy2016;60 1S:S23. NCT00304759 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/record/NCT00304759 (first received 20 March 2006). ">PROFIT 2016</a>: CTV = either prostate alone (if nodal involvement risk &lt; 155 according to Partin's nomogram; [<a href="./references#CD011462-bbs2-0088" title="PartinAW , KattanMW , SubongEN , WalshPC , WojnoKJ , OesterlingJE , et al. Combination of prostate‐specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multiple institutional update. JAMA1997;277:1445‐51. ">Partin 1997</a>]) or prostate + base of seminal vesicles (if nodal risk according to Partin's nomogram was 15% or greater). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011462-tbl-0009"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">RTOG/EORTC scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Organ tissue</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade 4</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lower gastrointestinal (modified) (</b><a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). "><b>Lukka NCIC 2005</b> </a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excess bowel movements twice baseline</p> <p>Slight rectal discharge or blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≤ 2 antidiarrheals/week</p> <p>≥ 2 coagulations for bleeding</p> <p>Occasional steroids for ulceration</p> <p>Occasional dilation</p> <p>Intermittent use of incontinence pads</p> <p>Regular non‐narcotic or occasional narcotic for pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 2 antidiarrheals/day</p> <p>≥ 1 blood transfusion or &gt; 2 coagulations for bleeding</p> <p>Steroids per enema</p> <p>Hyperbaric oxygen for ulceration</p> <p>Regular dilation</p> <p>Persistent use of incontinence pads</p> <p>Regular narcotic for pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dysfunction requiring surgery</p> <p>Perforation</p> <p>Life‐threatening bleeding</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lower gastrointestinal</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild diarrhea</p> <p>Mild cramping</p> <p>Bowel movement 5 times daily</p> <p>Slight rectal discharge or bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate diarrhea and colic</p> <p>Bowel movement &gt; 5 times daily</p> <p>Excessive rectal mucus or intermittent bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Obstruction or bleeding requiring surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Necrosis/perforation</p> <p>Fistula</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urinary (modified) (</b><a href="./references#CD011462-bbs2-0006" title="LukkaH , HayterC , JulianJA , WardeP , MorrisWJ , GospodarowiczM , et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. Journal of Clinical Oncology2005;23(25):6132‐8. LukkaH , HayterC , WardeP , MorrisJ , JulianJ , GospodarowiczM , et al. on behalf of Investigators. A randomized trial comparing two fractionation schedules for patients with localized prostate cancer. International Journal of Radiation Oncology, Biology, Physics2003;57(2):S126. NCT00201916 . A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. clinicaltrials.gov/ct2/show/NCT00201916 (first received 20 September 2005). "><b>Lukka NCIC 2005</b> </a><b>)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nocturia twice baseline</p> <p>Microscopic hematuria</p> <p>Light mucosal atrophy and minor telangiectasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate‐frequency nocturia &gt; twice baseline</p> <p>Generalized telangiectasia</p> <p>Intermittent macroscopic hematuria</p> <p>Occasional blood transfusions</p> <p>≤ 2 coagulations</p> <p>Regular non‐narcotics for pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe frequency and dysuria</p> <p>Nocturia more frequent than once every hour</p> <p>Reduction in bladder capacity (150 mL)</p> <p>Frequent hematuria</p> <p>Frequent transfusions</p> <p>&gt; 1 coagulation for hematuria</p> <p>Regular narcotic for pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe hemorrhagic cystitis</p> <p>Ulceration</p> <p>Requirement for urinary diversion or cystectomy, or both</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Urinary</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Slight epithelial atrophy</p> <p>Minor telangiectasia (microscopic hematuria)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate urinary frequency</p> <p>Generalized telangiectasia</p> <p>Intermittent macroscopic hematuria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe urinary frequency and dysuria</p> <p>Severe generalized telangiectasia (often with petechiae)</p> <p>Frequent hematuria</p> <p>Reduction in bladder capacity (&lt; 150 mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Necrosis/contracted bladder (capacity &lt; 100 mL)</p> <p>Severe hemorrhagic cystitis</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>EORTC: European Organisation for Research and Treatment of Cancer; RTOG: Radiation Therapy Oncology Group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">RTOG/EORTC scale</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011462-tbl-0010"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">NCIC CTCAE Toxicity scoring</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symptom</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade I</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade II</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade III</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade IV</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade V</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Gastrointestinal</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Anorexia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Diarrhea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increase of &lt; 4 stools per day over baseline</p> <p>Increase in ostomy output</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increase of 4–6 stools per day over baseline</p> <p>Moderate increase in ostomy output compared to baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increase of 7 stools per day over baseline</p> <p>Incontinence</p> <p>Hospitalization indicated</p> <p>Severe increase in ostomy output compared to baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Life‐threatening consequences</p> <p>Urgent intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gastrointestinal bleeding</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild symptoms</p> <p>Intervention not indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate symptoms</p> <p>Medical intervention or minor cauterization indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transfusion, radiologic, endoscopic or elective operative intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Life‐threatening consequences</p> <p>Urgent intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nausea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss of appetite without alteration in eating habits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral intake decreased without significant weight loss, dehydration or malnutrition</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain/cramping</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate pain</p> <p>Limiting instrumental ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe pain</p> <p>Limiting self‐care ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Vomiting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1–2 episodes (separated by 5 minutes) in 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3–5 episodes (separated by 5 minutes) in 24 hours</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 6 episodes (separated by 5 minutes) in 24 hours</p> <p>Tube feeding, TPN or hospitalization indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Life‐threatening consequences</p> <p>Urgent intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Bladder changes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cystitis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microscopic hematuria</p> <p>Minimal increase in frequency, urgency, dysuria or nocturia</p> <p>New‐onset incontinence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate hematuria</p> <p>Moderate increase in frequency, urgency, dysuria, nocturia or incontinence</p> <p>Urinary catheter placement or bladder irrigation indicated</p> <p>Limiting instrumental ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gross hematuria</p> <p>Transfusion, IV medications or hospitalization indicated</p> <p>Elective endoscopic, radiologic or operative intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Life‐threatening consequences</p> <p>Urgent radiologic or operative intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fistula</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐invasive intervention indicated</p> <p>Urinary or suprapubic catheter placement indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Limiting self‐care ADL</p> <p>Elective radiologic, endoscopic or operative intervention indicated</p> <p>Permanent urinary diversion indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Life‐threatening consequences</p> <p>Urgent radiologic or operative intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Genitourinary pain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate pain</p> <p>Limiting instrumental ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe pain</p> <p>Limiting self‐care ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hematuria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asymptomatic</p> <p>Clinical or diagnostic observations only</p> <p>Intervention not indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic</p> <p>Urinary catheter or bladder irrigation indicated</p> <p>Limiting instrumental ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gross hematuria</p> <p>Transfusion, IV medications or hospitalization indicated</p> <p>Elective endoscopic, radiologic or operative intervention indicated</p> <p>Limiting self‐care ADL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Life‐threatening consequences</p> <p>Urgent radiologic or operative intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ureteric obstruction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asymptomatic</p> <p>Clinical or diagnostic observations only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic but no hydronephrosis, sepsis or renal dysfunction</p> <p>Urethral dilation, urinary or suprapubic catheter indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic and altered organ function (e.g. hydronephrosis or renal dysfunction)</p> <p>Elective radiologic, endoscopic or operative intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Life‐threatening consequences</p> <p>Urgent intervention indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>ADL: activities of daily living; IV: intravenous; NCIC CTCAE: National Cancer Information Center Common Terminology Criteria for Adverse Events; TPN: total parenteral nutrition. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">NCIC CTCAE Toxicity scoring</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011462-tbl-0011"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Modified LENT‐SOMA radiation therapy late effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Toxicity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade I</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade II</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade III</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Grade IV</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Genitourinary</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nocturia twice baseline or non‐narcotic medication (e.g. α‐blocker) once per day increase over baseline </p> <p>Microscopic hematuria</p> <p>Light mucosal atrophy and minor telangiectasia</p> <p>Dysuria not requiring medication</p> <p>Incontinence or dribbling not requiring sanitary pad (over baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frequency ≤ every hour requiring α‐blocker &gt; once per day</p> <p>Nocturia &gt; twice baseline</p> <p>Generalized telangiectasias</p> <p>Macroscopic hematuria requiring ≤ 2 cauterization</p> <p>Dysuria requiring medication (non‐narcotic &gt; once per day or narcotic for pain ≥ 1 per day over baseline) </p> <p>≤ 2 dilations Foley or self‐catheterization for ≤ 2 weeks' incontinence requiring ≤ 2 pads (over baseline) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Frequency &gt; 1 every hour or dysuria requiring narcotic &gt; once per day</p> <p>Nocturia &gt; 1 per hour</p> <p>Reduction in bladder capacity (150 cm<sup>3</sup>) ≥ 1 blood transfusions or &gt; 2 cauterizations for bleeding </p> <p>Narcotic use &gt; once per day</p> <p>Hyperbaric oxygen</p> <p>Foley or self‐catheterization &gt; 2 weeks</p> <p>TURP or &gt; 2 dilations</p> <p>Incontinence requiring &gt; 2 pads (over baseline)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gross hematuria requiring &gt; 1 blooded transfusion</p> <p>Severe hemorrhagic cystitis or ulceration requiring urinary diversion with or without cystectomy </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>LENT‐SOMA: Late Effects Normal Tissue Task Force‐Subjective, Objective, Management, Analytic; TURP: transurethral resection of the prostate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Modified LENT‐SOMA radiation therapy late effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/full#CD011462-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011462-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hypofraction versus conventional fractionation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Prostate cancer‐specific survival (PC‐SS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7946</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.72, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 PC‐SS 3‐dimensional conformal radiation therapy (3DCRT) vs intensity‐modulated radiation therapy (IMRT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.72, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 3DCRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.42, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 IMRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.69, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 PC‐SS subgroup analysis (SGA) by dose 74 Gy or greater control arm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.72, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 &gt; 74 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.79, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 ≤ 74 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.36, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 PC‐SS &lt; 4 Gy equivalent dose in 2 Gy fractions (EQD<sup>2</sup>) vs ≥ 4 Gy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.72, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 EQD2 difference &lt; 4Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.66, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 EQD2 difference ≥ 4 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.56, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 PC‐SS androgen deprivation (AD) versus no AD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.72, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.81, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 No AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.47, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 PC‐SS quality assurance (QA) versus no QA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Radiation therapy (RT) QA process described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.57, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 No RT QA process reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.72, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 ≥ Grade II late gastrointestinal (GI) Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer (RTOG/EORTC) toxicity at 60 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.68, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Late GI RT toxicity by dose ≥ 4 Gy difference between arms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 EQD2 differs &gt; 4 Gy between study arms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.79, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 EQD2 differs by &lt; 4 Gy between arms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.38, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 SGA ≥ Grade II late GI RTOG/EORTC toxicity AD vs no AD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.68, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2637</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.96, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 No AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.46, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Late GI RT toxicity by QA vs no QA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 QA process reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.38, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 No QA process reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [0.78, 6.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Late genitourinary (GU) ≥ Grade II RTOG/EORTC toxicity at 60 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.93, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Late GU RT toxicity by dose ≥ 4 Gy difference between arms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 EQD2 differs by &gt; 4 Gy between study arms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.93, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 EQD2 differs by &lt; 4 Gy between study arms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.71, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 SGA late GU ≥ Grade II RTOG/EORTC toxicity: AD vs no AD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.93, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.85, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 No AD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.81, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Late GU RT toxicity by QA vs no QA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 QA process described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.82, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 No QA process described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.48, 6.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Metastasis‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.65, 1.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Biochemical relapse‐free survival Phoenix <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2889</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.68, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Acute GI ≥ Grade II RTOG/EORTC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.19, 1.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Acute GU ≥ Grade II RTOG/EORTC toxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.95, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Health‐related quality of life (HRQoL): ≥ Grade II sexual 'bother' (participant reported) at 60 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1084</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.88, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 HRQoL: ≥ bowel 'bother' <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.84, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 HRQoL: ≥ Grade II sexual 'bother' (doctor reported) at 60 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.90, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 HRQoL: erectile function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.55, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 PC‐SS sensitivity analysis (SA) dose ≥ 74 Gy conventional (α/β 4.14) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.72, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 ≥ 74 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.79, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 &lt; 74 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.36, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 PC‐SS SA dose control arm ≥ 74 Gy (α/β 0.58) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.72, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 Dose ≥ 74 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.79, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 Dose &lt; 74 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.36, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 PC‐SS SA &lt; 4 Gy EQD<sup>2</sup> vs ≥ 4 Gy (α/β 4.14) to 4 Gy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.72, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 EQD2 difference ≥ 4 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.66, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 EQD2 difference &lt; 4 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.55, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 PC‐SS SA EQD<sup>2</sup> &lt; 4 Gy vs ≥ 4 Gy (α/β 0.58)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.73, 1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 EQD2 difference ≥ 4 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.77, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 EQD2 difference &lt; 4 Gy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.36, 1.47]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hypofraction versus conventional fractionation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011462.pub2/references#CD011462-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011462.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011462-note-0016">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011462-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011462-note-0001">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD011462-note-0018">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011462-note-0017">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011462\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011462\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011462\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011462\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011462\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011462\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011462\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011462\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011462\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011462\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011462\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011462\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011462\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011462\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011462\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011462\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011462\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011462\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=f00EizoA&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011462.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011462.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011462.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011462.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011462.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727834742"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011462.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727834746"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011462.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb5bdda5e9368',t:'MTc0MDcyNzgzNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 